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Abstract 
 
Background 
Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) are atypical 
Parkinsonian disorders which are rapidly progressive. The impact that Parkinsonian disorders 
has on quality of life (QoL) is increasingly understood, though less work has been done in 
MSA and PSP compared to Parkinson’s disease. The role of Palliative Care in enhancing QoL 
is beginning to be translated into clinical practice though fewer studies have been done in 
MSA and PSP compared with Parkinson’s disease.  
 
Methods 
A cross-sectional study of 23 MSA patients and 24 PSP patients was carried out, assessing 
aspects of QoL, depression, palliative symptoms and clinical milestones such as dysarthria. 
Carers for each disease type were assessed in terms of carer strain and QoL. A range of QoL 
measures including subjective, disease-specific and general QoL scores were taken with the 
aim of achieving a holistic impression of QoL and symptom burden. A subset of participants 
were selected for interviews to obtain personal perspectives of living with these conditions. 
The interviews were evaluated using thematic analysis, to gain a still fuller, richer picture of 
the implications of these diseases on QoL for patients and carers. The use of both quantitative 
and qualitative methods was intended to complement each other, with the recognition that 
QoL is a complex and subjective concept and cannot be encompassed using a single type of 
assessment.  
  
Results  
Using multiple linear regression, QoL was predicted for by depression and palliative need in 
MSA and PSP, with severity having an influence in PSP only. Carer mental well-being and 
patient depression influenced different aspects of carer QoL. Issues with legs was the highest-
rated symptom in both groups and there was no significant difference in palliative need 
between MSA and PSP.  Subjective QoL using the SEIQoL-DW score produced diverse 
domains which people felt influenced their QoL. The most commonly nominated were 
‘family’ and ‘partner’; some domains in common were discussed in interviews. 
ii 
 
The overarching themes in interviews were connection to others, transitions (including 
adjustment) and seeking support, from peers, palliative care services and sourcing expertise 
for these rare conditions.  
 
Conclusion 
MSA and PSP have a profound effect on QoL, seen using a range of QoL scores. Depression 
and symptoms frequently managed in palliative care, predict for patient disease-specific QoL, 
though severity seems to have a greater impact on QoL in PSP compared with MSA. Carer 
QoL is impacted by patient depression and by carers’ own mental well-being. This work 
emphasises that QoL in progressive neurological disorders is heterogeneous and individual. 
Patients and their carers would likely benefit from an individualised, palliative approach 
supporting patients through the course of their disease, maximising QoL to enhance the 
experience of living with a progressive disease. 
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Introduction 
 
Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) are progressive 
neurodegenerative conditions and belong to a group known as the atypical Parkinsonian 
disorders.  The atypical parkinsonian disorders have some features of Parkinson’s disease 
(PD) but often with poor or transient levodopa response with distinct symptom profiles and 
more rapid progression and reduced survival (Bukki et al., 2014). They have significant 
symptom burden (Pillas et al., 2015). The atypical parkinsonian conditions considered in this 
review will be Multiple System Atrophy and Progressive Supranuclear Palsy. 
MSA is a sporadic condition with early and significant disability. It includes key features of 
Parkinsonism, autonomic failure and cerebellar symptoms (Diem-Zangerl et al., 2009). The 
subtype MSA-P (Parkinsonian) tends to occur more commonly in the West (Europe and 
United States of America) whereas the MSA-C (cerebellar) form is the prevalent form in the 
East, specifically in Korean and Japanese populations (Seo et al., 2010). PSP is characterised 
by early falling (usually backwards), supranuclear gaze palsy (with vertical gaze typically 
affected first) and cognitive problems (Williams et al., 2005). PSP-Richardson’s Syndrome 
(PSP-RS) describes the classical constellation of early falls, gaze problems and frontal 
cognitive dysfunction whereas PSP-Parkinsonism (PSP-P) has more prominent bradykinesia 
and tremor, is asymmetrical and is often diagnosed as idiopathic Parkinson’s disease (iPD) in 
the early stages (Williams et al., 2005; Jecmenica-Lukic et al., 2014). 
Quality of life (QoL) is increasingly recognised as an important outcome measure of patient 
status, as the significant symptom burden and extended morbidity of these conditions is 
appreciated. To this end, there has been increasing recognition of the benefit of palliative care 
(PC) input in patients with neurodegenerative diseases especially those with significant early 
morbidity, such as the atypical parkinsonian disorders (O'Sullivan et al., 2008; Bukki et al., 
2014). Palliative care can be challenging in the context of neurodegenerative disorders. The 
progression of disease can fluctuate with unforeseen rapid deterioration on a background of 
inexorable decline. Considerable loss of function and symptom burden can occur relatively 
early in the disease process resulting in significant periods of time with marked morbidity 
(Fallon and Foley, 2012). The burden of these conditions is heavy, both for patients and for 
their carers, and it has been described that patients with atypical Parkinsonism (AP) might 
benefit from early palliative care (Veronese et al., 2015). The complex combination of 
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symptoms displayed by this patient group has comparable levels of palliative care need as 
advanced cancer patients (Higginson et al., 2012).  
 
The aims of this MD project are to explore the demographics of the patients and carers, how 
important clinical milestones, such as needing a wheelchair, relate to the time of diagnosis 
and to find how palliative care need (symptom burden) compares between the two disease 
groups and what patients understand about palliative care as a service. Different aspects of 
QoL in patients and carers (and strain in the latter) will be analysed using validated measures 
and statistical analysis will be used to find any differences between them and whether these 
scores can be predicted for using other participant variables. Finally, individual perspectives 
will be sought using semi-structured interviewing of a subset of participants, seeking to 
complement the quantitative analysis with detailed and rich descriptions of living with MSA 
and PSP, to provide a full and holistic outlook to this work. 
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Chapter 1. Review of Literature 
 
1.1 Multiple System Atrophy and Progressive Supranuclear Palsy 
Idiopathic Parkinson’s disease is defined as bradykinesia or slowness of movement, akinesia, 
rest tremor, asymmetrical onset, postural instability and rigidity typically with a good 
levodopa response (Litvan, 1998; Brooks, 2002). When Parkinsonism is present but has 
additional or unusual features, this is known as atypical Parkinsonism. Multiple System 
Atrophy and Progressive Supranuclear Palsy are two sporadic atypical parkinsonian disorders, 
historically known as the Parkinson’s Plus disorders (see figure 1.1). 
 
Figure 1.1:  Classification of Parkinsonism from (Hughes et al., 2002; Martin, 2011) 
 
1.1.1 Diagnosis and diagnostic criteria 
The atypical Parkinsonian disorders tend to progress more rapidly than PD and have a 
response to levodopa therapy which can be absent or poorly-sustained (Litvan, 1998; Poewe 
et al., 2015). Distinguishing between PD and the atypical Parkinsonian disorders can be 
difficult especially in the early stages. Wenning et al. (1995) describes 75% of pathologically-
confirmed MSA initially being diagnosed with PD. 
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Hughes et al. (2002) emphasises the importance of specialist movement disorder clinics with 
integrated expertise in the diagnosis of atypical Parkinsonian disorders. In their study, 88.2% 
of pathologically-proven MSA cases were appropriately diagnosed in this specialist setting 
and in PSP, 84.2%. Timely, accurate diagnosis is important and it can allow preparation for 
the more rapid deterioration expected in these disorders, as well as prompt advance care 
planning and support to be provided.  
Diagnostic criteria have been formulated to facilitate accurate diagnosis in MSA and PSP. 
The NINDS-SPSP criteria only apply to the ‘typical’ or Richardson’s Syndrome subtype (see 
tables 1.1 and 1.2). It should be noted that in 2017 when this project’s data collection had 
been completed, new diagnostic criteria for PSP were published. However due to the timing 
of its publication, the new criteria could not be used for this study (Hoglinger et al., 2017). 
 
NINDS-SPSP criteria (applies to PSP-Richardson’s syndrome only) 
Possible PSP Progressive disorder 
 Onset 40 years or above 
 Vertical supranuclear gaze palsy OR 
 Slowing of vertical saccades and falls within first year 
 No evidence suggestive of other diseases 
Probable PSP Progressive disorder 
 Onset 40 years or above 
 Vertical supranuclear gaze palsy AND postural instability with falls in first year of 
onset 
Definite PSP Possible or probable PSP with autopsy confirmation 
Exclusion Criteria Alien limb syndrome, recent encephalitis, Alzheimer’s-type cortical dementia, 
prominent cerebellar signs, early dysautonomia, asymmetric Parkinsonian signs, 
relevant radiological abnormality and Whipple’s disease 
 
 
Table 1.1: The NINDS-SPSP (National Institute of Neurological Disorders and Stroke and Society for PSP 
consensus criteria developed in 1996 (Litvan et al., 1996) 
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MSA consensus criteria 
Possible 
MSA 
Sporadic and progressive disease 
Onset over 30 years of age 
Features of Parkinsonism (bradykinesia, rigidity, tremor) OR 
A cerebellar syndrome (ataxia, dysarthria, oculomotor features AND 
Features suggestive of autonomic dysfunction 
An additional suggestive feature such as poor levodopa response or stridor 
Probable 
MSA 
As above but with defined dysautonomia (drop of 30mmHg systolic/ 15mm Hg 
diastolic post 3 mins standing, erectile dysfunction or urinary 
incontinence/voiding difficulty). 
Definite 
MSA 
Possible or probable MSA with autopsy confirmation 
Table 1.2: The Second Consensus Criteria for MSA (Gilman et al., 2008) 
 
Prompt identification is crucial, not only for appropriate classification, prognostication and 
communication to patients, but to address patient needs (such as palliative care) which are 
apparent earlier than in PD. Furthermore, research in AP is growing and accurate diagnosis of 
disease allows patients the opportunity to participate in research, as has been the case in PD 
over recent years. Late diagnosis, uncertainty and a lack of information with specialist advice 
has been reported by patients and carers to be a cause of distress in PSP (Moore and Guttman, 
2014). Therefore, key features which may suggest MSA and PSP should be included as part 
of the diagnostic and review history, especially in the early phase of disease or if progression 
is unexpectedly rapid for PD. (see tables 1.3 and 1.4)  
 
AP type Atypical Features Presence in iPD Subtypes 
MSA Ataxia 
Autonomic dysfunction  
Cerebellar signs 
Pyramidal signs 
Stridor and hypoventilation 
Poor levodopa response 
Polyminimyoclonus 
No 
Late or treatment-related 
No 
No (except hyperreflexia) 
No 
Good levodopa response 
No 
MSA-C Predominant cerebellar 
features though Parkinsonism may 
also be present 
 
MSA-P Predominant Parkinsonism 
though cerebellar features may also 
be present  
Table 1.3: Atypical features of MSA (Litvan, 1998; Flabeau et al., 2010) 
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 Atypical Features Presence in iPD Subtypes 
PSP Early falls and instability 
Dysphagia and dysarthria 
Frontal release signs 
Marked axial rigidity 
(Vertical) Supranuclear gaze palsy  
Early wheelchair requirement  
Pyramidal signs 
Poor levodopa response 
Late 
Late 
No 
Limb rigidity more prominent  
No 
Unusual  
Late 
Good levodopa response 
PSP-RS vertical gaze 
palsy, axial rigidity, 
dysarthria and frontal lobe 
dysfunction 
 
PSP-P asymmetric 
parkinsonism, often a 
degree of levodopa 
response 
Table 1.4: Atypical features of PSP (Golbe and Ohman-Strickland, 2007; Arena et al., 2015) 
 
1.1.2 Differential Diagnosis 
Because of the clinical challenges in making an accurate diagnosis, research has considered 
several avenues to improve discrimination between PD and AP generally, as well as the more 
specific diagnosis of MSA or PSP (or indeed other AP forms such as Dementia with Lewy 
bodies (DLB) or Cortico-Basal Syndrome (CBS)). A full exploration of the search for 
biomarkers in the differential diagnosis of Parkinsonism is beyond the scope of this thesis, but 
some considerations will be mentioned. 
Autonomic testing: Work by Baschieri et al. (2015) using a combination of autonomic tests 
found that sensitivity to discriminating MSA from PD was 91% with a specificity of 94%. 
However, participants with comorbid diseases such as diabetes mellitus or cardiovascular 
disease which could interfere with autonomic testing were excluded; these groups are often 
those in which diagnostic uncertainty is most problematic. Similarly, pre-motor or early 
incontinence (as opposed to urinary urgency) or erectile dysfunction can be a helpful 
discriminator of MSA from PD but prior urological problems can mask this history. Also, the 
clinical picture is less clear in women, especially if there is a degree of prior stress 
incontinence (Chandiramani et al., 1997). 
Imaging: There is no imaging modality in common clinical use which can currently 
confidently discriminate AP from PD (or MSA from PSP). Some MRI sequences such as SWI 
can improve diagnostic certainty of MSA from 25% to 75% in the right clinical context and 
rADC is also being explored as a readily available MRI sequence which may add to 
diagnostic certainty (Brooks and Tambasco, 2016). Jin et al. (2016) have recently shown in a 
study with 67 participants with PD, MSA and PSP that early phase PET scanning with FP-
CIT may allow discrimination of MSA from PD due to different patterns of cerebral uptake 
but not PSP. 
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Biomarkers: CSF and blood biomarkers have been pursued as a means to distinguish AP 
from PD. Blood biomarkers would be especially valuable as they minimise the need for 
invasive procedures such as a lumbar puncture. Hansson et al. (2017)  has shown 
neurofilament light chains in blood have some promise in distinguishing AP from PD after 
finding higher levels in AP generally, compared with PD patients and controls.  
Other work: Patients with PD perform more poorly than those with MSA or PSP in olfactory 
testing, so this may have a role as part of diagnostic work-up in the future (Krismer et al., 
2016).  As speech dysfunction has been recognised as often being more profound in AP, voice 
analysis has been carried out to seek significant differences between groups, though work thus 
far has only found non-significant differences in men with MSA compared with PD and other 
AP patients (Huh et al., 2015).  
Diagnosis in AP remains clinical, albeit with a range of tests being further developed in terms 
of their utility in helping discriminate between PD and AP (and between AP types). A cohort 
of patients from the UK with AP (including MSA, PSP, CBS and DLB) recently illustrated 
the issues frequently encountered in trying to achieve a reliable diagnosis. 49% of participants 
had features considered ‘atypical’ for that type of AP e.g. severe cognitive dysfunction in 
MSA or cerebellar signs in PSP. 10% of participants received an alternative diagnosis during 
the study (Hirschbichler et al., 2016).    
In summary, though research is ongoing on many physiological parameters in the hope of 
improving the clinical accuracy of AP, at present there is often uncertainty and difficulty in 
the process of diagnosis, especially in early disease. This leads to uncertainty and stress for 
patients.  
 
1.1.3 Clinical milestones in disease progression and prognosis 
MSA and PSP have been observed to fall into distinct phenotypes. To allow better 
prognostication and advance care planning, studies have been carried out to determine 
whether the subtype of the AP, or the presence of certain symptoms or signs are associated 
with a more rapid decline. Dysautonomia and stridor are two such symptoms in MSA. 
Comparisons of outcome have been made between MSA-C and MSA-P subtypes. O'Sullivan 
et al. (2008) found that dysautonomia within 2 years, older age at onset and female sex were 
poor predictors of survival. There was an unexpected survival benefit in nursing home 
admission; one theory for this was professional catheter care. Japanese studies have also 
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found poorer outcomes with early dysautonomia (Tada et al., 2007). Stridor is a worrying 
symptom in MSA with a high degree of uncertainty. Reports of sudden death in connection 
with it have been made but consensus on the best treatment course is not established. Silber 
and Levine (2000) reported survival in a cohort as 3 years if stridor was present, 4 years if 
absent. However, survival was only 0.8 years if stridor occurred in the daytime. Four patients 
received tracheostomy - two died within the year. NIV did not seem to alter outcome. 
Wheelchair dependence occurs between 3.5-5 years (with mean survival at 7-9 years). 
Watanabe et al. (2002) found people with MSA-P deteriorated functionally faster than MSA-
C though survival was not statistically different. Other work has suggested MSA-C has better 
outcomes than MSA-P though the latter may reach more milestones before diagnosis (Schulz 
et al., 1994; Lee and Koh, 2012). Suggestions for this include the greater difficulty of 
recognizing MSA-C due to its cerebellar features. An analysis of 20 studies exploring MSA 
prognosis reported opposing conclusions on whether subtype of MSA, the presence of stridor 
or the age of onset affected outcome (Glasmacher et al., 2017).  
A number of variables have been theorized as being poor predictors of survival in PSP, 
including subtype, sex, age at onset and development of key symptoms or signs (see table 
1.4). PSP-RS has been described as having a worse outcome than PSP-P in a range of studies 
(O'Sullivan et al., 2008; Williams and Lees, 2009; dell'Aquila et al., 2013). Shorter survival 
was associated with male sex in a British cohort of pathologically confirmed cases 
(O'Sullivan et al., 2008) but not in other studies (Nath et al., 2003; Golbe and Ohman-
Strickland, 2007). Older age at onset of symptoms has been demonstrated in several studies to 
lead to reduced survival (Chiu et al., 2010; dell'Aquila et al., 2013). Falls in PSP tend to be 
the first milestone achieved (O'Sullivan et al., 2008; dell'Aquila et al., 2013) and poorer 
survival has been associated with shorter periods between symptom-onset and the first clinical 
milestone (Santacruz et al., 1998). In terms of specific symptoms which might predict a 
poorer outcome, a meta-analysis of studies observing progression in PSP, earlier dysphagia 
and cognitive problems had a shorter survival trajectory (Glasmacher et al., 2017).  
 
1.1.4 Comparisons between MSA and PSP 
Symptom-burden is significant in MSA and PSP; 93% of patients reach at least one milestone 
(of seven which the study selected as clinically significant and likely to be well-documented 
such as falls, wheelchair dependence and dysarthria) in a British cohort (O'Sullivan et al., 
2008). The first milestone overall, when all subtypes of MSA and PSP were considered was 
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frequent falls (Brooks, 2002; Lee and Koh, 2012). PSP patients tended to reach their first 
milestone earlier (mean 3.9 years) compared with MSA (5.9 years). Work by Jecmenica-
Lukic et al. (2014) supports the rapid progression to disability and reduced survival of PSP-
RS compared to other subtypes, though PSP-P was observed to have a better outcome in 
terms of survival than MSA-P. 
Overall there is evidence that survival is reduced in PSP and MSA overall compared with PD 
and that significant clinical milestones are reached early in all forms. Symptom-burden is 
considerable and marked disability is present early in the disease-course, producing extended 
morbidity as well as increased mortality in these unremittingly progressive conditions. In 
progressive conditions such as these, the focus of a palliative approach is quality of life.  
  
1.2 Quality of Life 
1.2.1 Defining Quality of Life 
The World Health Organization (WHO) defines Quality of Life as ‘an individual’s perception 
of their position in life in the context of their culture and value systems in which they live and 
their goals, expectations, culture and concerns’ (World Health Organisation, 1995). Quality 
of life has been described as a judgement which an individual makes of their life against 
criteria which that individual has developed for themselves. This is a subjective appraisal of 
one’s life (Pavot, 2009). 
In medical research, quality of life (QoL), and its measurement, has become increasingly 
prominent as it is recognized that clinical assessments or disease-rating scales do not 
encapsulate the patient experience of living with a progressive disease (Rejeski and Mihalko, 
2001; Litvan, 2005). This growing appreciation of the importance of QoL, rather than a pure 
focus upon mortality and disease-measures has led to the development of tools attempting to 
quantify QoL (Smith, 1999). QoL is a broad concept and difficult to capture in the clinical 
context. Therefore, the disease-focused ‘health-related quality of life’ (HR-QoL) has been 
developed. HR-QoL is restricted to perception of well-being relating to disease, treatment and 
its impact. HR-QoL is easier to describe but remains a multidimensional concept, dependent 
on the individual’s experience (Den Oudsten et al., 2007a). By contrast, health status (HS) has 
been thought of as an evaluation of the patient’s function, physically, psychologically and 
socially but not incorporating the individual’s judgments. Thus, HS can impact upon HR-QoL 
but is not equivalent (Murrell, 1999; Zubaran et al., 2008; Martinez-Martin et al., 2011). The 
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purpose of these measurements is to define outcomes meaningful to the patient. However, 
HR-QoL and HS are often used interchangeably in literature as ‘QoL measures’. It has been 
suggested that these are in fact complementary and it can be useful to assess both HS and HR-
QoL to gain a nuanced impression of the patient’s experience (Haave et al., 2006).   
 
1.2.2 QoL in PD  
The importance of recognising QoL in progressive neurodegenerative conditions such as PD 
and AP is increasing. Efforts are being made to maximize patient well-being with the finite 
societal resources available (Schrag, 2005). QoL research in PD is becoming well-established, 
as is the understanding of the personal experiences Parkinsonian diseases have on patients. 
It has been found that PD patients have lower scores across all well-being dimensions 
compared with patients with diabetes mellitus and individuals without chronic disease, 
reporting fatigue, pain and social isolation. Reviews of HR-QoL over four years in PD show a 
decline though no predictive factors have been identified (Karlsen et al., 1998; Karlsen et al., 
2000). Den Oudsten et al. (2007a) reviewed studies considering QoL in PD. In 61 studies, all 
claimed to measure HR-QoL; however only two actually measured HR-QoL, the remainder 
measured HS.  Poorer HS was associated with depression and with sleep disturbance. The 
authors concluded that use of HR-QoL was sparse and more work needed to be done to 
appraise well-being using HR-QoL, as the bulk of the literature concentrates on HS alone.   
The SEIQoL-DW is a measure that allows patients to define specific issues contributing to 
their QoL; whereas other HR-QoL instruments tend to impose issues which individuals may 
not find important (Hickey et al., 1996). A study evaluating PD using the SEIQoL-DW found 
87 meaningful domains were created when 123 patients were interviewed, reflecting the 
subjectivity of QoL and heterogeneity of patient experience. Subjective QoL was predicted by 
depression (Lee et al., 2006). The presence and severity of depression has been associated 
with HR-QoL/HS in PD in other studies (Kuopio et al., 2000).  Schrag (2006) described 
depression to have strong associations with HR-QoL in PD. Disease severity had only a 
moderate effect whereas disease duration had none. 
 
1.2.3 QoL in MSA and PSP 
It is recognised that MSA and PSP have marked impact on quality of life and health with a 
more rapid progression and reduced survival compared with PD (Schrag et al., 2003; Schrag, 
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2005; Winter et al., 2011). Therefore, as the impact of PD on HR-QoL has become 
understood, work has begun seeking the impact of MSA and PSP on HR-QoL.  
Living with chronic neurological conditions (including MSA and PSP), has been found to 
have marked impact on HR-QoL (Calvert et al., 2013). Winter et al. (2011) found 63% of 
MSA and PSP patients described serious issues in at least one aspect of their well-being using 
HR-QoL measures. Predictors of low HR-QoL included female sex, depression and cerebellar 
symptoms. By contrast, Schrag et al. (2003) found no association between gender or age and 
HR-QoL in individuals with PSP. Generic measures used, like the EQ-5D were reported by 
patients to lack recognition of their specific concerns in PSP, such as visual disturbance and 
falling. In PSP patients followed over one year, apathy was the only statistically significant 
variable found which predicted greater decline in HS (Pekmezovic et al., 2015). Benrud-
Larson et al. (2005) considered life-satisfaction in MSA patients. Depression was pervasive in 
the group; 36% had moderate to severe depression (contrasted with 19.6% in PD) and 5% 
described suicidal ideation. Depression was a significant factor in life-satisfaction though HS 
was not. However, a European study found that though moderate-severe depression was 
found in half of an MSA cohort and associated with lower HR-QoL scores; autonomic and 
motor problems had a stronger association (Schrag et al., 2006a). Therefore, depression is 
common in MSA and depression does influence QoL, but unlike in PD, it is not thought to be 
the principal determining factor. 
As well as negative factors having an influence on QoL in neurodegenerative disease, it is 
important to identify whether positive factors exist which might correlate with improved QoL. 
In Japanese patients with neurological disease, including PD and MSA, improved HR-QoL 
was associated with having someone to discuss concerns with, hobbies and attending patient-
groups. The perception that there were medical facilities that could care for them (should they 
require it) was also correlated with higher HR-QoL scores (Nishida et al., 2012). QoL is often 
thought of as being directly related to the severity of the disease of the individual, though this 
has not been borne out in studies in PD, MSA and PSP as described above. It is often 
assumed that QoL will fall as disease progresses. The description of the ‘response shift’ 
phenomena describes QoL as a more fluid construct, and factors considered to be important to 
the person can change over time. Re-evaluation of values and how QoL is perceived by the 
individual is likely influenced not only by changing circumstances of life as disease 
progresses but how the individual’s values adjust (Hickey et al., 1996; Spangers, 1999; Lee et 
al., 2006). QoL is significantly affected in patients with MSA and PSP. Tools to measure this 
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have been developed which are disease-specific, but lack comparability between groups (see 
Chapter 3. Methods). Although disease-specific QoL has begun to be studied in MSA and 
PSP and objective disease-specific QoL have been developed, there is a paucity of work on 
the AP disorders in terms of what the individual finds impacts upon their QoL. Neither 
subjective QoL measures nor qualitative work have been carried out in this diverse group, 
limiting the data available to the imposed criteria of traditional HR-QoL scores. 
Key determinants affecting HR-QoL have been explored in MSA and PSP though no 
consensus has been reached, unlike in PD where depression is strongly predictive in several 
studies. As well as the importance of finding and addressing factors which adversely affect 
QoL, positive factors which may preserve QoL are important as they may allow clinical teams 
to introduce measures to ameliorate decline in QoL in patient populations. QoL is a changing, 
subjective construct, and patients may adjust their values and expectations over time. This 
adjustment of values is more difficult to capture with the predetermined domains of many 
HR-QoL tools. This lack of a rounded evidence base, without subjective, holistic views of 
QoL (which by its very nature is a very reflective concept) is lacking in the literature in this 
patient and carer group. 
 
1.3 Carers  
1.3.1 Caregiving and its impact 
Caregivers and the importance of their role in the patient experience have been increasingly 
recognized and discussed as the burden of chronic disease rises. 80% of people with some 
assistance at home receive this from an informal source, usually their partner or family. Only 
10% rely purely on formal services, within the UK (Pickard, 2000). There are around 5 
million carers in England and Wales, nearly half over 65 years of age, and 37% provide more 
than 100 hours of care per week (Health and Social Care Centre, 2010). Carers for people 
with PD have been shown to have lower QoL compared with non-carers and may suffer an 
impact upon their mental well-being, social life and ability to earn (McCrone et al., 2007; 
Hasson et al., 2010; Shin et al., 2012). In MSA and PSP in the UK, unpaid care accounted for 
75% and 76% respectively of social costs in 2011 (McCrone et al., 2011). 
Older carers in the USA had increased 4-year mortality compared to normal controls of 63% 
when associated with self-reported strain (Schulz and Beach, 1999). A number of factors 
influencing caregiver strain have been explored. Strong correlations were found between the 
length of time carers have spent in the caregiving role, the number of hours caring per day and 
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strain. The higher the amount of care provided, the greater the caregiver burden (Litzelman et 
al., 2015). 
 
1.3.2 Factors influencing caregiver strain 
Behavioural and psychiatric problems, including depression tend to be associated with greater 
carer burden in conditions such as Alzheimer’s dementia (Jennings et al., 2015).  A meta-
analysis of 29 studies by Greenwell et al. (2015) found that in the context of PD, 
neuropsychiatric symptoms were associated with poorer caregiver QoL and with caregiver 
depression.  No consistent associations were seen between carer demographic factors, such as 
gender, and poor QoL in this analysis. Leroi et al. (2012) investigated apathy and impulse 
control disorders (ICDs) and the effect these have on strain experienced by carers. Apathy and 
the presence of ICDs were statistically significant in increasing caregiver burden.  
 
1.3.3 Adjustment in caregiving 
Although some studies have shown increasing patient dependency, disease duration and 
severity in PD lead to greater caregiver burden, other sources have found positive or 
stabilising trends in caregiver outlook can take place, with psychological adjustment over 
time (Martinez-Martin et al., 2005; Au, 2011; Oguh et al., 2013). In a Spanish study, there 
were correlations between Parkinson’s patients and their carers employing ‘coping responses’ 
and perceiving positive outcomes from the impact of the disease, such as personal growth and 
psychological adjustment. This adjustment, in turn led to improved QoL (using the PD HR-
QoL tool, PDQ-39) scores in caregivers (Navarta-Sanchez et al., 2016). Suzukamo et al. 
(2006) described the degree of psychological adjustment in PD patients having a greater 
impact on HR-QoL than the severity of their disease. This is of significance in atypical 
Parkinsonian disorders, which have more rapid progression and fewer treatment interventions 
than PD. If interventions to facilitate adjustment can improve HR-QoL in patients and 
caregivers, this might allow an avenue to improve well-being in a patient group with 
significant, progressive symptom burden. As associations between patient and caregiver QoL 
have been found in PD (Martinez-Martin et al., 2005), it seems logical that attempts to 
improve both patient and carer well-being may be effective in the AP disorders.  
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1.3.4 Caregiving in MSA and PSP 
There is a paucity of evidence for caregiver experiences specifically in the context of PSP and 
MSA. Uttl et al. (1998) investigated caregiver strain in PSP caregivers. It was found that 
strain increased with disease severity, then plateaued after 18 months. Patient aggression and 
low mood together with caregiver gender were reported to account for 37% of variance in 
caregiver strain (with female carers reporting more strain). Of relevance to caregiving in MSA 
and PSP, a study on caring in PD found correlations with caregiver stress and falling, 
neuropsychiatric problems and degree of disability. These are all problems which are usually 
seen earlier, and to a greater extent in AP compared to PD, particularly PSP (Schrag et al., 
2006c). From this work, it could be inferred that AP carers would be expected to have more 
strain than carers of people with PD. Qualitative work with PSP patients and their carers, 
found caregivers felt a burden of acting as educator, not only to the public about their 
relative’s disease but to medical and community practitioners. The importance of support and 
information-provision in PSP is in keeping with the findings in caregiving in PD, in which 
support, even if not accessed (‘perceived support’- the belief that help was available, should it 
be required) acted as a protective buffer against caregiver stress (Edwards and Scheetz, 2002; 
Martinez-Martin et al., 2014; Greenwell et al., 2015). 
The understanding of the impact progressive disease has upon caregivers is established. In the 
context of PD, the interrelationship between the QoL of patients and their carers has been 
described, as well as certain factors which can worsen caregiver strain such as patient 
depression. Informal care provides the bulk of support for patients with a large hidden cost. 
Efforts to understand the impact of care in MSA and PSP are needed to try and support carers; 
which, in turn may confer a positive effect on patient QoL. This is one of the aims of this 
study. 
 
1.4 Palliative Care  
1.4.1 Definition of Palliative Care 
The 2002 WHO definition of palliative care (PC) is ‘Palliative Care is an approach that 
improves the quality of life of patients and their families facing the problem associated with 
life-threatening illness, through the prevention and relief of suffering by means of early 
identification and impeccable assessment and treatment of pain and other problems, physical, 
psychosocial and spiritual’ (World Health Organisation, 2002).  
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The current definition of PC also takes account psychological and spiritual aspects of living 
with disease, the grieving process, quality of life and crucially, integration of PC to therapies 
intended to prolong life. There is also understanding of the needs of family and carers and 
how their needs can be addressed by comprehensive PC. PC should be utilised by existing 
healthcare systems to provide support throughout the course of illness. There is also the aim 
that PC should be offered across the health-care spectrum; by generalists as well as specialists 
and in community settings (Sepulveda et al., 2002).  
 
The current practice of PC arose from the care of patients with malignant disease. It is 
becoming increasingly apparent that patients with non-malignant, life-limiting conditions can 
benefit from a ‘palliative approach’. Review of evidence outlined this approach as applying 
PC principles early (the ‘upstream approach’) and adapting current practice to new 
populations of patients and practitioners caring for them (Borasio, 2013; Creutzfeld, 2016; 
Sawatzky et al., 2016). PC as an approach has a growing and important role in enhancing the 
experiences of patients with neurodegenerative disease and the people who care for them. 
Some of the characteristics of neurodegenerative diseases which lend themselves to the 
application of the palliative approach include prolonged morbidity with effect on QoL as well 
as social impact with issues which PC teams traditionally manage such as pain and nausea 
(Kristjanson et al., 2003). 
 
1.4.2 Specialist Palliative Care (SPC) versus the Palliative Approach 
There is a distinction between clinical professionals who specialise purely in palliative care, 
whether in hospital, hospice or community settings, known as Specialist Palliative Care (SPC) 
and practitioners, clinicians or medical-team members who employ the palliative approach. 
Different authorities have defined SPC in different ways, depending upon tradition, changing 
times and region but at its heart, SPC is carried out by MDT teams whose purpose is the care 
of patients and families with palliative needs, chiefly who require this care due to complexity 
(NICE, 2004). 
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Figure 1.2: The roles of the palliative approach and SPC and their overlap from Wiblin (2017). General 
palliative care may be thought of as holistic or multidisciplinary care in the context of other conditions 
 
The palliative approach is a style of care which can be employed by all medical and 
multidisciplinary practitioners. It considers the needs of the individual with chronic, 
progressive conditions, incorporating recognition of the whole person (not just medical 
needs), family needs and support in making decisions for the future. It can also be thought of 
as ‘basic’ palliative care, though a palliative approach undertaken by specialists in their own 
fields (such as renal medicine or neurology) can have profound and positive impacts on 
patients and families within the structure of a department very familiar with that type of 
disease (Sepulveda et al., 2002). There are challenges to this, including constraints of time, 
education and confidence to use a palliative approach on behalf of the clinician and whether 
the constellation of problems the patient has is especially complicated (Fox et al., 2016). This 
might prompt those familiar with the palliative approach to involve SPC. The distinction and 
overlap between the palliative approach and SPC is shown in figure 1.2 
In the context of life-limiting illnesses with uncertain trajectories which require advance care 
planning and complex symptom management, describing the approach of care as ‘a palliative 
approach’ is appropriate. Other conditions which may have marked effects on QoL but 
without reducing life expectancy should have the benefit of a similar strategy with time, 
rapport and multi-disciplinary care emphasised; but perhaps should be known as a holistic or 
multi-disciplinary approach.   
17 
 
Increasingly, as the needs of patients with complex diseases are delineated, the requirement to 
familiarise clinicians with palliative approaches, to educate and create links with SPC teams 
will grow to maximise patient well-being and quality of care (see figure 1.3). Different 
geographies and healthcare systems will necessitate different models to embrace this concept. 
Rural areas may comprise of community teams linking up to a hospital specialist clinic. Very 
rare conditions could have a super-specialist team who could advise and guide local teams, 
particularly if the patient becomes too frail to travel to a distant centre.  Handing over in a 
measured way with good communication to a colleague in community neurology or palliative 
care could maintain good care and connection with housebound patients. In the future, 
teleconferencing to allow liaising between teams, and possibly as a means for specialist 
review for patients too infirm to leave their homes, may offer an opportunity to continue a 
trusted relationship between a specialist and a family without a sense of abandonment when 
travelling to a clinic is no longer possible. 
 
Figure 1.3: A model of the palliative approach as chronic disease progresses from Wiblin (2017) 
 
1.4.3 Trajectories of decline and future planning 
Patterns of deterioration in disease have been studied in an effort to allow identification of 
patients approaching the end of their lives, allowing planning and mobilisation of services 
such as PC, carer-respite and hospice services. Glaser (1968) described four distinct 
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trajectories (though patients with the same disease may demonstrate different or mixed 
courses): 
1. Sudden death (acute illness or accident). 
2. Terminal decline, with low disability until a rapid decline is experienced. Classically 
described in cancer when the disease becomes refractory to life-prolonging treatment.  
3. Frailty, portrayed as a steady decline with accumulation of morbidity eventually 
leading to death. 
4. ‘Organ failure’ trajectory –background deterioration with unpredictable ‘crises’, 
leaving the individual with greater disability, should they recover.  This gradual 
decline in a very heterogeneous group with the added strain of uncertainty of a sudden 
terminal event can be a huge burden for individuals and families, and difficult for 
clinicians to assess and treat appropriately. The neurodegenerative diseases, 
encompassing PD, MSA and PSP as well as renal failure and progressive lung 
problems like chronic obstructive pulmonary disease (COPD) often fall into this last 
category (Lunney et al., 2002). 
A prospective study of older people in nursing homes delineated their course of decline and 
how these were managed in the community. ‘Uncertain dying’ took place in 7 of the 23 
deaths observed.  The hallmark of the uncertain course was a lack of predictability and lack of 
clarity as to whether patients would survive the worsening of their condition. This led to 
hospital admissions and in one case, death in hospital, when the nursing home was the 
preferred place of death. This is very pertinent in neurodegenerative disease, AP in particular. 
There is early morbidity and a complex symptom load. Exacerbations precipitated by 
infection have the possibility of being the terminal event. Most patients with AP will be in the 
community (home or nursing home) when they experience an acute worsening of their 
condition (Snell et al., 2009). Prior discussion and planning a setting for care may be 
reassuring for patients, relatives and medical and care practitioners, especially if patients 
cannot communicate their wishes by the time of the decline. By the very nature of fluctuating 
and heterogeneous (i.e. ‘uncertain’) neurological disease, it is difficult to anticipate time-
frames and outcomes accurately, but this study suggests that it might be prudent to consider 
discussion and planning with patients. One trigger to discussion might be residing in a nursing 
home with a progressive disease. Work has been undertaken to try and understand patterns of 
change which might predict decline in neurodegenerative disease such as MSA and PSP to 
allow discussions, and mechanisms to bring in more support, such as physical symptom 
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control and carer assistance (see table 1.5). Planning and communication of uncertainty in a 
sensitive way can be thought of as part of the patient management within the palliative 
approach (Murtagh et al., 2004; Barclay et al., 2014).  
 
Possible indicators of decline in MSA and PSP 
Weight loss 
Recurrent infection 
Increased frailty 
Significant cognitive impairment 
Aspiration pneumonia 
Dysphagia 
Frequent hospital admissions 
Increased complexity of symptoms 
Table 1.5:  Features that may predict deterioration in MSA and PSP. From Wiblin (2017) and the National 
Council for Palliative care (2009) 
 
Advance care planning (ACP) is a key part of palliative management which can empower 
patients and relatives by making their wishes known, especially if there is likely to be decline 
in cognition and/or communication as part of the disease process. ACP has been defined as 
decisions made by a patient, with the support and input of their medical team, family or 
friends, about their future care and preferences in the event they do not have the capacity to 
make decisions or communicate them meaningfully in the future (Detering et al., 2010)Like 
all PC, this is a process rather than a single statement of intent to be completed, then filed 
away. Statements of treatment preferences such as whether an individual would want a 
percutaneous endoscopic gastrostomy (PEG) to permit feeding should swallowing become 
markedly impaired, should be re-explored where appropriate. This is because people’s beliefs 
and choices can change over time. What may have seemed undesirable at an early stage of 
disease, such as a PEG, may now seem appropriate to the individual as they recalibrate and 
adjust to their new circumstances (Sudore and Fried, 2010; Bischoff et al., 2013). Thus, 
reassurance that decisions are not ‘set in stone’ must be made.  Patients can change their 
minds and the process should be more like a dialogue with patients, families and clinicians so 
that ultimately all the information possible is available for clinicians to facilitate informed 
decisions toward the end of life. This is particularly relevant if patients are no longer 
competent or able to take part in decisions as their disease advances (Sudore et al., 2014). The 
other key point is that choosing not to consider the future in terms of treatment options and 
decisions for the future; relinquishing this responsibility to clinicians (aided by family input) 
is equally as valid a choice, and considers patient wishes. For some, these discussions may be 
frightening and unwelcome. PC ought to take each person’s disease, outlook and evolving 
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ideas into consideration to improve their lives today and as disease evolves (Scott et al., 
2013). This reassurance is equally valid for family members with Lasting Power of Attorney 
(LPA) for Health, who may feel pressure to make difficult decisions for their family member, 
which can cause distress. They have the choice to defer their legal right to give a decision on 
behalf of the patient, should they wish to. Relatives with LPA may not be aware of this, and 
care should be taken to support them.  
There is some evidence that ACP can improve the patient experience at the end-of-life as well 
as reduce family stress and anxiety after death. A randomised controlled trial comparing 
formalised ACP with usual practice in elderly patients in Australia found significant 
differences in wishes of patients being known as observed, improved patient satisfaction and 
depression scores in relatives after patients in the ACP group had died (Detering et al., 2014). 
In terms of ACP when capacity is expected to be lost, possibly earlier in the course of disease 
due to cognitive decline or communication difficulty, it is important to recognise that the time 
for patients to consider and relate their wishes may be more limited, and patients and families 
need to be aware of this and supported through this to relay their preferences. Although there 
may be some interest to discuss these issues, it may be that the MDT needs to revisit and 
discuss these issues as patients and families may not take the initiative, which can be difficult 
when capacity could be lost in an uncertain timeframe. Work has shown that in a group of 
patients with dementia , patients and carers expressed some enthusiasm to make preparations 
and plans for the future but continued impetus was not maintained, especially if patients and 
families had to organise further discussions (Lewis et al., 2015). 
ACP has some evidence but is a difficult area to research, particularly in the context of 
cognitive impairment and collecting information at such a sensitive time as at the end-of-life. 
It has become part of SPC practice and is recommended as part of holistic care for progressive 
disease in the UK. ACP should be considered early in conditions with impacts on cognition 
and communication, which can add to the challenge of caring for these patient groups. 
 
1.4.4 Palliative need in Parkinsonian disorders 
In the Parkinsonian disorders, there is growing acknowledgement of the benefits for patients 
and carers in embracing a palliative approach to enhance management.  In a study involving 
109 patients with PD, symptom burden scores were comparable to that of patients with 
metastatic cancer (Miyasaki et al., 2012). PSP and MSA patients reach clinical milestones 
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such as wheelchair-dependence or frequent falls earlier in their disease and can live with these 
accumulating burdens for some years (O'Sullivan et al., 2008).  
 
A longitudinal study of advanced PD, MSA and PSP over 12 months, measured palliative 
care need, symptom burden and QoL measures.  Two thirds were living with profound 
symptoms and functional impairment. Most PSP patients had a Hoehn and Yahr score of 5, 
and nearly half (47%) had this score in MSA. Furthermore, half of the patients deteriorated in 
symptom burden or level of distress during the study; survival in MSA and PSP was poorer 
than in the PD sub-cohort. This suggests that the palliative care need in Parkinsonian 
disorders is present, serious and progresses over time. The observation that many of the 
symptoms which impact upon patients (such as pain and shortness of breath) are managed 
routinely and with effective interventions in PC settings for cancer patients, reinforces the 
appropriateness of a palliative approach in movement disorder services (Higginson et al., 
2012). In patients with severe neurodegenerative disease (including MSA and PSP), fast-track 
palliative care compared with usual care gave significant benefits in HR-QoL as well as pain, 
sleep-quality and bowel problems. An interesting finding was a decline in psychological well-
being. One theory is that this may be due to patients facing the progression of their life-
limiting illness. Although not discussed further, the process of adjustment might have been 
accelerated in this group by psychological interventions. Contrasting psychological well-
being between the intervention group and the control arm after a period might have shown 
whether this was the case (Veronese et al., 2015).  
 
1.4.5 Barriers to Palliative Care 
In practice, many practitioners find introducing PC as a concept to patients and relatives to be 
difficult. Barriers to accessing SPC have been explored in the context of cancer treatment in 
the USA. Analysis of surveys from practitioners identified inadequate training in the 
palliative approach and financial constraints to its use, preventing more extensive provision of 
PC to oncology patients in these centres (Davis et al., 2015; Ramchandran et al., 2015). A 
Japanese perspective showed a wide range of perceived barriers to PC provision from 
palliative care practitioners. These included inadequate training in communicating the nature 
of PC by non-specialists and poor public understanding. End of life care, euthanasia and 
palliative care were confused with each other (Miyashita et al., 2007). 
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To explore acceptability and negative associations, the term ‘palliative care’ and ‘supportive 
care’ have been compared. Oncologists were recruited to explore with their patients, their 
perceptions of the terms ‘supportive care’ and ‘palliative care’. Supportive care was seen 
more favourably by patients. Palliative care was described by some respondents as care given 
to people at the end of their lives, whereas the impression of supportive care seemed to be 
holistic, encompassing psychological support and information. One interesting inclusion in 
the article was the refusal of one oncologist to participate in the study as they did not want to 
use the term ‘palliative care’ with their patients (Maciasz et al., 2013). This suggests that the 
perception of PC held by some physicians, as well as the public, remains in the end-of-life 
domain. Whether the ‘brand’ of palliative care needs to be reviewed by a name-change or by 
education, the obstacles to incorporating palliative management are multifactorial but 
perception plays a role. Might differentiating between general palliative care and end-of-life 
care improve acceptability of an integrated service? 
Finally, as well as enhancing QoL it may be that patients who receive prompt PC have better 
outcomes. In patients with non-small cell lung cancer, early PC did not shorten survival. The 
early palliative care group actually had longer survival, required a shorter hospice stay at the 
end-of-life (‘less aggressive end-of-life care’) and significantly improved QoL and depression 
(Temel et al., 2010). This suggests that early optimisation of symptom-control and contact 
with palliative care is of long-term benefit. It has been theorised that better QoL can produce 
survival benefit, at least in terms of non-small cell lung cancer (Movsas et al., 2009; Irwin et 
al., 2013). A study looking specifically at palliative care intervention in patients with PSP and 
CBS, found that after admission to a PC setting for symptom-control, 68% of admissions led 
to improvement or stabilisation of symptoms. 75% could be discharged home. There was 
marked burden of symptoms found in this group and the finding that hospice admission 
helped control these symptoms and in some cases, improve patient status and facilitate 
discharge, shows PC has a role in managing AP. 
There is growing recognition of the benefit of the palliative approach in neurodegenerative 
conditions. Evidence is emerging showing AP patients would benefit from addressing 
palliative care need. Further work to explore the palliative need of MSA and PSP patients and 
QoL in patients and their carers may help develop interventions to improve QoL, especially 
pertinent with the reduced survival of these disorders. 
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1.5 Summary 
Quality of life is an important issue to consider in the treatment of MSA and PSP. Given the 
multidimensional and subjective nature of QoL, one way to facilitate this is through 
assessment of palliative care requirement and application of a palliative approach. Diagnosis 
and management of AP is often not straightforward, as they are heterogeneous disorders with 
uncertain trajectories. This presents challenges for not only patients but also their carers and 
clinical teams hoping to treat and prepare patients for the future. This work hopes to clarify 
and discuss some of these issues, from the patient and carer point-of-view, with a mind to the 
clinician caring for patients with these complex conditions.  
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Chapter 2. Aims 
 
The aims of this MD project will be explored over three results chapters and then evaluated in 
a discussion chapter. This project will explore the demographics of the patient and carer study 
cohort, the onset of important clinical milestones (such as need for a wheelchair) and their 
relationship to diagnosis. Palliative care need using a validated scale will be compared 
between the two disease groups and patients’ understanding of palliative care services will be 
assessed. QoL will be compared between groups (patients and carers) using a range of 
measures such as disease-specific and subjective and factors which might predict for these 
different aspects of QoL will be analysed. The final results chapter will investigate the 
personal outlooks of patients and carers, using semi-structured interviewing with a sub-set of 
participants which will be thematically analysed. This aims to add a fuller, patient-centred 
dimension to this work. 
 
2.1 Chapter 4 aims 
In Chapter 4, the first aim was to determine whether the patient demographics of this cohort 
were in keeping with previously described literature on MSA and PSP. Following this, the 
second aim was to describe the onset of ten key clinical milestones and how they related to 
the time of their diagnosis. Thirdly, patients’ symptom burden (palliative care need) in terms 
of features such as pain or depression were described and a validated scale for palliative care 
need (POS-PD) was completed by all patients in order to quantify and compare differences in 
symptom burden between MSA and PSP patients. Finally, perspectives on palliative care and 
its purpose were examined in the two patient groups. 
 
2.2 Chapter 5 aims 
In Chapter 5, QoL was explored in the MSA and PSP patient groups. The first aim was to 
appraise disease-specific QoL in participants with MSA and PSP and whether demographics 
or other study variables might predict for these scores using regression analysis. Secondly, 
subjective QoL using the SEIQoL-DW score was measured in MSA and PSP patients, their 
scores were compared to each other, and then whether any study variables might predict for 
these scores, again using regression. Finally, the domains participants nominated in the 
SEIQoL-DW were evaluated. 
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2.3 Chapter 6 aims 
In Chapter 6, the demographics of the carer participants were assessed, and their level of 
strain and QoL were investigated using validated questionnaires. Firstly, demographic 
information was analysed using descriptive statistics. Secondly, caregiver strain was analysed 
using the MCSI; comparison was made between the two carer groups. Then study variables 
that might predict for MCSI were evaluated using regression analysis. Thirdly, a specific 
scale exploring QoL in carers of people with Parkinsonism was used, comparison was made 
between the two carer groups, and regression analysis was used to see if any study variables 
predicted for this. Lastly, subjective QoL was assessed using the SEIQoL-DW and regression 
analysis was used to look for predictors for these scores. Finally, comparisons between the 
two carer groups (and also the two patient groups) in terms of subjective QoL were made. 
 
2.4 Chapter 7 aims 
In Chapter 7, the aim was to explore the concerns and perspectives of a subset of participants 
(using purposive sampling to achieve a balance of viewpoints in terms of sex, patient and 
carer as degrees of severity, including communication difficulty) by analysis of semi-
structured interviews. The goal in this section was to attain a rich, nuanced description of 
living with these conditions from a patient or carer perspective, which may provide insight on 
how clinical systems serve this group and avenues for meaningful research in the future. The 
semi-structured interviews were designed to give participants an opportunity to describe their 
experiences in-depth, but the schedule afforded guidance to the interviewer and participant to 
cover key topics such as the process of diagnosis, living with a chronic, progressive condition 
and outlooks on services such as palliative care.  
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Chapter 3. Methods 
 
This chapter will describe the procedures and methods used in the study. Elements specific to 
particular chapters will be discussed in the respective introductions.  
 
3.1 Methodology 
This study used both quantitative and qualitative methods. Each of these distinct methods 
uses different assumptions and has advantages and disadvantages in their application. I will 
discuss these two paradigms and the reasons for their use in this study. 
 
3.2 Quantitative methods 
Quantitative methods seek to explain observations numerically, usually by the application of 
statistics or other mathematical modelling. The quantitative paradigm assumes positivism (a 
fixed reality which is not affected by observer perception), which is reliant on certain 
assumptions such as empiricism or measurement of observable phenomena, that scientific 
method is value-free, and that subjective perceptions or beliefs have no bearing on the 
scientific truth. Positivism was developed in the context of the natural sciences (Green and 
Thorogood, 2014). 
A theory or hypothesis is tested by measuring variables and analysing relationships or making 
predictions from this. It is assumed that the researcher is objective during this process and 
their attitudes should not influence what is being studied. To this end, many techniques have 
been developed to enable this, including randomisation, blinding, and highly structured 
procedures/protocols to produce standardised responses that are amenable to numerical 
analysis and to reduce bias. The results generated are therefore considered to be generalisable 
beyond the sample of the population studied. The quantitative model is deterministic 
(meaning that actions and events cause or determine further events) (Sale et al., 2002; 
Yilmaz, 2013).  
In order to allow quantitative analysis of trends or perceptions in a population, structured 
surveys can be used which produce objective and comparable results which can then be 
generalised from the study population to wider populations (Creswell, 2009b). The 
quantitative method can be summarised as requiring a hypothesis or theory which the 
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researcher then seeks to disprove using formal experiment and deduction. Table 3.1 covers 
some strengths and limitations of the quantitative approach.  
 
Key Features in the Quantitative Approach 
Useful in establishing extent of correlations, 
associations and predictions 
Lacks flexibility 
Empirical method reproducible and more objective Does not permit recognition of human behaviour as 
unpredictable and varied 
Efforts to be objective methods to reduce bias 
(important in randomised controlled trials) 
Large numbers preferable to provide sufficient 
statistical power 
Generalisable Experiences must be “fitted” into fixed responses e.g. 
closed response questionnaires 
Results can be summarised succinctly (numerically) Statistical analysis may produce a simplification or 
misleading view of phenomena 
Table 3.1: Features of the quantitative paradigm in research. From Green and Thorogood (2014), Baum (1995) 
Yilmaz (2013) Klassen et al. (2012) 
 
3.3 Qualitative methods; considerations, thematic analysis 
Qualitative methods cannot be defined by their methods of data-collection, nor by the type of 
data collected; though qualitative methods do tend to use language-based data rather than 
numerical and use certain techniques such as interviews (though quantitative methods may 
explore linguistic data or use interviews in some cases) (Green and Thorogood, 2014). 
Whereas the quantitative method tests a theory via measurement and statistical analysis of the 
relationship between variables, the qualitative method attempts to describe the ‘how’ and 
‘why’ of phenomena. The aim is to understand more about subjective perceptions of a subject 
rather than seek to measure variables on the subject (Pope and Mays, 1995). The overarching 
qualitative method (which comprises of many theoretical and epistemological schools) is 
defined by Gay and Airasian as ‘the collection, analysis and interpretation of comprehensive 
narrative and non-numerical data to gain insights into a particular phenomenon of interest… 
qualitative researchers do not necessarily accept the view of a coherent and stable world.’ 
(Gay, 2013). Although there are many differences in qualitative methods and theoretical 
stand-points in this diverse approach, some commonalities can be seen in qualitative work, 
which I have discussed below. Figure 3.1 shows the hierarchy of standpoints in research, from 
the overall theory of knowledge, down to methods or techniques used.  
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Figure 3.1: Hierarchy of understanding in research theory and positions. From Gray (2014) and Crotty (1998) 
 
Interpretivist: In contrast to the positivist philosophy espoused in quantitative work, many 
qualitative methods are based within interpretivism. This describes the differences between 
the natural reality which can be explained by laws of science (for example, gravitation) and 
the social reality of how individuals perceive events and therefore how their behaviour is 
affected. Consequently, the methods used to attempt to understand and explain human 
behaviour must be distinct from the empirical methods of natural science, trying to take this 
individual reality into account. This is important in the context of health and social sciences, 
where human factors and the interplay with disease require an understanding of why people 
behave how they do, to understand how to better manage healthcare (Gray, 2014; Green and 
Thorogood, 2014). There are ‘intermediate’ standpoints. The standpoint of realism has some 
features in common with positivism in that it states that there is a reality that can be 
understood. Critical realism tries to integrate natural sciences and the social sciences. A 
researcher can use analysis and generate theory in order to better understand the social reality 
they are studying, in order to try and produce change or improvements (this is a commonly 
subscribed theory in economics and the social sciences) but the researcher’s concept of reality 
is not the only reality (as positivism would have it) (Fletcher, 2017).  
Naturalistic: Bearing in mind the contextual importance in human behaviour, qualitative 
methods recognise the importance of research in as-natural an environment as possible to try 
and capture a more realistic view of the subject. In-depth interviewing is one approach to this. 
It must be kept in mind however, that the setting of an interview is still fairly artificial, though 
may allow a more natural response than techniques used in quantitative work (Bryman, 
2008b). Table 3.2 discusses some of the strengths and limitations of the qualitative approach.  
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Flexibility:  a process of ongoing reflection and refinement of methods, allowing 
modification of the research method and question as analysis is carried out (Braun and Clarke, 
2006). 
 
Key Features in the Qualitative Approach 
Produces rich, detailed accounts exploring the 
‘why’ of phenomena 
Lacks reproducibility and generalisability 
Small samples can be used; useful for rare 
conditions 
Methods to ensure transparency and rigor less defined  
Flexibility of approach More difficult to succinctly represent results 
Allows contextual understanding of different 
viewpoints 
Researchers must account for their own beliefs in 
their analysis (reflexivity) 
Table 3.2: Features of the qualitative paradigm in research. (Bryman, 1984) (Sale et al., 2002; Bryman, 2008b; 
Yilmaz, 2013; Green and Thorogood, 2014) 
 
A plethora of methods exist within the qualitative armoury, such as observational 
ethnography, focus groups, in-depth interviews and analysis of written documents. This 
project has used a combination of quantitative methods, namely validated questionnaires and 
structured clinical examination, together with semi-structured participant interviews. These 
methods were selected pragmatically to achieve meaningful results allowing comparison, 
correlation and some prediction between conditions as well as exploring perspectives on 
living with these rare conditions, and their impact upon the individual.   
 
3.3.1 Thematic analysis 
Thematic analysis (TA) is increasingly seen as a key method in qualitative analysis, one 
reason being that learning to generate themes is held in common throughout many techniques 
used in the qualitative approach. Although some qualitative researchers regard thematic 
analysis as a technique learned within different qualitative disciplines, Braun and Clarke 
(2006) argue that thematic analysis is a practical method in itself which can be carried out in a 
systematic way, yet with the advantage of flexibility. This flexibility is borne of thematic 
analysis’ freedom from theoretical constraints and assumptions which other techniques such 
as Grounded Theory (producing a theory from the data ‘grounded’ within it) are subject to 
(Charmaz, 2006). This can be understood by TA being a method or technique rather than a 
theory-embedded methodology that can be employed within many theoretical models as 
appropriate (Braun and Clarke, 2013). 
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TA of in-depth interviews was selected as the analytical method for this research project due 
to its versatility and the key feature of producing themes to give nuanced views of data, 
themes being a common feature of many types of qualitative methods. Although many studies 
which use TA as a method claim to adhere to Grounded Theory (GT), they may not fully 
conform to the true methodology, as GT requires the ground-up production of theories from 
data collected, without preconceptions from previous literature. The defined research aim 
(crucial in most research proposals in terms of ethical and funding applications) are also not 
true to GT which requires the question to be generated as the data is collected and analysed 
(Bryman, 2008b; Creswell, 2009b). 
The suitability of TA to this study is its power to allow detailed description of heterogeneous 
subjects (participants with differing conditions at varying stages of severity, carers of 
differing ages, and sex) and explore similarities or differences. The flexibility of TA is helpful 
considering the theoretical stance of the project; a compromise between an inductive approach 
to the data, making conclusions from ongoing analysis but conceding that some deductive 
(theory-driven) element exists, in that a prior literature review took place and a research aim 
was in place from the beginning, albeit a broad one (Boyatzis, 1998; Frith and Gleeson, 
2004). 
 
3.3.2 Assumptions and standpoints at outset 
It is important to define viewpoints and the position of the interviewer at the outset of a 
qualitative project, as reactions to different individuals may vary (for example, participants 
may respond differently to men and women interviewing). These declarations are important in 
terms of transparency and trustworthiness in qualitative work (Golafshani, 2003). I have laid 
out these statements below. 
As the interviewer carrying out the interviews, I was also a clinician with prior doctor-patient 
relationship with many of the participants. This may have affected the power dynamic of the 
interviews and the discussion of disease and perspectives on clinical input by the participant. 
In some cases, it was difficult to widen the focus of interviews, at least initially, as 
participants (particularly patient-participants) seemed to treat the interview as a clinical 
consultation and described their symptoms, though all were able to give wide and varied 
accounts; the semi-structured design of the interviews was helpful with this.  
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The approach taken to analysis was mainly an inductive or data-driven one, rather than 
imposing pre-conceived theory upon the data. However, a literature review was carried out in 
preparation of the project as well as conceiving the research aim prior to beginning data 
collection.  Therefore, some theoretical context was known before data collection in relation 
to the research question.  
The theory of knowledge held when the project was designed was a realist one, assuming that 
that individual’s perceptions and motivations have a straightforward relationship with 
language used. The contrast to this is constructivism, which considers the psychosocial 
frameworks that bring about individual’s responses rather than the meanings of individual 
responses themselves. Realism looks for meaning in the individual’s descriptions whereas 
constructivists are concerned with contexts and interactions and how these might shape 
individual accounts (Braun and Clarke, 2006; Creswell, 2009b; Gray, 2014). Throughout the 
project, my standpoint did not alter and I feel the epistemology remained realist throughout 
data-collection and analysis.  
 
3.3.3 Sampling for qualitative phase 
Sampling from the quantitative arm of the study for the interviews was conducted using 
purposive sampling rather than random selection from those who consented to being included 
in the interview arm. This was to achieve good representation of different groups for example, 
patients and carers, MSA or PSP carers, male and female and different stages of 
severity/communication ability. Some special sampling was used to include participants with 
marked communication problems as their contribution was seen to be especially valuable, as 
previous research has not included participants with these difficulties. By necessity, 
pragmatism had to be used as many of these patients have advanced, complex disease so 
participants who interviewed were selected purposively in the main, but were those who were 
physically well enough during the data-collection period and were enthusiastic to take part. 
This is a limitation to be aware of, though efforts were made to interview as diverse and 
representative a range of individuals as possible (Pope and Mays, 1995; Plano Clark, 2008). 
 
3.3.4 Process of Thematic Analysis 
Practitioners of TA, like GT have sought rigour in terms of the process of analysis. Braun and 
Clarke (2006) have described guidelines to this process.  It is an essential part of the 
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qualitative approach to remember that throughout data collection, transcription and analysis, a 
cyclical process should be followed rather than a linear one. The data, codes and themes 
should be revisited and re-explored as the project advances and is analysed (Bryman, 2008b). 
See figure 3.2.  
 
Figure 3.2: Stages of Thematic Analysis from Braun and Clark 2006 
 
The data produced from interviewing of participants is extensive. Some of the interviews 
were transcribed by the primary researcher, namely the first two to allow familiarization of 
the process and appreciation of the process of verbatim transcription, as well as interviews 
which were challenging to transcribe due to speech difficulties or semantic problems of the 
participants. Others were transcribed by a reliable transcription service which has been used 
by Newcastle University and local NHS services in the past. 
When transcription was completed into a Word file, repeated reading and note-taking began, 
coupled with listening to the original recorded interviews to ensure context and meaning were 
not lost, including non-verbal responses, pauses and intonation affecting meaning (especially 
34 
 
if the transcript was produced by the transcription service). Field notes were also considered 
during analysis. Codes were then produced. Coding gives a name to a section of data in an 
effort to sort and understand it (Charmaz, 2006). In this report, codes are distinct from 
themes, the latter being a more refined, and overarching product of analysis of constituent 
codes produced from the data. Coding was data-driven (derived from the data available rather 
than codes produced looking specifically in response to research questions and then data 
‘fitted’ into it, though as the interviews were semi-structured, some a priori theoretical 
‘scaffold’ does exist. 
As codes were produced from interviews, themes began to coalesce from the many codes 
generated. Themes are patterns within the data, seen by the process of encoding it and permits 
explanation or interpretation of an aspect of the data (Boyatzis, 1998). At this point, 
reviewing literature against these themes and reviewing the coding as well as thematic 
structure began. Themes were then defined and labelled and the report was constructed using 
meaningful extracts from the data to support the analysis (Braun and Clarke, 2006; Braun and 
Clarke, 2013). Interviews were ongoing throughout these stages and ended when no more 
important patterns were recognised during analysis. Nineteen interviews were carried out in 
total, above the initial estimate (of ten), as saturation was not felt to occur until that point. 
Theoretical saturation, originally defined in the context of GT, describes the point at which no 
new insights are being added by further data collection (Bryman, 2008b). 
 
3.4 The Mixed Methods approach 
Quantitative and qualitative methods, as discussed above, have different strengths and 
limitations. To try and embrace this, a combination of methods, the concept of ‘mixed 
methods research’ integrates these paradigms together to gain a more comprehensive view. 
The aim of mixed methods work is to offset the perceived failings of one outlook by using 
techniques from the other. There are varying definitions and approaches to mixed methods 
research and there does not need to be equal weighting of the two disciplines; a study may 
have a majority of quantitative method yet still conform to a mixed method model for 
example (Bryman, 2008a) 
There are some proponents that claim mixed methods as a concept is not feasible as the 
quantitative positivism and qualitative intrepretivism are at odds. Therefore, how can they be 
combined? Pragmatism tries to reconcile these viewpoints by seeking to adhere to a position 
of compromise. It states that an ideology is of no use if its paradigm acts to constrain the 
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acquisition of knowledge and a more ‘realistic’ view of the world. Therefore, a research 
outlook should be based on an intermediate standpoint, taking into account elements of 
positivism and interpretivism, provided this stance allows the acquisition of knowledge which 
will bring benefit to learning and/or society. In some ways, pragmatism requires the 
combination of quantitative and qualitative techniques, else there cannot be truly nuanced 
understanding of complex subjects where there is a combination of numeric and human 
factors, such as those found in medicine and economics (Feilzer, 2010) 
There are a number of ways that methods can be mixed. There are also a number of terms to 
describe how the combining of methods can be achieved and what form of mixed methods 
project will be produced. One type of mixed method construct is sequential design. Either a 
quantitative portion can precede a qualitative portion (explanatory sequential - the qualitative 
work is guided by the typically greater weighting of the quantitative work) or initial 
qualitative data informs what quantitative data is gathered (exploratory sequential).  Other 
techniques may be embedded, collecting quantitative and qualitative information 
simultaneously. Data is often transformed so that it can be integrated together meaningfully 
for analysis. This is often described as ‘triangulation’ in which multiple data types collected 
by differing methods are analysed together to seek validity and consistency of findings. There 
are arguments that qualitative data cannot be ‘numericised’ or made to fit in with quantitative 
work in a way that retains its content, though matrices, sometimes using computer software 
are available (Bryman, 2008a; Bryman, 2008c; Creswell, 2009a).  
Mixed method studies cannot be assumed to negate the inherent problems in quantitative and 
qualitative research but a well-designed project may produce a richer and more considered 
perspective on complex research questions.  
Is this project a mixed methods study? I would argue that, despite the advantages of claiming 
it as mixed methods, it is not truly so. It could be posited that the study takes the form of a 
sequential mixed methods project with a degree of results-combination at the point of 
analysis. However, I would argue that mixed methods studies require integration; either at the 
data collection or analysis stage (or both). This study evolved from a purely quantitative study 
mainly concerned with exploring QoL. The importance of subjective QoL became clear 
during the planning and literature review stage and this then led naturally to the utility of 
qualitative interview work as a means to gain detailed, personal accounts from participants 
using qualitative analysis. There was separate analysis and then results were described in a 
complementary but not integrated way. Therefore, this study could be described as using 
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quantitative and qualitative methods to achieve fuller, richer conclusions rather than 
sequential mixed methods work. 
 
3.5 Quantitative and qualitative summary 
Quantitative and qualitative methods have differing approaches and outlooks. Pragmatically, 
these approaches can explore different problems or issues in different but often 
complementary ways. For example, a positivist, deductive outlook using a quantitative 
approach in drug trials to reduce bias, allows comparison and summarises results 
parsimoniously, which is important when judging the safety and efficacy of a drug. An aspect 
of the drug trial which requires a more subjective view, is exploring the reasons people have 
for taking part in a drug trial. This would suit a qualitative approach, perhaps using interviews 
or focus groups and a range of qualitative methodologies such as grounded theory or thematic 
analysis. Some research seeks to use the strengths of these approaches together, employing 
‘mixed methods’, overcoming conflict between the two paradigms. This can be done in 
different ways but all combine quantitative and qualitative methods to look at the same data, 
known as triangulation (Plano Clark, 2008). 
This project is not a true mixed methods study according to this definition, as it uses the 
quantitative approach for some of its aims and a qualitative approach to others without trying 
to integrate the results. It uses these paradigms in a complementary fashion, seeking a more 
holistic view of the overall conditions being investigated. However, this project does use 
some mixed methods, especially when interviews’ overarching themes are compared with 
their SEIQoL-DW nominated areas (which were gathered in the quantitative portion of the 
study). This was an effort to understand if the more concise SEIQoL-DW can act to capture 
some of the concerns voiced by participants in their interviews (which are shown in Appendix 
C). 
 
3.6 Evaluating research validity 
In quantitative, cross-sectional research, quality is measured by replicability, reliability, and 
validity. In this study, efforts were made to ensure:  
Replicability by using a defined protocol of questionnaires and examination instruments for 
each participant group e.g. MSA patient, PSP patient, MSA carer or PSP carer. This could be 
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carried out by a research practitioner (with training in the use of the instruments employed) if 
they had access to the protocol. 
Reliability or consistency of a measurement. All questionnaires used in the study have been 
deemed reliable in multiple studies looking at Parkinsonism or care-giving.  
Validity or whether an instrument intended to measure something actually does so. There are 
different ways to consider this. Face validity, at the most basic, shows whether an instrument 
seems to assess what is under study e.g. QoL. This is usually appraised by an expert or body 
of experts. Other forms of validity include content validity (whether important points on the 
topic are included) and construct validity (whether the tool can give information which cannot 
be derived by direct observation) (Golafshani; Bryman, 2008b; Dowrick et al., 2015). 
 
All questionnaires used in this study have been found to be reliable in patient and carer groups 
and have been validated in Parkinsonism or caregiving. Any non-validated information, e.g. 
disease duration, was recorded in identical fashion using standardised pro-forma. 
In qualitative research, the quality of analysis is described as reliability or validity. Although 
these terms are interpreted in different in different ways by various practitioners, 
trustworthiness and credibility are frequently used to encompass the need for quality and rigor 
in interpretivist work (Golafshani, 2003; Bryman, 2008b). Criticism of validity and reliability, 
as applied to qualitative research, are that many of the underlying principles have parallels 
with quantitative analysis, indeed they were developed from that paradigm. For example, 
validity as whether ‘you are observing, identifying or “measuring” what you say you are’ 
(Mason, 1996).  Methods like using inter-user reliability (another researcher to ‘test’ codes 
produced) are not helpful if there is an assumption that there is a subjective reality of both the 
researcher and the subjects involved. 
By contrast, Yardley (2000) suggests four alternative criteria which they nominate as being 
more appropriate for the qualitative approach: 
1. Sensitivity to context: the context including potential ethical, psychosocial 
and theoretical issues 
2. Commitment and rigor: having the appropriate expertise, wish to engage 
with the topic under review and methodical process of collecting and 
analysing data 
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3. Transparency and coherence: definition of methods used and declaration of 
researcher assumptions, belief and motivations (reflexivity) 
4. Impact and importance: will the work have implications for academic 
theory, the group under study (and in clinical or applied humanities work) 
will it influence policy or practice? 
Published qualitative work often uses the COREQ (Consolidated Criteria for Reporting 
Qualitative Research) guidelines as a means to evaluate how the research was carried out, 
standpoints of the researchers, and a check for quality without imposing positivist ideals on 
the work. The COREQ is divided into three domains; research team and reflexivity, methods 
and analysis, and findings. The COREQ covers the similar points as Yardley, but in a more 
structured way, which can be reassuring for those seeking rigour in qualitative work using 
different methods and viewpoints (Tong et al., 2007). A COREQ checklist is included in 
Appendix E. 
There are many different criteria to try and appraise the quality of qualitative work. As 
opposed to quantitative studies which can summarise method, methodologies and results 
succinctly, the subjective and diverse nature of qualitative approaches make this more 
complex. However, maintaining as much of an understanding of prior assumptions and how 
this may affect the process of data collection and analysis is imperative to having rigorous and 
reflexive practice. 
 
3.7 Procedures 
3.7.1 Ethics 
Ethical permission for this study was sought from and granted by Yorkshire & The Humber – 
Bradford-Leeds Research Ethics Committee via proportionate review. Newcastle upon Tyne 
Hospitals Joint Research Office sponsored the study. St Benedict’s Hospice, Ryhope and 
James Cook University Hospital, Middlesbrough acted as Participant Identification Centres 
with permissions obtained from their local research and development departments.  
Participation in this study was voluntary and required informed consent.  
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3.7.2 Protocols and visit plan 
The study was a pilot observational, cross-sectional design. Potential participants had a 
known diagnosis of Multiple System Atrophy or Progressive Supranuclear Palsy and an 
informal (not paid) carer. Participants were identified via the Newcastle upon Tyne Hospitals 
NHS Foundation Trust movement disorder service, South Tees Hospitals NHS Foundation 
Trust Neurosciences movement disorder service or St Benedict’s Palliative Neurology-
themed clinic. Potential participants were given Participant Information Sheets at clinic with 
contact details of the PI should they have any questions. The PI would discuss the information 
with them (if present in the clinic) or would contact after a week, should the potential 
participant have completed a ‘permission to be contacted’ form. If participants were willing to 
take part, after time to consider and opportunity to ask questions, a research visit at CRESTA 
clinic, Newcastle Hospitals, St Benedict’s Hospice, or a home visit was arranged at a time 
suitable for the participants.  The clinical (questionnaire-based) portion of the study was 
completed in the majority of cases within a single visit. The tasks that required a researcher to 
assist were prioritised so should the participant become fatigued the remainder could be 
completed in their own time and posted with a postage-paid envelope left for this purpose. 
Telephone support to complete these questionnaires was offered, though was never required. 
Different QoL measures were recorded on the same day wherever possible, so that direct 
comparisons could be made, although participant fatigue was considered and visits were split 
if required. Table 3.3 shows the protocol for patient-participants in both groups. Table 3.4 
shows the protocol for carer-participants of both groups.  
PSP patient-participants MSA patient-participants 
Consent process Consent process 
Demographic information Demographic information 
Hoehn and Yahr staging Hoehn and Yahr staging 
Progressive Supranuclear Palsy Severity Scale 
(PSPRS) 
Unified Multiple System Atrophy Rating Scale 
(UMSARS) 
Progressive Supranuclear Palsy Quality of Life Scale 
(PSP-QoL) 
Multiple System Atrophy Quality of Life Scale (MSA-
QoL) 
Short Form/RAND 36 (participant-reported measure of 
health status) 
Short Form/RAND 36 (participant-reported measure of 
health status) 
Bristol Activities of Daily Living Score (BADLS) Bristol Activities of Daily Living Score (BADLS) 
Palliative care/Patient Outcome Score (POS-S-PD) Palliative care/Patient Outcome Score (POS-S-PD) 
Depression Anxiety Stress Scale (DASS-21) Depression Anxiety Stress Scale (DASS-21) 
Schedule for Evaluation of Individual Quality of Life - 
Direct Weighting (SEIQoL-DW) 
Schedule for Evaluation of Individual Quality of Life - 
Direct Weighting (SEIQoL-DW) 
If purposively selected and consented to do so, semi-structured interview 
Table 3.3: Protocol of questionnaires for MSA and PSP patient-participants 
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PSP carer-participants MSA carer-participants 
Consent process Consent process 
Demographic information Demographic information 
Modified Carer Strain Index (MCSI) Modified Carer Strain Index (MCSI) 
Parkinsonism Carers Quality of Life questionnaire 
(PQoLc) 
Parkinsonism Carers Quality of Life questionnaire 
(PQoLc) 
Short Form/RAND 36 (participant-reported measure of 
health status) 
Short Form/RAND 36 (participant-reported measure 
of health status) 
Schedule for Evaluation of Individual Quality of Life -
Direct Weighting (SEIQoL-DW) 
Schedule for Evaluation of Individual Quality of Life - 
Direct Weighting (SEIQoL-DW) 
If purposively selected and consented to do so, semi-structured interview 
Table 3.4: Protocol of questionnaires for MSA and PSP carer-participants 
 
If participants gave their consent for a semi-structured interview and were purposively 
selected, the participant was contacted to arrange a further research visit in CRESTA, St 
Benedict’s clinic or a home visit as chosen by the participant. Interviews were carried out 
after consent was re-discussed and confirmed. A digital recording device was used to capture 
interview content. All participants interviewed consented to a recording being made.  A semi-
structured sequence of questions was used to guide the interview if required for both patient-
participants and carer-participants. The style of interview was, in part, a traditional social 
science interview with set open-ended questions (responding to answers with follow-up 
exploratory responses to elicit a more thorough reply) and a pragmatic interview, seeking 
input on problems and issues which could be developed into possible solutions or approaches. 
An interview guide or schematic was drawn up with the assistance of Dr Katie Brittain (KB) 
who has expertise in interviewing practice and with reference to literature (see Appendix B). 
The advantage of such a framework is that it allows flexibility but within a structure which 
ensures key points or questions are relayed to the interviewee. The framework is especially 
helpful in keeping ‘on topic’ when there is limited time or participants may be at risk of 
fatigue, so the crucial research areas are explored with the interviewee (Patton, 2015). The 
question structure appeared to allow participants to discuss their experiences according to 
their personal perspectives, whilst addressing the research questions. No changes to the semi-
structured interview format were made throughout the qualitative portion of the study 
consequently, and to maintain consistency. 
 
3.7.3 Sampling 
The study aimed to recruit a minimum of 20 patients with MSA and 20 patients with PSP 
with their carer, totalling 40 patients with atypical Parkinsonism and 40 carer-participants. 
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There was no upper limit of recruitment and recruitment was scheduled to end in December 
2016 to allow sufficient time for data processing and analysis. All patients and carers 
underwent the questionnaire portion of the study. These numbers were selected as a feasible 
number for the clinical sites involved in the study, the time the study would be conducted 
over and estimates that pilot work should generally aim to have 10-40 participants per group 
to try and establish some significant findings within the confines of preliminary work.  This 
range of 10-40 per group is often described for rare conditions or difficult-to-reach 
populations, as in this study (Hertzog, 2008). No upper limits were selected to maximise the 
significance of statistical analysis in the quantitative arm and to allow for saturation in the 
qualitative arm (discussed in the Qualitative methods section). Sampling and statistical 
analysis methods were reviewed by a statistician at intervals throughout the project.  
A subgroup of patient and carer-participants was selected for semi-structured interviews using 
purposive sampling to explore experiences and concerns around living with atypical 
Parkinsonism, the process of diagnosis and perceptions of palliative care. 37 of the 47 patient-
participants and 40 of the 46 carer-participants consented to being considered for the 
interview arm. 14 participants (six patient-carer pairs, one individual patient-participant and 
one individual carer-participant) were approached to interview but this did not take place due 
to illness and difficulties scheduling interviews with their other commitments such as respite, 
appointments and holidays.  As well as the interviews, QoL questionnaires, depression 
questionnaires and carer-strain questionnaires were carried out privately to avoid bias or 
pressure on the participant when discussing personal or emotive issues. 
 
3.7.4 Data entry 
Hard copies of participant clinical research data (case report forms, CRF) were held within a 
secure document storage facility within the Clinical Ageing Research Unit (CARU), 
accessible by the PI and relevant regulatory individuals (sponsor, auditing and quality team). 
Research data from patients, including transcripts were stored on a university computer with a 
password protected login. The data was anonymised so not to permit identification of the 
participant without the demographic data (which was held in the Master Site file, in the secure 
document storage facility within the CARU). Data was entered onto a purpose-built Excel 
template designed by the PI and re-checked prior to analysis. Transfer of data from Excel was 
carried out using the import function of statistics package IBM SPSS Statistics for Windows, 
Version 22.0. (Armonk, NY: IBM Corp).  
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3.7.5 Clinical issues 
In the event of concerns being elicited during the research visit, the PI (an experienced 
neurology clinical practitioner) was able to assess whether urgent intervention was required in 
the context of the patient-participants’ neurological disease. Any routine observations which 
came to light from a neurological point-of-view were communicated by letter to the patient’s 
Neurology consultant and/or Parkinson’s disease Specialist Nurse. Notice of patient-
participants’ involvement in the study was routinely communicated by letter to their General 
Practitioner (GP); the GP was contacted by telephone and/or letter should any observations be 
made that might require medical input or review. Carer-participants’ GPs were not routinely 
informed of their involvement within the study but the protocol and consent forms discussed 
that any issues that might arise from a clinical research visit would be discussed with the 
appropriate GP or practitioner if there was concern for the participant from a physical or 
mental health perspective. This did not arise during the study. 
 
3.8 Inclusion and exclusion criteria 
3.8.1 Inclusion criteria 
1. Diagnosis of PSP or MSA according to clinical coding and inclusion on 
specialist clinic lists and clinical database.  During the study process, patients 
were reviewed against the consensus statement diagnostic criteria for MSA or 
NINDS-SPSP for PSP. 
2. Patient has regular carer who provides majority of care (not a paid 
employee). 
3. Valid, written, informed consent given by patient and carer to take part. 
4. Ability for carer and patient to give interviews in English, which can be 
recorded and transcribed. 
5. Ability to travel to CRESTA/St Benedict’s clinic for interviews and to use 
telephone for surveys or receive home visit by PI 
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3.8.2 Exclusion criteria  
1. Diagnostic uncertainty 
2. Difficulty of communication at primary interview stage 
3. Irregular or paid carers 
4. Inability to consent to inclusion in the study 
 
3.8.3 Duration of participant participation 
Participation in the study ranged from one day to four weeks, depending upon whether they 
consented to and were selected for interviewing after the quantitative battery of 
questionnaires. There were never more than three contact visits for any participants, this being 
on the rare occasions that a ‘split’ visit was required to allow participants to complete the 
questionnaires and then took part in interview.  
 
3.9 Questionnaires 
A number of questionnaires and scales were used in this study. I will briefly describe each 
measure and the rationale for its use below. Several scales such as severity scales (PSPRS and 
UMSARS), HR-QoL scales (MSA-QoL and PSP-QoL) and POS-S-PD are the only widely-
known and validated scales in AP. All questionnaires can be found in Appendix A. 
 
3.9.1 PSPRS (Progressive Supranuclear Palsy Rating Scale) 
A dedicated rating scale for PSP, developed by Golbe and Ohman-Strickland in 2007 and 
called the Progressive Supranuclear Palsy Rating Scale (PSPRS). Prior to this, severity was 
assessed by PD-specific rating scales such as the UPDRS (United Parkinson’s Disease Rating 
Scale) but such scales do not capture symptoms or signs which might be expected in PSP 
(Cubo et al., 2000). This score was developed longitudinally with a cohort of 162 patients 
with PSP of varying severities and subtypes. The overall score for the PSPRS is between 0-
100 and has 6 sub-categories (history, behaviour, bulbar, ocular, motor and gait). The scale 
has good inter-rater reliability. The PSPRS is frequently used in clinical research studies as a 
specific measure of severity in PSP (Schrag et al., 2003; Boxer et al., 2014; Bang et al., 
2016). 
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3.9.2 UMSARS (United Multiple System Atrophy Rating Scale) 
The Unified Multiple System Atrophy Rating Scale or UMSARS is a disease-specific scale 
which was developed by Wenning et al. (2004). Originally developed with 40 MSA patients 
of both subtypes, diagnosed according to the (first) consensus criteria. It is reliable and valid 
for assessing severity of MSA.  The scale is divided into four parts; history, motor system 
examination, autonomic and disability rating. The UMSARS uses a 1-5 Likert scale for the 
history and motor sections comprising of a 12-question symptom review and a 14-point 
examination. The autonomic section measures their lying and standing blood pressure and 
heart rate. The UMSARS is owned and recommended by the MDS and has been used 
extensively in clinical research studies (Novak et al., 2012; Low et al., 2015; Ahn et al., 
2016). 
 
3.9.3 RAND-36 
The RAND-36 or Short Form (SF)-36 was selected as a generic health status score (though 
described by the authors as a health-related QoL score) (Ware and Sherbourne, 1992). The 
SF-36 was developed with a cohort of over 2000 Americans with chronic diseases ranging 
from hypertension to depression (Tarlov et al., 1989). The SF-36 (the RAND-36 being the 
version in the public domain) has been used extremely widely in many groups including PSP, 
MSA and Parkinson’s disease patients (Den Oudsten et al., 2007b; Pekmezovic et al., 2015; 
Kubo et al., 2016) as well as in carers of individuals with serious health conditions including 
Parkinsonism to allow comparisons between patient and carer (Schrag et al., 2006c; 
Greenwell et al., 2015; Corallo et al., 2016). The RAND-36 comprises eight sub-scores 
evaluating different dimensions of well-being such as physical functioning, role limitation due 
to physical problems, role limitations due to emotional problems and energy/fatigue. Two 
overall scores; physical and mental composite scores (PCS and MCS) can also be derived 
from the eight sub-scores. It is straightforward to complete and takes between 10 to 20 
minutes to administer (Ware and Sherbourne, 1992). The SF-36 is recommended as a possible 
tool for assessing well-being in Parkinson’s disease by the Movement Disorder Society and 
has been used in clinical trials to assess well-being in AP (Apetauerova et al., 2016; MDS, 
2017). It has the advantages of being used for many years as a general measure in 
Parkinsonism and having mental and physical well-being summary scores. In this thesis, I 
will use the abbreviation RAND-36 to mean the public domain version of SF-36.  
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3.9.4 MSA-QoL (Multiple System Atrophy Quality of life) 
MSA-QoL was developed to address specific symptoms which affect patients with MSA 
affecting HR-QoL. Prior to its development, generic QoL scores such as SF-36 and scores 
designed for PD were used. It was developed with the input of MSA patients regarding their 
disease-related concerns and was tested on MSA patients of both subtypes. MSA-QoL has 
good reliability, is specific and correlates well with established QoL scales used in 
Parkinsonism (specifically PD) such as PDQ-39 (Schrag et al., 2006a). MSA-QoL has been 
assessed with other scales such as the UMSARS to verify sensitivity to clinical change. 
UMSARS is more sensitive to change, possibly as QoL constructs are distinct to severity 
(Meissner et al., 2012; Matsushima et al., 2016). 
 
3.9.5 PSP-QoL (Progressive Supranuclear Palsy Quality of life) 
Like the MSA-QoL, the PSP-QoL was designed with the intention of being able to capture the 
problems individuals tend to experience in PSP. Like the MSA-QoL, patients with PSP were 
interviewed to ascertain issues of import to them in its design. However, it was not clear 
whether original testing involved PSP-RS and PSP-P though it has been used in both groups 
subsequently.   The PSP-QoL is a disease-specific measure with the advantage of addressing 
disease-specific features. The scale has good validity and reliability and correlates with the 
PDQ-39 amongst other measures (Schrag et al., 2006c). 
 
3.9.6 DASS (Depression, Anxiety and Stress scale) 
DASS has been used in PD as well as many different adult populations in clinical and 
research settings. It has good internal consistency and validity (Simpson et al., 2013). There is 
a longer DASS scale and the briefer DASS-21, both of which have been used in the context of 
research in PD (Bucks et al., 2011; Landau et al., 2016).  The scale is quick and has the 
advantage of giving three measures of altered mental well-being; depression, anxiety and 
stress (Troeung et al., 2014). The score is not a measure of suicidality risk and must be 
assessed separately from the DASS. Suicidality was not explored in this project. The 
depression and stress subscales have been found to have good reliability in the context of PD, 
however the anxiety subscale may have some overlap with the physiological symptoms of PD 
(e.g. presence of tremor) so may be less reliable for Parkinsonian individuals than the 
depression or stress results (Johnson et al., 2016). The instrument will be referred to as 
DASS-21. Subscores will be specified as in terms such as “DASS-D” or “DASS-depression” 
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for the depression domain of the tool. The instrument was decided upon as it gave degrees of 
severity and several subscales, though depression was the key outcome it was used for. 
During the planning of this study, no evidence was found for particular depression scales 
being more suitable in the context of frontal cognitive issues (Sheehan, 2012). 
 
3.9.7 BADLS (The Bristol Activities of Daily Living Scale) 
The Bristol Activities of Daily Living Scale (BADLS) was developed in 1996 by Bucks et al. 
(1996) as a simple-to-complete questionnaire to assess functional abilities of patients living in 
the community with mild cognitive impairment. The scale was designed for caregivers to 
contribute their impression of the ability of the person to carry out their regular activities. It is 
sensitive to change, is reliable and sensitive (Bucks and Haworth, 2002). The advantage of 
this scale is that it acknowledges cognitive impairment in functional ability and is intended for 
caregivers’ input, whereas many similar scales are not. This is important in MSA and PSP 
where cognitive impairment is present (in MSA, variable and often underestimated).  It has 
been used in AP and PD (Allan et al., 2006; McKeith et al., 2006) as well as other 
neurological conditions (Stephens et al., 2005). The BADLS is brief and was used as a 
functional surrogate of severity (disability) in this study when comparing the two disease 
groups. The BADLS was selected ahead of the Schwab and England score (also commonly 
used in research with patients with Parkinsonism) as it has a continuous scoring and is 
designed with carer input in mind. 
 
3.9.8 POS-S-PD (Palliative Outcome Scale-Symptoms Parkinson’s disease) 
The palliative outcome scale (POS) is widely used clinically and in research studies for 
assessing palliative requirements in patients with a range of conditions including malignancy, 
renal disease and neurological conditions (Hearn and Higginson, 1999). The POS is a generic 
measure and this and further developments like the IPOS (Integrated Palliative Care Outcome 
Scale) are often used to assess change in patient status and response to intervention in 
palliative settings.  The POS-S-PD asks about symptoms in Parkinsonism, yielding a score 
that reflects palliative need (Saleem et al., 2013). It was designed from work with 82 patients 
with Parkinsonism (48 PD, 18 MSA and 16 PSP), considered to have advanced symptoms. 
Therefore, the tool from its conception did consider AP, though most patients who have been 
assessed with it from the literature had PD.  
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3.9.9 The Modified Caregiver Strain Scale (MCSI) 
The MCSI was developed from the Caregiver Strain Index (CSI) produced in 1983. The 
authors discriminate between the concepts of stress, strain and burden for clarity which are 
often used as substitutable terms in the literature. It has good internal and retest reliability and 
compared to the CSI, the change from dichotomous yes/no scoring to an ordinal scale 
including a ‘sometimes’ option was introduced after feedback from pilot testing. The MCSI 
has slightly better internal reliability than the CSI (Thornton and Travis, 2003). The MCSI 
and CSI have been used in studies of caregiver strain in Parkinson’s disease, cognitive 
impairment and palliative care, which was why it was selected for this study (Greenwell et al., 
2015; Hoefman et al., 2015; Jennings et al., 2015). 
 
3.9.10 PQoLc (Parkinsonism carers Quality of Life) 
The Parkinsonism Carers QoL is a purposively designed instrument which specifically 
assesses the impact upon QoL of carers looking after individuals with atypical Parkinsonism. 
The instrument was designed via pilot testing with patients with both MSA and PSP and was 
found to be reliable and consistent. The advantage of this scale is its specificity in assessing 
QoL of carers for people with MSA and PSP (Pillas et al., 2015). 
 
3.9.11 SEIQoL-DW (The Schedule for the Evaluation of Individual Quality of Life – Direct 
Weighting) 
The Schedule for the Evaluation of Individual Quality of Life (SEIQoL) was developed in 
1993 in response to the recognition of the need to assess individuals’ quality of life and well-
being in the context of disease. One concern in appraising HR-QoL was that most instruments 
used for the purpose impose external values and ideas, failing to allow issues important to the 
person to be explored (Hickey et al., 1996). The SEIQoL-DW was developed to be quicker to 
apply from the original SEIQoL. The SEIQoL-DW is interview-based and asks the 
interviewee to volunteer five areas of import to them as individuals; then line-drawing and 
adjustment of coloured interlocking disks are used to assign functioning and relative 
importance to the life areas. A continuous score out of 100 (higher values having a higher 
QoL) can then be generated out of a series of subscores. The output is complex and can be 
analysed in a range of ways. The SEIQoL-DW has been used in diverse conditions such as 
HIV/AIDS, malignancy, MND and Parkinsonism, including MSA and PSP, though it has 
never been used to exclusively assess MSA and PSP patients and has not to our knowledge 
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been used to assess MSA and PSP carers (Neudert et al., 2004; Lee et al., 2006; Saleem et al., 
2013). 
 
3.10 Statistical methods  
Statistical analysis was carried out using the IBM SPSS version 23 software package. Graphs 
were produced using either SPSS or Microsoft Excel where appropriate. Data was tested for 
normality using visual inspection of histograms and the Shapiro-Wilk (SW) test as this has 
greater power to detect differences in smaller samples (therefore is often used when smaller 
samples of below 50 are used) (Ghasemi and Zahediasl, 2012).  To find differences between 
means, independent t-tests were carried out. If there was a non-normal distribution found, a 
non-parametric alternative to the independent t-test was used, the Mann Whitney U-test. As a 
non-parametric test, rather than detect the differences in means between the samples, the 
Mann-Whitney U detects differences in ranked scores. If differences were being investigated 
between three or more non-normally distributed continuous scores, the Kruskall-Wallis-H test 
was used to see if the ranked scores were significantly different. If there were differences, 
post-hoc pairwise comparisons were run to see between which of the categories the 
differences lay. Dunn’s comparison was used as the standard post-hoc test after Kruskall-
Wallis-H in SPSS (Howitt and Cramer, 2014).  
If differences between two groups were being explored and the variables were categorical or 
nominal, a test of two proportions or chi-square test for homogeneity was carried out. This 
was used in descriptive analysis, for example whether proportions of males and females were 
statistically different between the two disease groups.  
Relationships between variables were explored using Pearson’s Correlation Coefficient if 
normally distributed. If there was a non-normal distribution, Spearman’s Rho which ranks the 
data to account for non-normality, was used.  If correlations between discrete dichotomous 
variables (male or female, yes or no), and a continuous dependent variable were being 
investigated, point biserial (PBS) correlation was used (Pallant, 2007; Field, 2014). The 
strength of association was described using Cohen’s guideline which is summarised in table 
3.5 (Cohen, 1988). 
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Correlation Coefficient (r) Strength of Association 
<0.1 Trivial 
0.10 – 0.29 Small 
0.30 – 0.49 Medium 
0.50 – 1.0 Large 
Table 3.5: Descriptions of strength of associations from Pallant (2007) and Cohen (1988) 
 
Regression analysis was used to look for predictive power of variables, if correlation analysis 
suggested a relationship. Simple linear univariate analysis was used initially to see if the 
variable could significantly predict a proportion of the dependent variable. Multiple linear 
regression was then used if more than one predictor was being considered together. As an 
exploratory study, stepwise regression was used (with backward elimination). This placed all 
variables being tested into the model initially; testing for any loss of significance as each 
independent variable is removed. This method is frequently used in medical and health 
research. Stepwise regression has been suggested as more suitable to producing models for 
exploratory or pilot work with hierarchical regression a more suitable method for model 
validation (Thayer, 2002; Jacobs et al., 2006; Hanna and Cronin-Golomb, 2012). Unless 
specifically stated otherwise, all variables used in regression analysis in this study were 
continuous and quantitative. 
The assumptions and tests used for linear regression were: 
• All independent variables considered were tested for multicollinearity. 
Multicollinearity would mean independent variables correlate too strongly 
with each other, producing problems with producing the regression model.  If 
this was present, this was discussed and adjustments made (such as removing 
the variable with the lesser correlation coefficient). 
• Each dependent variable was tested for the presence of a linear relationship 
with the dependent variable, required in multiple linear regression. 
• Homoscedasticity or similarity of variances of the dependent variables 
against predicted regression values. This was judged by plotting standardized 
residuals against standardized predicted values. A random, evenly spaced set 
of points would suggest homoscedasticity. 
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• Any outliers found in a regression model were assessed for their influence on 
the overall model using Leverage values and Cook’s distances. This was 
discussed in the text if the situation arose (Pallant, 2007; Field, 2014). 
In terms of the number of subjects per dependent variable to carry out regression analysis, 
there are varying opinions of how many are required. This ranges from 200 overall subjects in 
any regression analysis to 2 per dependent variable. Green has suggested between 10 and 20 
subjects per dependent variable ideally, but recommends a minimum of 5 per subject variable 
(Green, 1991; Austin and Steyerberg, 2015). In the exploratory regression analyses 
performed, the minimum subjects per dependent variable was between 5-10. To check the 
validity of the regressions produced, all model residuals were tested in terms of SW normality 
tests and visual inspection of histograms. 
Generalized linear models comparing variance using a covariate (ANCOVA) have been 
used to detect differences between disease groups whilst accounting for a covariate. The 
comparison then can compare the two adjusted groups with the influence of the covariate 
removed. The assumptions are that the dependent variable and covariate are continuous, the 
independent variable is categorical and that the observations are independent from another.  
Other assumptions were tested before carrying out this test.  
• These were the presence of a linear relationship between the covariate and the 
independent variables being testing (using scatter plots).  
• Another assumption which must be considered before carrying out this test is 
homogeneity of regression slopes which looks for interactions between the covariate 
and the independent variable. This is tested by carrying out a Shapiro-Wilk (SW) 
normality test on the combined term of the covariate and the test variable. If the SW 
test is not statistically significant, there is not interaction between covariate and the 
dependent variable which might interfere in the test.  
• Homoscedasticity is a requirement of ANCOVA; this is defined as the size of the 
errors that exist in the relationship between the independent and the dependent 
variable being uniform. Homoscedasticity can be shown by plotting the standardised 
residuals against the predicted values. If the error terms are equal, an even spread of 
points and no pattern will be generated.  
• Levene’s test was used to test whether the variance of the residuals was the same 
between the two testing groups, as significant differences can produce problems in the 
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analysis; the assumption was not violated if there was no statistically significant result 
(p < 0.05).  
• Testing for the influence of outliers was carried out and is assumed not be present if 
standardized residual values were approximately below ±3SD. Normality testing of 
residuals within the groups was tested by visual inspection of histogram and SW 
testing of standardised residuals in each group. 
Other specific statistical tests are described in the methods sections of individual chapters.  
 
3.11 Interviewing and interview analysis 
Unlike the quantitative portions of this study, the demographics of the participants in the 
qualitative arm will be included in the methods chapter. See table 3.6. 
All interviews were transcribed verbatim from recordings. Interviews were either transcribed 
by the investigator or by a specialist transcription service, then reviewed to ensure accuracy. 
The semi-structured interview plan was designed in the context of known literature regarding 
AP and PD and with input from KB, who is an expert in interviewing methods and the 
qualitative methodology. Sampling was purposive and pragmatic.  Open coding was used to 
generate initial codes which were then refined into overarching themes as data collection and 
ongoing thematic analysis continued.  
QSR International NVIVO version 11 was used as an aid to analysis and data retrieval in 
thematic analysis. Interviewing ceased when saturation took place i.e. when no more 
meaningful codes were being generated. 
All quotations used from the qualitative arm to illustrate description are indented and italic. 
Punctuation has been used pragmatically (commas for short pauses and full stops for natural 
breaks in speech). Ellipses (…) were used to show omissions and square brackets to show a 
change to the quote (replacing true names for pseudonyms for example). Sounds considered 
superfluous have been removed to aid flow and readability e.g. “um”. Speech marks are used 
to show the interviewee is quoting another.  
Two participants used speech aids; a tablet computer with a ‘speech’ function and a light 
writer. Their typed responses, ‘spoken’ by the device are shown in bold. The reason for this is 
partly to distinguish from the spoken word but also to emphasise that their voice has been 
missing from research and therefore I wished to make their contribution more prominent. 
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Noises that illustrate their difficulty in speaking have been included in these participants, as 
they sometimes made efforts to produce intelligible speech that is integral to the content and 
meaning of their interviews. 
 
Pseudonym Sex Condition Role Age Profession Marital status 
Matthew  Male MSA Patient 64 Retired lawyer Married to Sally 
Emma  Female MSA Carer 61 Retired charity worker Married to Matthew 
Sally  Female PSP Carer 70 Retired dental nurse Married 
Bryce  Male PSP Patient 76 Retired technician Single 
Doris  Female MSA Patient 59 Retired librarian Married to Bill 
Bill  Male MSA Carer 57 Director Married to Doris 
Rose  Female MSA Patient 71 Retired teacher Married to Jackie 
Jackie  Male MSA Carer 73 Retired head teacher Married to Rose 
Julia Female MSA Patient 62 Retired hotelier Married to Tiberius 
Tiberius  Male MSA Carer 66 Retired hotelier Married to Julia 
Sarah*   Female PSP Patient 67 Retired teacher Married to Tom 
Tom  Male PSP Carer 70 Retired oil chemist Married to Sarah 
Helen  Female PSP Patient 68 Retired newsagent Married to Earl 
Earl  Male PSP Carer 70 Retired accountant Married to Helen 
Mary*  Female PSP Patient 69 Retired newsagent Married to Bob 
Bob  Male PSP Carer 69 Retired newsagent Married to Mary 
Gary  Male PSP Patient 58 Retired project manager Married to Pat 
Pat  Female PSP Carer 62 Analyst Married to Gary 
Jack  Male PSP Patient 71 Retired HGV manager Married 
Table 3.6: Summary and demographic information of patients and carers who gave interviews. All names are 
pseudonyms. * = used communication device due to speech difficulty.  
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Chapter 4. Symptoms and Palliative Care Need  
 
4.1 Introduction 
MSA and PSP are known to have a range of symptoms, physical, cognitive, as well as 
emotional, that exert marked burden upon sufferers for an extended period. 
A study combining patients with advanced PD, MSA, and PSP (Hoehn and Yahr 3-5) found 
that Parkinsonism in this patient group overall, had moderate palliative needs with symptoms 
which are routinely and effectively treated by palliative care teams, such as pain, constipation 
and drooling (Saleem et al., 2013).  
Palliative care is now beginning to be integrated into the medical model of Parkinson’s 
disease management, particularly in the advanced stages, when symptoms are especially 
complex or when the condition becomes refractory to, or the patient is not a candidate for 
further treatment, such as deep brain stimulation (Lokk and Delbari, 2012). It must be noted 
however, that patients who have received complex therapy like deep brain stimulation should 
not be excluded from palliative care as their disease will continue to progress.  
MSA and PSP, as discussed in more detail in Chapter 1, have earlier complications such as 
wheelchair requirement and falls, relentless and accelerated progression compared to PD and 
an extended palliative phase often without good symptomatic treatment response 
characterised by the ‘honeymoon period’ of PD. There is a lack of work that specifically 
characterises particular symptom burdens in subtypes of AP that this chapter aims to address 
in part.  
 
4.2 Aims  
This chapter will discuss the demographics of the patient-participants involved in this study. It 
explores the specific symptom profiles of MSA and PSP, time scales of symptoms and their 
onset. It also explores the similarities and differences of symptoms, the prevalence of 
palliative care input amongst the cohort, and perceptions of palliative care amongst the 
patient-participants. 
 
54 
 
4.3 Methods 
The results in this section were analysed using quantitative statistical methods. The statistics 
software package used was the IBM SPSS version 23 software package. Graphs were 
produced on Microsoft Excel (2016) or SPSS 23.  Differences between groups were assessed 
using independent t-tests to explore whether there were overall differences between the two 
disease groups or sexes. ANCOVA testing was then carried out which takes into account 
another variable (or covariate) and corrects for this (in this chapter degree of disability, using 
the BADLS score). One condition of ANCOVA (the other assumptions and tests used before 
an ANCOVA analysis takes place are discussed in the Methods chapter) is that there is a 
consistent, continuous covariate which is comparable between the groups being tested. For 
that reason, degree of disability was used as a surrogate for severity (BADLS was used in 
both groups). UMSARS and PSPRS are not directly compatible and Hoehn and Yahr, though 
a comparable measure of severity in both groups, is categorical rather than continuous.  Chi-
squared tests of homogeneity were used to look for differences in proportions between groups 
where the variables are categorical or nominal e.g. mild, moderate and severe, or male and 
female. If there were insufficient numbers for chi-squared testing (requires five variables per 
group), Fisher’s exact test was used instead and stated. Milestones were reviewed and plotted 
on graphs to visually represent their onset, such as speech problems, relative to diagnosis (‘-’ 
numbers signifying before diagnosis and ‘+’ after). The diagnosis point ‘0’ denotes when the 
patient was diagnosed with AP, not a prior, revised diagnosis such as PD. Median scores were 
used to describe these onset times as their distributions were not normal on visual inspection 
of histograms and Shapiro-Wilk (SW) tests. 
 
4.4 Results 
4.4.1 Demographics of patients 
The overall patient-participant demographics are shown in table 4.1. 
   
Total Mean age 
(SD), years 
Median Disease 
duration, months  
 Disease duration 
IQR, months  
Female Male Overall 
   
MSA 11 12 23 64.6 (10.1) 33.0 29.0 
PSP 10 14 24 71.6 (6.8) 25.5 30.8 
Overall 11 26 47 68.2 (9.2) 29.0 30.0 
Table 4.1: Basic demographic information of patient-participants. SD-standard deviation. IQR-Interquartile 
range. Age is measured in years, duration of disease in months 
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4.4.2 Sex 
There were 47 patient-participants enrolled into the study. There were 23 patients with MSA. 
Of these 11 were female and 12 were male. There were 24 patients with PSP, of which 10 
were female. There was an even balance between sexes (with a slight male preponderance in 
PSP) in keeping with current thinking that the sexes in MSA and PSP are likely equally 
affected (Glasmacher et al., 2017).  
 
4.4.3 Duration of disease and age 
Duration of disease was non-normally distributed. The median time since diagnosis was 29 
months overall, with MSA patients at 33.0 months and PSP patients at 25.5 months.  
Interquartile range (IQR) was similar at 29.0 months for MSA and 30.8 for PSP. The mean 
overall patient-participant age was 68.2 years; in MSA 64.6 years and in PSP 71.6 years. As 
PSP is described as affecting individuals at an older age than MSA, this was expected. See 
tables 4.2 and 4.3.  Duration of disease is considered from diagnosis of MSA or PSP. 
Although pre-diagnosis symptoms may precede diagnosis by varying amounts, diagnosis time 
was used for consistency.   
 
 
Median disease duration, 
months 
Mean Age (SD), 
years 
Disease duration IQR, 
months 
Total N (%) 
MSA-P 29.0 65.8 (10.8) 28.8 16 (69.6) 
MSA-C 34.0 61.9 (8.2) 59.0 7 (30.4) 
Total  33.0 64.6 (10.1) 29.0 23 (100) 
Table 4.2: Duration of disease in months and age for subtypes of MSA.  
SD = standard deviation  IQR = Interquartile range 
 
Using Mann-Whitney U tests, there was no significant differences between the subgroups of 
MSA in terms of duration of disease or age (p = 0.349).  
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Median disease duration, 
months 
Mean Age (SD), 
years 
Disease duration IQR, 
months 
Total N (%) 
PSP-RS 21.0 71.8 (2.1) 24.5 13 (54.2) 
PSP-P 28.5 71.0 (6.3) 53.0 10 (41.7) 
PAGF 51 76 (-) - 1 (4.2) 
Overall 25.5 71.6 (6.8) 30.8 24 (100) 
Table 4.3: Duration of disease in months and age for subtypes of PSP.  
SD = standard deviation  IQR = Interquartile range.  
 
Using Mann-Whitney U tests, there was no significant differences between PSP-RS and PSP-
P in terms of duration of disease or age (p = 0.693). PSP-PAGF was excluded as there was 
only a single case. 
 
4.4.4 Severity  
Severity for each condition was graded using disease-specific measures, the UMSARS and 
the PSPRS for MSA and PSP respectively. These are not directly comparable. For descriptive 
purposes, the Hoehn and Yahr scales for the participants are shown below. The Hoehn and 
Yahr staging was designed for grading the severity of Parkinson’s disease but it is useful to 
consider the severity of Parkinsonism using this scale. The median score for both groups was 
4 and there were no significant differences between the ranks of scores between the two 
disease types using the Mann Whitney U test (p = 0.116).  
There were no participants at stage one of the Hoehn and Yahr (unilateral disease only). 
Stages 4 and 5 of the scale would be expected to be reached after 7.5-14 years on average 
with Parkinson’s disease (Poewe, 2006). By contrast, 18 (78.3%) of MSA participants were 
Hoehn and Yahr stage 4 or 5, with a median duration of disease of only 33 months (2.8 years) 
and 21 (91.3%) of the PSP participants with a median disease duration of 25.5 months (2.1 
years). See figure 4.1.  This describes the rapid progression and accumulation of disability as 
discussed in Chapter 1.  
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Figure 4.1: Hoehn and Yahr staging of severity of disease showing MSA patients (blue) and PSP participants 
(green). Mean score for MSA 3.9, median score 4. Mean score for PSP 4.3, median score 4. 
 
All patient-participants answered questions regarding their symptom onset, diagnosis, the 
timing of ten key milestones relative to their diagnosis being made, and their medication.  
Other relevant results regarding depression and use of therapies, are included in this section. 
 
4.4.5 Diagnosis 
Overall, 22 out of 47 patients had a prior diagnosis before receiving a diagnosis of MSA or 
PSP. This project does not take account referrals to specialist centres or where/from which 
speciality they received the prior diagnosis. 11 out of 23 MSA patients were diagnosed with 
PD before their diagnosis was revised to MSA. The median duration between the original 
diagnosis and the final diagnosis was 41 months. All the MSA cases who previously had a PD 
label were MSA-P except for one case of MSA-C.  12 out of 24 PSP patients had a prior 
diagnosis before being diagnosed with PSP. Unlike the MSA group, several diagnoses were 
made. Nine cases were diagnosed with PD, seven of which were revised to PSP-P, the 
remaining two were revised to PSP-RS. One patient was diagnosed as having FTD, another 
mixed dementia and a third as ‘stroke disease’. The latter three diagnoses were all later 
revised to PSP-RS. The median time to revision of diagnosis was also 41 months.  
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In the cases in which PD had been given as a prior diagnosis overall, the median time to 
revision to AP diagnosis was 36 months. 84.2% (N=16) were re-diagnosed as having the 
Parkinsonian variant of MSA or PSP, suggesting that early stages of these subtypes are more 
difficult to differentiate from PD in the early stages whereas PSP-RS was diagnosed as 
dementia in 23.1% (N=3) of the PSP-RS cases in this cohort, but none of the PSP-P cases. 
 
4.4.6 Key symptoms 
The ten key milestones used in this study were selected on the basis they were likely to be 
well-documented, memorable events which relate to the degree of severity and challenges 
patients face. These are listed in tables 4.4 and 4.5. The milestones were decided upon with 
reference to previous work in the literature and discussions with the lead supervisor of this 
project who is an expert in movement disorder (Ben-Shlomo et al., 1997; O'Sullivan et al., 
2008; dell'Aquila et al., 2013).  
The presence or absence of these key symptoms was recorded for each subtype, as well the 
proportion who had these symptoms prior to their diagnosis of AP (see tables 4.4 and 4.5). 
One patient was excluded from the catheter category in the MSA group as he had received a 
catheter 26 years prior following prostate surgery. One patient was excluded from the PSP 
wheelchair category as they had required a wheelchair since a fall resulted in vertebral 
fractures 11 years earlier. It was considered unlikely that that these milestones occurred due to 
their AP; for transparency however, these results are taken into account in the tables below 
and are labelled with an asterisk.  
Milestone Milestone 
present 
Onset prior 
to diagnosis 
Median onset 
(months) 
IQR 
Falls 19 11 -1 30 
Wheelchair 12 2 14.5 35 
Autonomic 20 11 -5.5 56 
Speech 21 7 10 33 
Swallowing 7 0 23 64 
PEG insertion 2 (pending) - - - 
Catheter 7 (8*) 1 (2*) 25 (21*) 27 (36*) 
Acute Admissions 11 4 4 30 
Institutionalization 3 0 46 57 
Tracheostomy 0 - - - 
Table 4.4: Presence and median onset of milestones in MSA. * represents values if excluded patient milestones 
included. N=23 
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Milestone Milestone 
present 
Onset 
prior to 
diagnosis 
Median onset 
(months) 
IQR 
Falls 22 18 -18.5 50 
Wheelchair 12 (13*)  1 (2*) 17 (16*) 28 (26*) 
Autonomic 2 1 3.5 - 
Speech 18 8 4 32 
Swallowing 12 1 12.5 22 
PEG insertion 0 - - - 
Catheter 4 0 31 42 
Acute Admissions 13 6 0 36 
Institutionalization 1 0 - - 
Tracheostomy 0 - - - 
Table 4.5: Presence and median onset of milestones in PSP. * represents values if excluded patient milestones 
included. N=24 
 
At the time of review the most frequently present milestones reached in MSA were speech 
difficulty (defined as ‘when others began to have trouble understanding me’) at 91% of the 
MSA group, autonomic symptoms at 87% of the group and falls at 78%. In the PSP group, 
the most frequent milestones achieved were falls at 92%, speech difficulty at 75% and 
wheelchair requirement and swallowing difficulties were tied at 50%.  
As the distribution of durations to milestones were non-normally distributed, median 
durations were calculated rather means. Negative values suggest the median onset occurred 
prior to diagnosis whereas positive values show median values tending to fall after diagnosis. 
This is represented graphically in figures 4.2 and 4.3, below for each disease-type. 
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Figure 4.2: Timeline of onset of key milestones for each MSA patient (left) and proportion having reached milestone (right). One patient was excluded from the catheter 
category as they had received one 26 years earlier for prostate carcinoma.  
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Figure 4.3: Timeline of onset of key milestones for each PSP patient (left) and proportion having reached milestone (right). One patient was excluded from the wheelchair 
category as they had required wheelchair since a fall resulted in vertebral fractures 11 years previously. 
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In the MSA group, two milestones had a median which fell before diagnosis; autonomic 
symptoms (median 5.5 months prior to diagnosis) and falls (median 1 month before 
diagnosis). All other median milestones occurred after diagnosis. In the PSP group falls had a 
median onset of 18.5 months prior to diagnosis.  
 
4.4.7 Subjective Symptoms 
All patient-participants were questioned on whether they had symptoms of pain, drooling, 
problems sleeping, anxiety or depression. It was made clear to the participants that they 
should answer according to whether they felt these symptoms were present rather than if they 
had been given a diagnosis, or symptoms had been identified by a clinician. This was asked as 
part of a designed proforma rather than a validated scale. These findings are summarised in 
tables 4.6 and 4.7.  
 
 
MSA Participants (N=23) 
 
Present 
(%) 
Absent 
(%) 
Treated Not treated 
(refused treatment) 
Never 
acknowledged 
Pain 17 (73.9) 6 (26.1) 12 5 (0) 0 
Drooling 15 (65.2) 8 (34.8) 4 3 (8) 3 
Sleep issue 10 (43.5) 13 (56.5) 7 3 (0) 0 
Anxiety 10 (43.5) 13 (56.5) 8 1 (1) 1 
Depression 10 (43.5) 13 (56.5) 9 0 (1) 0 
Table 4.6: Presence of symptoms, whether acknowledged and if treatment given in MSA cohort. Treatment 
includes pharmacological and non-pharmacological therapies. 
 
 
 
PSP Participants (N=24) 
 
Present 
(%) 
Absent 
(%) 
Treated Not treated 
(refused treatment) 
Never 
acknowledged 
Pain 15 (62.5) 9 (37.5) 11 2 (2) 1 
Drooling 19 (79.2) 5 (20.8) 9 3 (7) 3 
Sleep issue 8 (33.4) 16 (66.6) 4 2 (2) 2 
Anxiety 5 (20.8) 19 (79.2) 5 0 0 
Depression 6 (25) 18 (75) 5 1 1 
Table 4.7: Presence of symptoms, whether acknowledged and if treatment given in PSP cohort. Treatment 
includes pharmacological and non-pharmacological therapies. 
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4.4.8 Pain 
In the MSA group, 17 (73.9%) patients experienced pain. Of these, 70.6% (12/17) were being 
treated for pain. All of the MSA patients with pain felt that their pain had been acknowledged 
by a professional though five were not receiving treatment.  
In terms of pain in the PSP group, 62.5% experienced pain. 73.4% of these (11/15) had 
received treatment for pain, in one case non-pharmacological treatment. One patient did not 
feel that their pain had been acknowledged and was not on analgesia.  
 
4.4.9 Drooling 
65.2% of MSA patients had drooling. Of this group, 80% (12/15) had had this problem 
acknowledged by a health professional. 53.4% (8/15) of the MSA-drooling group had refused 
treatment for this symptom and 4 had received symptomatic treatment.  
In the PSP group, 79.2% (19/24) reported drooling. This was acknowledged in 84.2% of cases 
(16/19) and treated 47.4% (9/19) of the time. 3 patients in the drooling group had not been 
offered treatment and 7 had refused it.  
 
4.4.10 Sleep Problems 
In the MSA group 43.5% (10/13) perceived problems with sleep which included rapid eye 
movement (REM) behaviour disorder, insomnia and fragmented sleep. All felt their sleep 
issues had been acknowledged by a professional and 70% of these had had treatment in an 
effort to address it.  
In the PSP group 33.3 % (8/24) admitted to sleep difficulty. 75% (6/8) had this acknowledged 
and half of this total had received treatment (4/8). 2 had refused treatment and 2 had not 
received treatment.  
 
4.4.11 Anxiety 
In the MSA group 10/23 described anxiety (43.5%) with 9/10 (90%) acknowledged by health 
professionals. 5 had had their anxiety addressed with treatment, 1 had refused input and 3 had 
had non-pharmacological input.  
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In the PSP group, 5/19 of the cohort felt that they had anxiety (20.8%) and of these all had 
their anxiety recognised and all had received treatment with medication (4/5) or talking 
therapies (1/5).  
 
4.4.12 Depression 
Depression has been found to be an important factor in QoL and life satisfaction as assessed 
on varying scales in conditions such as renal failure and COPD as well as PD and AP 
(Karlsen et al., 1998; Benrud-Larson et al., 2005; Lee et al., 2006; Schrag et al., 2006c; Yoo 
et al., 2016). In this study the DASS-21 scale was used to assess the presence of depression as 
well as anxiety and stress. However, as discussed in Chapter 3, the anxiety scale has some 
overlap with the physiological symptoms and may be less reliable than the depression or 
stress scores. 
When patient-participants were asked whether they perceived themselves as having 
depression 43.5% (10) of the MSA patients felt that they did. Of these, nine participants were 
being treated for low mood with the remaining patient refusing treatment for low mood. In the 
PSP group, participants felt that they had low mood in 25% (6/24) of cases. Of these 
participants 84% (5/6) were treated for low mood. Only one participant with PSP who felt 
they had low mood had not received treatment and felt their mood problems had not been 
acknowledged.  
When low mood was assessed objectively using the DASS-21 scale, 12/23 (52.2%) of the 
MSA group were found to have some depression as compared to the subjective 43.5%. None 
were categorised as having severe or very severe depression on the DASS-21. In the PSP 
group, the overall presence of depression on the DASS-21 scale was 9/24 (37.5%) of 
participants and 2/24 (8.4%) were in the severe category (compared with perceived low mood 
of 6/24 or 25%). As previously discussed, the DASS-21 is not a measure of suicidality and no 
patients were thought to have suicidal ideation during assessment. See figure 4.4.  
Mann Whitney U tests looking for statistical differences between groups did not find any such 
differences in the degree of depression between MSA and PSP (p = 0.798), nor between male 
and female participants (p = 0.715). 
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Figure 4.4: Levels of depression as shown on the DASS-21 scale for both disease groups 
 
4.4.13 Treatments in MSA and PSP 
Other treatments thought relevant to the multiple symptoms and issues were recorded and are 
shown in figure 4.5. These treatments were verified from history taking, patient notes and 
patient prescriptions where possible. It was not possible to verify treatments previously tried 
then discontinued as patient recollection and documentation was inconsistent. A greater 
proportion of MSA patients were taking dopaminergic therapies (78.3% or 18/23) than the 
PSP group (45.9% or 11/24). Similar proportions were taking analgesics, and bone protection. 
As might be expected from the symptom-profile in MSA, greater proportions of MSA 
patients compared to PSP were using medications for urinary symptoms and orthostatic 
hypotension (9/23 versus 3/24 and 5/23 versus 1/24 respectively). Only 6 patients overall 
were known to be on bone protection. Antidepressant use and medication for drooling was 
discussed previously but are also shown in figure 4.5.  
This suggests that there may be better perceived dopaminergic treatment response in MSA 
groups than in PSP groups though the numbers here are small. This does not take into account 
previous responsiveness which may have been lost nor the fact that PSP patients may require 
higher doses to get any response (which means that side effects may preclude its use) 
(Brooks, 2002). 
66 
 
 
Figure 4.5: Numbers of patients from each disease group taking symptomatic treatments 
 
More MSA patients were taking dopaminergic agents than patients with PSP. The majority of 
the patients with MSA taking dopaminergic medications felt they had some beneficial 
response to them (16/18, 88.9%). See figure 4.6. Of the 7 MSA-C patients, 5 were not taking 
dopaminergic medication.  In the PSP group 11 patients, 5 PSP-RS and 6 PSP-P, were taking 
dopaminergic medication, and all of these patients felt they had some benefit from these 
medications. It should also be considered that stimulation of the dopaminergic reward centres 
could drive some subjective feeling of benefit rather than symptom improvement (Wolters et 
al., 2008). 
Some implications from this may be considering more rigorous assessment for depression in 
PSP, and reviewing why acceptability of treatments in drooling issues for MSA is poor. Have 
medications with fewer centrally-acting effects been considered, including non-
pharmacological measures? In terms of dopaminergic therapy, the majority of people 
receiving it felt benefit (though this was subjective, which has limitations). This should be 
borne in mind that despite the higher incidence of poorer responsiveness, there is a possibility 
of a degree of benefit and these therapies should be at least trialled.  
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Figure 4.6: Comparison of participants taking dopaminergic treatments and whether there is subjective benefit 
compared across disease types 
 
4.4.14 Palliative Care Need Using POS-S-PD Scale 
The POS-S-PD scale was used as a surrogate of palliative care need in the context of 
symptoms associated with Parkinsonism. Previous work has included patients with MSA and 
PSP as well as PD. Saleem et al. (2013) whose paper introduced the POS-S-PD, described the 
score obtained on the POS-S-PD as the palliative care need with regards to symptoms relevant 
to Parkinsonism. 
All 47 patient-participants in the study completed the POS-S-PD. The overall scores for all 
patients and for MSA and PSP groups separately were normally distributed on SW scores and 
visual inspection of histograms. The mean score of the POS-S-PD was 27.2 ± 11.5 (n = 47). 
In Saleem’s study including advanced PD (with MSA and PSP) the mean score was 10.68 ± 
3.89, for comparison. See table 4.8.  
 
Overall POS Scores for Patient-Participants 
Participants Mean (SD) N 
Overall (MSA and PSP) 27.2 ± 11.5 47 
MSA  29.4 ± 11.5 23 
PSP 25.2 ± 11.3 24 
Table 4.8: POS scores for all patients, MSA and PSP subgroups. Mean scores shown with SD.  
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4.4.15 Differences between disease groups using POS-S-PD 
An independent t-test was carried out to compare the POS-S-PD scores of the MSA group 
compared with the PSP group. No statistical differences were found between the two disease 
types in terms of overall POS-S-PD score [(95% CI, -2.4710 to 10.9203), t(45) = 1.271, p = 
0.210]. There was also no influence on patient sex in terms of POS-S-PD score when 
independent t-tests were carried out [(95% CI, -1.224 to 12.086), t(45) = 1.643 , p = 0.107]. 
In order to assess the degree of palliative care need whilst accounting for the degree of 
disability (BADLS score), differences between the two disease groups POS-S-PD scores were 
explored using ANCOVA; removing any influence that disability has on POS-S-PD scores. 
No differences were seen between the two groups using the ANCOVA when amount of 
disability was accounted for; F(1,44) 2.431, p = 0.126, partial η2 0.052, 95% CI  (-1.469, 
11.511). Therefore, in this study, the palliative need as measured by the POS-S-PD was not 
statistically different between MSA and PSP, which remained the case when the degree of 
disability was accounted for. 
 
4.4.16 Highly-Rated Symptoms on POS-S-PD 
The most highly nominated symptoms for the overall cohort were problems using legs, 
communication, falls, fatigue and difficulty with bladder control. This is shown in figure 4.7.  
 
Figure 4.7: Ten most highly scored symptoms in whole cohort on POS-S-PD. Tied results included.  
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In both the MSA and PSP subgroups, problems with legs (including walking problems) was 
the most highly scored symptom. In the MSA subgroup, the greatest cumulative scored 
symptoms (as well as leg problems) were fatigue, bladder problems, communication issues 
and sleepiness. In the PSP group (as well as leg symptoms) falls, dribbling, communication 
issues and fatigue were the most highly scored. See figure 4.8.  
 
Figure 4.8: Ten most highly scored (cumulative score) symptoms in MSA group (left) and PSP group (right) on 
POS-S-PD. Tied results included.  
 
A breakdown of median scores overall, median scores for each disease group, and frequency 
of responses for each degree of severity for symptoms is shown in table 4.9. Median scores 
have been used, as the POS-S-PD used a Likert scale. 
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Symptom Median Score 
Overall 
Median Score 
MSA, PSP 
None N (%) Slight N (%) Moderate N (%) Severe N (%) Overwhelming N (%) 
   
MSA PSP MSA PSP MSA PSP MSA PSP MSA PSP 
Pain 2 2, 0.5 6 (26.1) 12 (50.0) 3 (13.0) 2 (8.3) 7 (30.4) 4 (16.7) 5 (21.7) 5 (20.8) 2 (8.7) 1 (4.2) 
Spasm/Cramp 1 1, 0 8 (34.8) 15 (62.5) 6 (26.1) 3 (12.5) 4 (17.4) 2 (8.3) 4 (17.4) 3 (12.5) 1 (4.3) 1 (4.2) 
Fatigue 2 3, 2 0 5 (20.8) 5 (21.7) 6 (25.0) 6 (26.1) 7 (29.2) 8 (34.8) 4 (16.7) 4 (17.4) 2 (8.7) 
Shortness of Breath 1 1, 0 8 (34.8) 14 (58.3) 5 (21.7) 4 (16.7) 7 (30.4) 5 (20.8) 3 (13.0) 1 (4.2) 0 0 
Nausea 0 0, 0 13 (56.5) 19 (79.2) 4 (17.4) 2 (8.3) 4 (17.4) 1 (4.2) 1 (4.3) 2 (8.3) 1 (4.3) 0 
Vomiting 0 0, 0 18 (78.3) 20 (83.3) 3 (13.0) 1 (4.2) 2 (8.7) 2 (8.3) 0 1 (4.2) 0 0 
Poor Appetite 0 0, 0 14 (60.9) 16 (66.7) 7 (30.4) 3 (12.5) 1 (4.3) 1 (4.2) 1 (4.3) 3 (12.5) 0 1 (4.2) 
Dysphagia 0 0, 0 2 (8.7) 6 (25.0) 13 (56.5) 7 (29.2) 7 (30.4) 5 (20.8) 1 (4.3) 5 (20.8) 0 1 (4.2) 
Sleepiness 2 2, 2 0 8 (33.3) 6 (26.1) 2 (8.3) 9 (39.1) 6 (25.0) 5 (21.7) 8 (33.3) 3 (31.0) 0 
Poor Sleep 1 1, 0 10 (43.5) 13 (54.2) 5(21.7) 4 (16.7) 4(17.4) 3 (12.5) 3 (13.0) 4 (16.7) 1 (4.3) 0 
Constipation 1 2, 1 5 (21.7) 9 (37.5) 6 (26.1) 6 (25.0) 8 (34.8) 5 (20.8) 1 (4.3) 3 (12.5) 3 (13.0) 1 (4.2) 
Problems with Bowel Control 1 2, 0 6 (26.1) 13 (54.2) 5 (21.7) 4 (16.7) 3 (13.0) 3 (12.5) 5 (21.7) 4 (16.7) 4 (17.4) 0 
Problems with Bladder Control 2 3, 1.5 1 (4.3) 10 (41.7) 7 (30.4) 2 (8.3) 2 (8.7) 5 (20.8) 8 (34.8) 5 (20.8) 5 (21.7) 2 (8.3) 
Problems with Arms 2 2, 2 6 (26.1) 6 (25.0) 5 (21.7) 4 (16.7) 4 (17.4) 8 (33.3) 7 (30.4) 5 (20.8) 1 (4.3) 1 (4.2) 
Pressure Sores 0 0, 0 19 (82.6) 21 (87.5) 3 (13.0) 1 (4.2) 1 (4.3) 0 0 2 (8.7) 0 0 
Problems with Legs 3 3, 3 2 (8.7) 1 (4.2) 2 (8.7) 1 (4.2) 3 (13.0) 5 (20.8) 10 (43.5) 8 (33.3) 6 (26.1) 9 (37.5) 
Communication Difficulties 2 2, 2 1 (4.3) 6 (25.0) 3 (13.0) 2 (8.3) 10 (43.5) 6 (25.0) 6 (26.1) 7 (29.2) 3 (13.0) 3 (12.5) 
Dribbling 2 1, 2 4 (17.4) 3 (12.5) 8 (34.8) 5 (20.8) 5 (21.7) 7 (29.2) 4 (17.4) 5 (28.8) 2 (8.7) 4 (16.7) 
Falling 2 1, 3 5 (21.7) 4 (16.7) 7 (30.4) 2 (8.3) 3 (13.0) 5 (20.8) 5 (21.7) 5 (20.8) 3 (31.0) 8 (33.3) 
Hallucinations 0 0, 0 19 (82.6) 20 (83.3) 3 (13.0) 3 (12.5) 0 0 1 (4.3) 0 0 1 (4.2) 
 
Table 4.9: Median scores for each symptom on the POS-S-PD scale including median overall score for each disease type 
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Chi-squared tests of homogeneity (or Fisher’s exact test where appropriate) were performed 
to analyse whether there was a statistical difference in the proportions of individuals with 
more severe symptom ratings compared to milder symptoms (none to moderate compared 
with severe to overwhelming) from the POS-S-PD assessment.  The highest rated symptoms 
were included.  There were no statistically significant differences in proportions between the 
two groups. There was a trend towards difference however in two symptoms; bladder 
problems and fatigue which all had a greater proportion of patients with MSA in the more 
severe category. See table 4.10.  
 
Symptom χ2 p 
Leg Problems 0.009 0.924 
Falls 1.785 0.181 
Fatigue 3.670 0.055 
Communication 0.031 0.859 
Bladder issues 3.595 0.058 
Sleepiness 0.011 0.917 
Dribbling 0.704 0.401 
Arm Problems 0.537 0.464 
Pain 0.173 0.677 
Constipation 0.004* 1.000 
Dysphagia 3.952* 0.097 
Table 4.10: Chi-square tests of homogeneity comparing rated symptom severity between disease groups.  
* = indicates Fisher’s exact test used. Items shown in bold approach show a trend toward statistical significance 
 
4.4.17 Perceptions of Palliative Care 
Patient-participants were asked if they understood what palliative care was. Their responses 
were recorded as yes or no. 27 participants felt that they understood the purpose of palliative 
care and 13 of those (48.1%) had actually received PC input of some kind (listed in table 
4.11). None had refused PC input. 
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  Day 
Hospice 
None Macmillan 
Team 
PC Clinic Refused Total 
Understand what 
PC is 
Yes 6 13 3 5 0 27 
No 4 12 1 2 1 20 
Total 10 25 4 7 1 47 
Table 4.11: Cross-tabulation participants who felt they understood what PC was and whether they actually 
received it 
 
20 participants felt that they did not know what PC was, though 7 of these had received some 
in the form of SPC clinics, day hospice or Macmillan team input. 13 of the 20 (65%) had not 
received PC intervention (1 having refused it); a greater proportion than those who felt they 
had some understanding of PC. 
Participants were then asked what they thought palliative care as a service or concept meant, 
even if they had said they did not know above; some tried to give a definition. These 
definitions were taken down verbatim and were grouped into themes; seven similar 
definitions in total. If multiple themes were contained within a response, participants were 
asked what they thought the most important aspect of palliative care was and this was the 
definition used. 29 patient-participants gave a definition, 18 responded with ‘do not know’. 
The second most frequent response was ‘end-of-life’ or ‘easing suffering for the dying’. 
41.1% of those who gave a definition felt that this was what PC was. The next most frequent 
response (34.5% of those who gave a definition) was grouped into ‘help and care’ which 
included ‘extra help’, and ‘more caring medicine’. Only one person felt that PC was a service 
for people with a cancer diagnosis. See table 4.12 and figure 4.9. 
 
 Frequency Percentage 
End of life/dying 12 25.5 
Help and care 10 21.3 
Serious/debilitating illness 2 4.3 
Cancer 1 2.1 
Making life easier 2 4.3 
Pain and symptom control 1 2.1 
Dignity 1 2.1 
Don’t know 18 38.3 
Total 47 100.0 
Table 4.12: Definitions for PC grouped into similar themes 
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Figure 4.9: Pie chart of perception of Palliative Care by Patient-Participants grouped into similar themes 
 
4.5 Discussion 
In terms of recruitment, there was an even representation of individuals with MSA and PSP 
(n=23 and 24, respectively). The median disease duration was 33.0 months in MSA compared 
with 25.5 months in PSP, with the latter having a larger IQR of 30.8 months compared with 
29 months. Over 2/3 of the MSA cases were MSA-P which is in keeping with proportions of 
MSA subtypes seen in European populations (Kollensperger et al., 2010). The MSA-C 
subgroup had a longer disease duration than MSA-P at 34 compared with 29 months, 
respectively. Previous work has suggested that patients with MSA-C may have a modestly 
longer survival, which may account for this (Ben-Shlomo et al., 1997). In the PSP group, over 
half had the PSP-RS form and only one pure akinesia with gait freezing. Again, this is in 
agreement with literature describing a predominance of PSP-RS and PSP-PAGF as a ‘rare’ 
phenotype, with PSP-RS having a shorter disease duration. PSP-RS has a more progressive 
course than the PSP-P variant (Williams et al., 2005; dell'Aquila et al., 2013). The mean ages 
of individuals with MSA was in their 60s whereas individuals with PSP were in their 70s, in 
keeping with work predicting older age of onset in PSP (O'Sullivan et al., 2008). This 
suggests that the cohort recruited was representative of the disease groups in terms of 
subtypes and characteristics and that inferences are more likely to be generalisable. 
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In terms of severity of disease, despite the range of patients enrolled (from having been 
diagnosed 5 months ago to having carried a diagnosis for 17 years), 83% of the 47 enrolled 
patients were categorized as H&Y 4 or 5. This emphasises the relentless progression and early 
morbidity that patients with AP face. By contrast, patients with Parkinson’s disease are 
expected to reach H&Y stage 4 at between 7 and 14 years after disease onset (Poewe, 2006). 
When the milestones of disease were considered, falls overall were a key symptom which 
occurred prior to diagnosis and fits with previous work and recommendations that early falls 
are red flags for both conditions (Tada et al., 2007; O'Sullivan et al., 2008; Kollensperger et 
al., 2010). However, in MSA, there was a median time of 1 month before a diagnosis was 
reached and in PSP 18.5 months. This may be because MSA is diagnosed in a timelier manner 
than PSP, or that PSP produces instability and a tendency to fall in advance of other features 
which might facilitate the diagnosis. Speech problems were more numerous in both 
conditions than swallowing issues and the latter tended to follow speech problems (though 
speech is arguably more subjective than swallowing problems). Approximately half of both 
groups had required acute hospital admissions related to their AP and half of each group 
needed a wheelchair for anything other than short distances.  
Being able to predict the onset of key milestones such as early speech disturbance or falls, is 
not only helpful when seeking to make a diagnosis of AP but also in guiding clinicians on 
preparing patients and families for choices and challenges ahead in a timely way, such as the 
swallowing issues which may require patients to choose whether they would have a PEG tube 
or need for wheelchair triggering adaptations to their home. Therefore, these trends are 
helpful as a guide as to when, on average, problems might be expected to arise and how to 
plan with them, though work on larger cohorts is required.   
An interesting finding was the suggestion that patients themselves underestimate the presence 
of low mood in the context of their disease, which has implications for clinicians asking about 
mood and depression and should be borne in mind as a complicating factor, even if patients 
initially feel their mood is not low. This was particularly so in the PSP group (though also to a 
lesser extent in the MSA group) where subjective depression was lower than objective 
depression using the DASS-21 scale. 
This difference in the PSP group between perceived low mood and objective mood scores 
could be explained in several ways. If someone does not think they are depressed but score 
highly on a rating scale do they just not realise it? Can someone be depressed if they do not 
perceive it? It may be that the DASS-21 has detected apathy for example, rather than low 
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mood. Is there a ‘distancing’ effect i.e. are the frontal cognitive problems ‘sparing’ PSP 
patients some of the distress of reflecting upon progressing disease? Further work should 
explore different research tools measuring depression against measures of apathy and 
cognitive impairment in PSP and other diseases with this pattern of cognitive impairment, 
seeking validity in depression measurement for these groups.  
The symptoms that were represented in the ten most highly scored issues in both disease 
groups were leg problems (incorporating walking), falls, difficulties using arms, dribbling, 
communication issues, sleepiness, bladder problems, and fatigue. In Chapter 7, which 
explores the experience of living with AP using qualitative methods, communication and 
speech was frequently discussed as a fundamental issue influencing QoL in both conditions, 
affecting the ability to connect to others and impacting the perception of self. Interestingly, 
though falls were present in 83% of MSA patient-participants, they were not thought to be 
one of the chief difficulties that MSA patients experience in terms of symptom-burden and 
came seventh. There was no significant difference between palliative symptom burden using 
POS-S-PD using t-tests nor when the degree of disability was accounted for using ANCOVA 
testing, suggesting that, at least in this small cohort, palliative need is equivalent in both 
conditions though different symptoms may predominate. When the symptoms with the 
highest cumulative scores in the POS-S-PD tool were compared between groups using chi-
squared testing, there were not significant differences though there were trends towards 
greater urinary disturbance and fatigue in the MSA group. Finally, palliative care in terms of 
its meaning and whether patients received it was explored. Nearly half of the overall cohort 
had received some palliative input (22/47, 46.8%) including Macmillan nurse visits, day 
hospice access or SPC clinic. In fact, some patients were not aware that these services 
represented palliative care. Of those who had received some PC input, 7/22 or 31.8% could 
not define it. Does this matter if recipients of PC derive benefit from the service? An issue 
which may arise from a lack of public knowledge of the mandate of PC and the benefits it 
could bring, include anxiety should patients be referred and refusal due to this concern. It 
should be noted that nearly half of those who gave a definition, felt PC was ‘end-of-life care’, 
though a PC approach is increasingly being offered earlier in disease to maximise QoL in life-
limiting conditions. Therefore, perceptions of PC as “just for the end-of-life” could be a 
barrier for patients who could derive benefit from it. It is of interest that seven participants 
who were receiving palliative care felt they could not give a definition for it, though they 
valued it nevertheless. This could mean that the holistic nature of PC is not explained well to 
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patients or possibly that explanations are not retained but nevertheless the essence of the care 
is appreciated.  
In conclusion, the demographics of the study cohort appear to be representative of AP in 
terms of proportions, gender and subtypes, as described in previous work. Palliative symptom 
burden is high, almost double that shown in previous work made up mainly of PD (H&Y 4 
and 5) and is not statistically different between disease type or gender. Leg problems, 
communication and fatigue were highly rated in common between both disease types and 
larger studies in future on AP should pay consideration to these concerns. Milestones which 
tended to occur prior to diagnosis in MSA were autonomic symptoms and falls and in PSP 
falls alone, but far earlier than the onset of MSA (a difference of 17.5 months in the median 
onset). Depression was not felt to be present as often as objective depression scores 
suggested, which may suggest deficiencies in the scales available for these patients and PC as 
a concept could not be explained by many patients and the most frequently-cited response 
given was ‘end-of-life care’.  
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Chapter 5. Quality of Life in Patients with MSA and PSP 
 
5.1 Background 
As described in Chapter 1, QoL is increasingly recognised as an important area of research. 
How various factors can impact upon QoL in PD has been described though few similar 
studies have been carried out in atypical Parkinsonism.  
In this study, three different QoL measures were used to assess patient participants; the 
disease-specific MSA-QoL designed for patients with MSA and the disease-specific PSP-QoL 
designed for patients with PSP. The details of these scales and how to administer them is 
given in Chapter 3.  These are specific to the particular condition, but not comparable between 
groups. All participants also received the SEIQoL-DW, which is a general, subjective scale 
intended to represent a more holistic instrument as opposed to concentrating purely on how 
QoL is affected in relation to disease.  In this chapter, the continuous overall output score 
from the SEIQoL-DW, MSA-QoL and PSP-QoL was used to establish associations and 
correlations and then explored using regression modelling, looking for factors predicting these 
QoL measures. 
Later, the SEIQoL-DW will be analysed in terms of its descriptive components, looking at 
domains which patients nominated and found meaningful, and whether there were any 
differences between the two disease groups. 
 
5.2 Aims 
The aims of this chapter were to find associations with QoL measures in the patient groups, 
considered together and in the MSA and PSP disease subgroups.  Differences between the 
MSA and PSP groups in terms of their quality of life were then investigated taking into 
account degree of disability. The SEIQoL-DW was then explored as a rich tool, which gives a 
wealth of information on subjective quality of life. 
 
5.3 Methods 
The results in this section were analysed using quantitative statistical methods. The statistic 
software package used was the IBM SPSS version 23 software package. Differences between 
groups were assessed using independent t-tests to explore whether there were overall 
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differences between the two disease groups. ANCOVA testing was then carried out, which 
takes into account another variable (or covariate) and corrects for this, as was used in Chapter 
4. Correlations between variables were tested using Pearson’s or Spearman’s Rho (the former 
if normally distributed, the latter if not) and multiple linear regression methods were used to 
models whether factors could predict for outcomes. More details of these statistical tests are 
provided in Chapter 3: Methods. 
 
5.4 Results 
5.4.1 Associations between disease specific QoL and other factors 
Disease-specific QoL scores for MSA and PSP were utilised in this study as they were 
constructed and validated to include issues that might be of particular concern to that group of 
patients e.g. questions on apathy in PSP-QoL and postural hypotension symptoms in the 
MSA-QoL. 
As the two QoL scores are distinct and not directly comparable, tests of correlation were 
carried out on each of the QoL scores, seeking associations with key variables such as disease 
severity, duration and age. The MSA-QoL and PSP-QoL have a scoring system which rises as 
the disease-specific QoL falls. 
 
5.4.2 Correlations with MSA-QoL 
The MSA-QoL was tested for normality of distribution using histograms and the Shapiro-
Wilk (SW) test was performed. The SW test did not violate the null hypothesis of normality 
(SW statistic 0.928, p = 0.100) though the histogram showed some skew. Other variables 
which were tested for their association with MSA-QoL were also assessed for normality using 
the same methods. If a non-normal distribution was found, correlation was assessed using 
Spearman’s correlation. Correlations with dichotomous variables used point-biserial 
correlation. See table 5.1 
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Variable Coefficient correlation Significance (p-value) 
Age  -0.140R 0.525 
Sex (PBS) -0.322b 0.134 
BADLS (disability) 0.366P 0.086 
Disease-specific severity 0.399P 0.59 
Depression (DASS-D) 0.821P 0.001 
Anxiety (DASS-A) 0.711P 0.001 
Palliative need (POS-S-PD) 0.772R 0.001 
Duration of disease (months) 0.308P 0.153 
Table 5.1: Correlation coefficients between MSA-QoL and other study measures. R=Pearson’s correlation 
coefficient, P=Spearman’s Rho correlation coefficient, b=point-biserial correlation.  
Rows in bold represent significant correlations between variable and MSA-QoL. 
 
There was a large, positive strength of association between MSA-QoL and depression 
(DASS-D), anxiety (DASS-A) and palliative need score (POS-S-PD), respectively. There was 
no significant association between disease-specific QoL, disability or severity (as measured 
on UMSARS), though there is a trend towards small-moderate level of correlation for the 
latter. When shown plotted on a scattergraph, visual inspection does not show a strong linear 
relationship (see figure 5.1).  
 
Figure 5.1: Scatterplot of MSA-QoL against UMSARS severity score. R=0.399 
 
By contrast, MSA-QoL plotted against palliative care need or DASS-depression shows a good 
linear relationship (see figures 5.2 and 5.3) 
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Figure 5.2: Scatterplot of MSA-QoL against 
palliative care need (POS-S-PD), R=0.772 
 
Figure 5.3: Scatterplot of MSA-QoL against DASS-
depression score, R=0.830
 
5.4.3 MSA regression modelling 
Multiple regression analysis was carried out using the three study variables which correlated 
with MSA-QoL score as independent variables (MSA-QoL being the dependent variable). 
The method of multiple regression used was backwards elimination; all predictors 
(independent variables) are placed in a regression model and then eliminated to judge the 
significance of its removal. If the predictor is not making a significant contribution to the 
predictive value of the model, it is removed. The remaining predictors are then assessed in a 
similar way. Here, predictors were only included in regression models if they correlated with 
the dependent variable in question. Variables which had significant correlation were tested 
with univariate regression to ascertain if they could predict for MSA-QoL. They were then 
combined together into a backward elimination regression to obtain a basic model. 
A basic model containing POS-S-PD and DASS-depression score gave an adjusted R2 of 0.76 
(76%), F (3,22) = 35.896, p = 0.001. DASS-anxiety did not contribute significantly to the 
model and was removed. Therefore, the POS-S-PD score, together with DASS-depression 
score, could explain 76% of the variance of the MSA-QoL score. The distribution of the 
residuals was approximately normal and the KS/SW tests of unstandardized and standardized 
residuals were not significant. See tables 5.2 and 5.3.  
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 β SE p-value 95% CI R2 adj F-value 
    LB                 UB   
POS-S-PD 0.772 0.378 0.001 1.318 2.892 0.577 30.949 
DASS-
depression 
0.830 0.642 0.001 3.049 5.721 0.675 46.607 
DASS-anxiety 0.658 1.336 0.001 2.568 8.124 0.406 16.019 
Table 5.2: Univariate regression coefficients for MSA-QoL. Significant results in bold text. SE= Standard error, 
CI=Confidence Interval, LB=Lower bound, UB=Upper bound, R2 adj=R2 adjusted value 
 
 
 β SE p 95% CI R2 adj F 
    LB                 UB   
POS-S-PD 0.401 0.375 0.009 0.312 1.877 
0.76 35.896 DASS-
depression 
0.569 0.726 0.001 1.489 4.520 
Table 5.3: Overall basic regression model for MSA-QoL when non-significant predictors removed. Significant 
results in bold text. SE=Standard error, CI=Confidence Interval, LB=Lower bound, UB=Upper bound,  
R2 adj=R2 adjusted value 
 
In this cohort of MSA patients, 76% of the variance of HR-QoL using the MSA-QoL can be 
predicted for by palliative need (POS-S-PD score) and depression (DASS-D). 
 
5.4.4 Correlations with PSP-QoL 
Similarly, the PSP-QoL was tested for normality of distribution using histograms and the 
Shapiro-Wilk (SW) test was performed. The SW test did not violate the null hypothesis of 
normality (SW statistic 0.986, p = 0.980) and the histogram demonstrated a normal 
distribution. Other study variables, such as age and severity, were also assessed for normality 
using the same methods. If a non-normal distribution was found, correlation was assessed 
using Spearman’s correlation, correlations with dichotomous variables using point-biserial 
(PBS) correlation. See table 5.4.  
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Variable Correlation coefficient Significance (p value) 
Age  -0.292R 0.167 
Sex (PBS) 0.000b 0.998 
BADLS (disability) 0.680R 0.001 
Disease-specific severity 
(PSPRS) 
0.781R 0.001 
Depression (DASS-D) 0.744P 0.001 
Anxiety (DASS-A) 0.428P 0.037 
Palliative need (POS-S-PD)  0.755R 0.001 
Duration of disease (months) -0.092P 0.670 
Table 5.4: Correlation coefficients between PSP-QoL and other study variables. R=Pearson’s correlation 
coefficient, Ρ=Spearman’s Rho correlation coefficient, b=point-biserial correlation. Rows in bold represent 
significant correlations between independent variable and PSP-QoL. 
 
Disease-specific severity, disability, palliative need and depression had a strong positive 
correlation with PSP-QoL scores. Anxiety had a medium strength of positive correlation with 
PSP-QoL score. Scatterplots of the associations with disease-specific severity and palliative 
need are shown below to illustrate this (figures 5.4 and 5.5).
  
 
Figure 5.4: Scatterplot of PSP-QoL against PSPRS 
severity score, R=0.781 
Figure 5.5 Scatterplot of PSP-QoL against POS-S-
PD, R=0.755 
 
5.4.5 PSP regression modelling 
Backward multiple regression analysis was carried out using the four study variables which 
correlated with PSP-QoL score as independent variables (PSP-QoL being the dependent 
variable). Univariate analysis with each predictor variable was carried out (see table 5.5) and 
significant predictors were then considered together in a regression model (see table 5.6).  
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 β SE p 95% CI R2 adj F 
    LB                 UB   
PSPRS 0.781 0.313 0.001 1.183 2.480 0.592 34.339 
BADLS 
(disability) 
0.680 0.375 0.001 0.853 2.410 0.438 18.893 
DASS-
depression 
0.708 0.780 0.001 2.050 5.285 0.479 22.111 
DASS-anxiety 0.346 1.532 0.098 -0.531 5.824 0.079 2.983 
POS-S-PD 0.755 0.418 0.001 1.395 3.130 0.551 29.245 
Table 5.5: Univariate regression coefficients for PSP-QoL. Significant results in bold text. SE= Standard error, 
CI=Confidence Interval, LB=Lower bound, UB=Upper bound, R2 adj=R2 adjusted value 
 
 
 β SE p 95% CI R2 adj F 
    LB                 UB   
POS-S-PD 0.292 0.354 0.023 0.136 1.615 
0.82 36.029 
PSPRS 0.474 0.253 0.001 0.584 1.638 
DASS-
depression 
0.357 0.553 0.003 0.698 3.006 
Table 5.6: Overall basic regression model for PSP-QoL when non-significant predictors removed. Significant 
results in bold text. SE= Standard error, CI=Confidence Interval, LB=Lower bound, UB=Upper bound,  
R2 adj=R2 adjusted value  
 
The regression model containing PSPRS, POS-S-PD and DASS-depression score gave an 
adjusted R2 of 0.820 (82.0%). Therefore, PSPRS and POS-S-PD, together with DASS-
depression score could explain 82% of the variance of the PSP-QoL score. The distribution of 
the residuals was approximately normal and the KS/SW tests of unstandardized and 
standardized residuals were not significant.  
 
5.4.6 SEIQoL-DW regression modelling 
Associations with SEIQoL-DW were then tested using other study variables. It is worth 
noting, as discussed in the methods section that as QoL improves, SEIQoL-DW rises 
(compared to MSA-QoL and PSP-QoL which rise with worsening QoL). See table 5.7.  
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Correlations between SEIQoL-DW and study variables (combined and in disease subgroups) 
Variable SEIQoL-DW  
coefficient (p-value) 
MSA SEIQoL-DW 
coefficient (p-value) 
PSP SEIQoL-DW  
coefficient (p-value) 
BADLS (disability) 0.205R (0.183) 0.270R (0.225) 0.66R, (0.770) 
DASS-depression -0.323P (0.032) -0.239P (0.283) -0.379P. (0.082) 
DASS-anxiety -0.225P(0.142) -0.156P (0.487) -0.268P, (0.228) 
POS-S-PD -0.338R (0.025) -0.064R (0.777) -0.661R, (0.01) 
Duration of disease  0.176P (0.253) 0.212P (0.343) 0.150P (0.506) 
Table 5.7: Correlations between SEIQoL-DW score and other study variables. Significant results shown in bold 
R=Pearson’s coefficient, P=Spearman’s Rho. Duration of disease shown in months. 
 
When MSA and PSP patients were considered together, the model containing POS alone 
predicted 9.3% of the variance of SEIQoL-DW and the model was significant. F (2,41) = 
5.434, p = 0.025. 
There were no independent variables which predicted for SEIQoL-DW scores in the MSA 
group. In the PSP group POS-S-PD score accounted for 40.9% of the variance in SEIQoL-
DW in the PSP group, and was significant (p = 0.001); therefore, rising palliative need in the 
PSP group only produced a fall in subjective QoL. This suggests that the small predictive 
value of POS-S-PD for SEIQoL-DW in both groups combined, is driven by the moderate 
predictive value of POS in the PSP subgroup.  
 
5.4.7 Differences between patient groups 
As both MSA and PSP patient groups had completed the SEIQoL-DW, any differences in 
scores were investigated. 22 MSA and 22 PSP patients completed the SEIQoL-DW 
assessment. The mean MSA score was 55.3 (±22.4) and in PSP, 67.0 (±15.3). There was not a 
statistically significant difference between SEIQoL-DW score in patients with MSA and PSP 
using independent t-tests (95% CI -23.1 to 0.26), t(42) = -1.973, p = 0.055. However, there is 
a trend towards significance for MSA having a lower subjective QoL than PSP.  
The SEIQoL-DW scores were then explored for differences between the MSA and PSP 
groups accounting for level of disability (standard severity scores UMSARs and PSPRS are 
disease-specific and not directly comparable.  As most participants were at Hoehn and Yahr 
stage 4 or 5, this classification was less meaningful also. Therefore, the BADLS disability 
score was used to account for differences in level of disease and how this impacted activities 
of daily living. ANCOVA was used to compare the SEIQoL-DW scores between the disease 
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groups, using BADLS score as a covariate. Unadjusted means of SEIQoL-DW were 55.6 for 
MSA and 67.0 for PSP. Adjusted for disability, the mean scores were 55.9 for MSA and 66.7 
for PSP. After the effect of disability was accounted for, there was no significant difference 
between the means of MSA and PSP SEIQoL-DW scores. F (1,41) = 3.5, p = 0.068, partial ɳ2 
= 0.079. This is represented in figure 5.6. As the p-value is further from significance than 
using the t-test, this may suggest that degree of disability does account for some of the 
difference in QoL scores between the groups. 
 
Figure 5.6: Box plots showing SEIQoL-DW scores between MSA (green) and PSP (blue) disease groups. There 
is overlap in their distributions. 
 
5.4.8 SEIQoL-DW breakdown 
The SEIQoL-DW is a flexible tool which can produces a great deal of information about 
different aspects of the participant’s QoL beyond a continuous end-index. All patient-
participants had the opportunity to take the SEIQoL-DW. This was timed (from the 
completion of the rater’s explanation to the completion of the instrument). A judgement was 
then made by the rater as to the participant’s understanding of the tool, degree of fatigue and 
therefore validity of the results. All assessments were done alone with the rater only to reduce 
the bias which may be produced from having a family member present e.g. may feel 
compelled to rate ‘family’ as having greater importance etc. The SEIQoL-DW administration 
data is given in table 5.8.  
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Carers had the opportunity to take the SEIQoL-DW after it was added to the protocol using an 
ethical substantial amendment; in part due to the interest carers took in the process when 
applied to their family member and interest in trying for themselves. The carers’ nominated 
domains will also be considered in this section for completeness sake.   
 
Variable MSA (N=22) PSP (N=22) 
Time taken, excluding 
explanation (minutes) 
17.8 mean 
16.0 median 
SD 6.43 
23.3 mean 
24 median 
SD 5.41 
Assistance needed None 14 (63.6%) 
Part 4 (18.2%) 
Full 4 (18.2%) 
None 6 (27.3%) 
Part 10 (45.5%) 
Full 6 (27.3%) 
Fatigue None 19 (86.4%) 
Some 3 (13%) 
A lot 0 
None 16 (66.7%) 
Some 4 (18.2%) 
A lot 2 (9.1%) 
Understanding Good 21 (95.5%) 
Some 1 (4.5%) 
Good 22 (95.7%) 
Some 0 (0%) 
Poor 1 (4.3%) 
Validity Valid 22 (100%) Valid 20 (83.3%) 
Some 1 (4.2%) 
Questionable 1 (4.2%) 
Table 5.8: SEIQoL-DW completion data for all patients. 
 
Overall, 58 different domains were nominated when all groups were considered. These are 
shown in Appendix C. Although all statements of nomination of life areas were recorded, by 
necessity these had to be simplified into domains to allow analysis. There were 36 domains 
nominated by MSA patients and 36 by PSP patients; 24 of these domains were shared 
between the patient groups. In the MSA carer group 34 domains were nominated and in the 
PSP carer group 29 domains were nominated; 25 of these were shared between the carer 
groups. When domains were compared between the four groups, 19 were nominated in 
common. This suggests that QoL is made up of very diverse and broad categories according 
to individuals, but there is some overlap in concerns, even between different forms of AP and 
between patients and carers.  
The most frequently nominated domains are shown in figure 5.7 below. In all groups, the 
most frequently nominated domain was ‘family’ (nominated by 82% of MSA patients and 
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77% of PSP patients and by 80% of MSA carers and 94% of PSP carers). Marriage or partner 
featured in all top five domains for each category (included tied positions) ranging from a 
frequency of 59% in PSP patients to 25% in PSP carers. 
 
Figure 5.7: Bar charts showing most frequently nominated domains in SEIQoL-DW between respondent groups 
(5 most frequently nominated shown, tied totals included). 
 
5.4.9 RAND-36 score comparisons 
The RAND-36 comprises of eight sub-scores and two overall composite scores. This is 
explained in the methods section. These ten categories were compared between the groups 
using Mann-Whitney U testing.  The scores which showed significant differences between the 
groups were the overall mental and physical composite scores (RAND-36 MCS and PCS), 
energy level and general health. The median scores for these domains are shown in table 5.9.  
The categories which showed no significant differences between groups were physical, 
physical role, emotion, emotional role, social functioning and pain.  The composite scores 
were derived by using the weightings described in Farivar et al. (2007). In terms of both 
physical and mental well-being, MSA patients had lower median scores representing poorer 
well-being compared to PSP patients. Of the eight sub-scores, energy levels, and general well-
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being were significantly different between the two disease types. MSA had lower median 
scores than PSP in both of these subdomains also. 
 
RAND-36 domain Mann Whitney U 
(p-value) 
Median score for disease groups if 
significant differences 
  MSA PSP 
Physical Composite Score 0.049* 27.1 31.3 
Mental Composite Score 0.028* 31.2 38.4 
Physical 0.464 0.0 5.0 
Physical role 0.720 0.0 0.0 
Emotional 0.359 64.0 72.0 
Emotional role 0.447 0.0 16.7 
Energy 0.009* 20.0 45.0 
Social functioning 0.244 12.5 25.0 
Pain 0.280 45.0 57.5 
General 0.028* 25.0 40.0 
Table 5.9: Summary of Mann Whitney U comparisons between disease groups for RAND-36 domains.  
Significant results shown in bold and marked with * (p significance level = 0.05) 
 
5.5 Discussion 
When disease-specific QoL was considered, palliative care need and depression were found to 
be predictive in MSA. While in PSP, palliative care need, depression and disease-specific 
severity were predictive of QoL. Some possible reasons for this include lesser cognitive 
impairment in MSA allowing greater insight into condition, which may cause distress earlier 
in disease course.  Or, in contrast, these patients may have the cognitive capacity to adjust to 
their condition in later stages. Similarly, concrete thinking and frontal lobe dyscognitive 
symptoms in PSP could interfere with adjustment and acceptance, making the physical 
manifestations of illness impact more directly on QoL. Another possibility is that PSPRS as a 
scale reflects severity more accurately than the UMSARS scale, and therefore, has a greater 
predictive power in HR-QoL. This is probably unlikely as both scales are validated and 
widely used internationally in observational and randomised-controlled trials.  
When subjective QoL was analysed (subjective and individual-focussed as opposed to HR-
QoL which concentrates on QoL in relation to disease), there were far fewer associations seen 
with study variables or patient demographics. When all patients were considered together 
there was a small predictive effect of palliative care need. However, when MSA and PSP 
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patients were considered separately, it was found that there was a medium-sized predictive 
value for palliative care need in the PSP group and no predictions could be made in the MSA 
group. One possibility for this is that patients with PSP may be more impacted by physical 
symptoms, whereas in MSA there may be other factors influencing subjective QoL which 
have not been explored in this study. Maybe MSA patients focus on other aspects of life 
beyond disease symptoms due to their retained cognition, whereas PSP patients remain more 
fixed on the physical manifestations of their disease.  
Some considerations are that SEIQoL-DW as an individual and subjective representation of 
QoL is much more heterogeneous and as such, straightforward relationships with any one 
measure might be less likely. SEIQoL-DW does not focus the patient on their disease and 
activities they can no longer do as a consequence, but is open to all aspects of the patients’ 
life. This may act as a reminder of the factors which can improve QoL in the populations we 
care for. When it is considered that neither the MSA nor PSP patient groups considered 
‘health’ as one of the most frequently nominated domains and that ‘walking’ was tied only 4th 
in the PSP group, there are significant areas of the patient experience which contribute to QoL 
beyond their disease. It must be noted that ‘family’ and ‘marriage/partner’ were the most 
highly rated domains across all both patient and carer groups. These are opportunities to 
enhance the patient experience in the face of a condition for which there is no disease-
modifying therapy yet available. Palliative care, with its inclusive ethos of supporting families 
and carers during the disease course, and after the death of the patient, is well-suited to 
enhance these aspects of QoL for these patients, as well as the health-related symptom aspects 
which impact disease-specific QoL.  
In terms of differences between the MSA and PSP groups, there were no significant 
differences in the overall SEIQoL-DW scores, though mean MSA scores were lower and 
there was a trend toward significance. When accounting for degree of disability using BADLS 
there were still no significant differences, though MSA patients had lower mean scores, both 
unadjusted and adjusted for disability. When RAND-36 scores were compared, there were 
significant differences between patient groups in terms of overall physical and mental well-
being (Physical and Mental Composite Scores), energy and general health. In all RAND-36 
scores where there were significant differences, MSA patients had lower ranked median 
scores (thus lower well-being) than PSP patients. These scores are generic, so not disease-
specific but unlike SEIQoL-DW they take a fairly ‘mechanistic’ view to well-being, looking 
chiefly at functional abilities in each domain and not including reflection or judgement (the 
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key difference between health status and QoL scores). Therefore, MSA patients may reflect 
more upon their disability than PSP patients, again a possible consequence of the greater 
frontal cognitive deficits which tend to be seen in PSP.  
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Chapter 6. Carers of Individuals with MSA and PSP 
 
6.1 Introduction 
This chapter will explore associations and relationships found in terms of carers of 
participants with MSA and PSP.  All but one participant (who had PSP-PAGF) had a carer 
who took part in the study. The patient was keen to take part and had input from a family 
member but they did not later attend to take part in the study. It was decided to retain and use 
the data collected by this patient-participant rather than exclude their contribution as their 
carer chose not to attend (his data was used in the analysis in Chapters 4, 5 and 7).  
 
6.2 Aims 
The aims of this chapter are to explore the descriptive data to describe similarities and 
differences in the care-givers of participants with MSA and participants with PSP, to find 
whether there are differences in the levels of strain and QoL (using various measures) 
between the MSA carer group and PSP carer group, and whether any associations existed 
between study variables collected, carer strain and carer QoL. Finally, comparisons will be 
made between patients and carers using generic measures, looking at whether certain groups 
have particular issues which may be of interest clinically.  
 
6.3 Methods 
In this chapter, comparison of variables between the MSA and PSP groups was carried out, 
first using independent t-tests and then using ANCOVA, accounting for disability in each 
case. This method makes adjustments for the variable being tested, accounting for a covariate 
and then looks for any significant differences. Fisher’s exact test was used instead of chi-
squared when proportions between groups were compared and there were scarce numbers in 
one category. Fisher’s exact test generates a significance value only and no other test statistic.  
The statistical tests used in this chapter have been discussed in Chapter 3. 
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6.4 Results 
6.4.1 Carer Demographics. 
There were 46 carers who took part in this study and all were informal carers (i.e. not paid or 
employed to provide care), as required by the study criteria. As discussed in the introduction, 
there was a single patient-participant who did not have a carer. 
There were 23 carers of participants with MSA and 23 PSP carers. Their demographic 
information is shown in table 6.1.  
 
  
Disease type Total Test of 
proportions 
2 (p-value) 
  
MSA n (%) PSP n (%) n (%)  
Carer sex Female 15 (65.2) 13 (56.6) 28 (60.9) χ2(1) = 0.546 
p = 0.763 
 
Male 8 (34.8) 10 (43.5) 18 (39.1) 
      
Employment 
status 
Employed 12 (52.2) 6 (26.1) 18 (39.1) 
χ2(1) = 3.286 
p = 0.130  Unemployed 0 0 0 (0) 
 Retired 11 (47.8) 17 (73.9) 28 (60.9) 
      
Driving Driver 18 (78.3) 18 (78.3) 36 (78.3) χ2(1) = 0 
p = 1  Non-driver 5 (21.7) 5 (21.7) 10 (21.7) 
      
Relationship 
to patient 
Spouse/Partner 18 (78.3) 19 (82.6) 37 (80.4) 
p = 0.724 *  Daughter/Son 4 (17.4) 3 (13.0) 7 (15.2) 
 Friend 0 (0) 1 (4.3) 1(2.2) 
 Sibling 1 (4.3) 0 (0) 1 (2.2) 
Table 6.1 Demographic information of carer-participants. Test of 2 proportions have used to detect differences 
between groups, *=indicates Fisher’s exact test was used 
 
There was a preponderance of female carers in both the MSA and PSP groups; 15 in the MSA 
group and 13 in the PSP group. A test of two proportions was performed, and this showed 
there was not a statistically significant difference between the two carer groups in terms of the 
proportions of male and female carers (χ2(1) = 0.546, p = 0.763). See table 6.1 and figure 6.1.  
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Figure 6.1: A cluster column chart showing frequency of carer sexes in MSA and PSP groups 
 
6.4.2 Age 
In terms of carer ages, the median age in the MSA group was 63.0 years (IQR 18.0) and in the 
PSP group, 69.5 (IQR 9.5). There was no statistical difference between the carer groups when 
the median ages were compared (using Mann-Whitney U tests due to their non-normal 
distribution). Nevertheless, more carers were in their 60s and 70s in MSA and in their 70s in 
PSP, as demonstrated by figure 6.2.  
 
Figure 6.2: Histograms showing distribution of carer ages in MSA (green) and PSP (blue) 
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The median duration of care-giving was 36 months in the MSA group and 48 months in the 
PSP group so a trend was seen toward longer duration of care in the PSP group.  
The distributions of care-duration for each condition were not normally distributed. Mann 
Whitney U tests were used to compare the distribution of care duration between the two 
disease types and no significant differences were found. The distribution was skewed toward 
a shorter duration of care of less than 100 months in both conditions, see figure 6.3.  
 
 
Figure 6.3: Histograms of carer age for MSA (green) and PSP patients (blue). Neither show a normal 
distribution. 
 
6.4.3 Relationship to patient 
The majority of carers who took part in the study were the partners or spouses of the patient. 
Of the 42 patient-partner pairs, there were 41 mixed-sex relationships and one same-sex 
relationship. This partner-as-carer majority reflects the previous literature which has found 
that partners (especially in degenerative diseases which tend to affect people in middle-age or 
older), tend to provide the bulk of unpaid care (Goldsworthy and Knowles, 2008; Greenwell 
et al., 2015).  Only one participant in the PSP group had a non-relative carer (who was not a 
partner).  When comparing proportions between groups, there were insufficient numbers in 
each category to use chi-squared tests so Fisher’s exact test was used to compare proportions 
between partners and non-partner groups (as Fisher’s exact can only be used to compare 2 
groups). There was no significant difference between groups, p = 0.724.  See table 6.1.  
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6.4.4 Carer Employment 
Carers were asked about their employment status. They were asked whether they were still 
working, seeking work/unemployed or retired.  No participants defined themselves as 
unemployed. 52.2% of MSA carers were still in paid work compared with 26.1% of PSP 
carers. A test of two proportions did not find a significant difference in the proportions of 
carers still in work between the two disease groups though a greater proportion of MSA carers 
were still employed. (χ2(1) = 3.286, p = 0.130) See table 6.1 and figure 6.4. 
 
 
Figure 6.4: Bar chart of employment frequencies for carers in MSA and PSP groups 
 
6.4.5 Driving 
Driving, which may be important in terms of care-giving and mobility to hospital 
appointments and similar, had an equal distribution in the MSA and PSP groups. There was 
no significant difference between drivers and non-drivers between the MSA and PSP carer 
groups (see table 6.1). When a cross-tabulation was produced looking at the proportions of 
non-drivers by sex, 28.6% (8) women were non-drivers whereas only 11.1% (2) men were 
non-drivers. As the sample size was too small for a test of two proportions, Fisher's exact test 
was run. There was no statistically significant difference in proportions of men and women 
who were non-drivers, p = 0.274 
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6.5 Associations and Predictions 
6.5.1 Carer strain (MCSI) associations and predictions  
The first carer variable to be considered was strain using the MCSI. Overall, including all 
carers, the MCSI had an approximately normal distribution on histogram and SW testing did 
not show significance when carer groups were divided into MSA and PSP groups, therefore 
there was no evidence against normal distribution.  
When mean scores of MCSI were compared using independent t-tests, there were no 
significant differences between carers of patients with MSA and PSP. MSA carers had a mean 
score of 13.4 (± 6.4) and PSP carers a mean score of 12.9 (± 6.1). Again, when independent t-
testing was carried out between male and female carers there were no significant differences 
between mean scores for these categories (mean male score 13.2, ± 5.8, mean female score 
13.1, ±6.5).  
An ANCOVA adjusting for degree of disability was carried out, looking for differences 
between MCSI score in MSA and PSP carers with the influence of degree of patient disability 
removed. Disease type did not affect MCSI score when disability was taken into account 
F(1,43) = 0.233, p = 0.632, ηp2 = 0.005. 
MCSI was tested for associations with carer demographics such as gender, age, duration of 
time as a carer, care afforded per week, and duration of relationship. Previous work in other 
conditions has given mixed results on factors such as carer sex and age but has suggested that 
amount of time as a carer might impact on carer strain and QoL. Carer physical and mental 
well-being and patient variables tested in the study such as depression, disability and QoL 
were also tested, all of which have been investigated for associations with carer strain and 
QoL in other conditions including PD (Morley et al., 2012; Corallo et al., 2016). See table 
6.2.  
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Independent variable Coefficient 
correlation 
Significance (p-value) 
Carer sex (PBS) 0.019b 0.903 
Carer age -0.150P 0.327 
Duration of care 0.119P 0.430 
Care given per week -0.047P 0.759 
Duration of relationship -0.296P 0.046 
Carer physical well-being (RAND-36 PCS) -0.094P 0.533 
Carer mental well-being (RAND-36 MCS) -0.232R 0.121 
Carer subjective QoL (SEIQoL-DW) -0.269R 0.107 
Patient depression (DASS-21) 0.261P 0.080 
Patient disability (BADLS) 0.188R 0.210 
Palliative need score (POS-S-PD) 0.176R 0.241 
Patient disease-specific QoL (MSA-QoL/PSP-QoL) 0.184R 
0.274R 
0.402 
0.206 
Patient subjective QoL (SEIQoL-DW) 0.018R 0.910 
Table 6.2: Correlations of MCSI with carer and patient variables. R=Pearson’s correlation coefficient, 
P=Spearman’s Rho correlation coefficient, b=point-biserial correlation.  
Significant associations shown in bold text. 
 
The duration of relationship (measured in months) was the only significant association found 
between carer demographics and the amount of strain they reported on the MCSI scale. The 
duration of relationship was found to be negatively correlated with amount of strain 
experienced. This suggests that duration of relationship has a protective effect against carer 
strain. Duration has been tested before in this way but no associations have been found 
previously in American or Japanese cohorts of carers of people with PD (Tanji et al., 2013). 
Sex, age and the amount of care given, in terms of overall duration and per week, had no 
statistically significant correlation nor did patient variables, such as degree of disability or 
QoL, though there was a non-significant trend in the case of depression.  
Univariate analyses were then carried out on duration of relationship and patient DASS-
depression, to see if they predicted for MCSI scores. See table 6.3.  
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 β SE p-value 95% CI R2 adj F-value 
    LB            UB                 
Relationship 
duration 
-0.324 0.005 0.028 -0.022 -0.001 0.085 5.156 
DASS-
depression 
0.287 0.143 0.053 -0.004 0.573 0.062 3.956 
Table 6.3: Univariate regression coefficients for MCSI. Significant results highlighted in bold text.  
SE=Standard error, CI=Confidence Interval, LB=Lower bound, UB=Upper bound,  
R2 adj=R2 adjusted value 
 
The overall basic regression model produced was in keeping with univariate analysis and 
contained only relationship duration as a significant predictor of carer strain, measured with 
MCSI. The adjusted R2 was 0.085 (accounting for a variance of 8.5% of MCSI score), 
meaning that the duration of carer relationship could predict for 8.5% of the carer strain score 
assessed using the MCSI. Therefore, relationship duration is a significant predictor of carer 
strain but the effect size is trivial to small. See table 6.4.  
 
 β SE p-value 95% CI R2 adj F-value 
    LB           UB   
Relationship 
duration 
-0.324 0.005 0.028 -0.022 -0.001 0.085 5.156 
Table 6.4 Overall basic model of regression coefficients for MCSI. Significant results highlighted in bold text.  
SE=Standard error, CI=Confidence Interval, LB=Lower bound, UB=Upper bound,  
R2 adj=R2 adjusted value  
 
6.5.2 Carer QoL (PQoLc) associations and predictions 
The second variable to be tested was the QoL in the carer group and this was measured with 
PQoLc. This is a specific QoL measure which appraises QoL in the context of caring for a 
person with AP. Higher scores represent a lower QoL. PQoLc was found to be normally 
distributed on visual inspection of histograms and SW testing suggested a normal distribution 
for each group.   
When PQoLc scores for MSA carers and PSP carers were compared using independent t-tests 
there were no significant differences between the two. MSA carers had a mean score of 43.9 
(± 20.3) and PSP carers a mean score of 45.8 (± 24.6). The carers were then considered for 
differences between PQoLc scores in terms of sex. Again, there were no significant 
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differences between the groups. Male carers had a mean score of 43.3 (± 19.4) whilst female 
carers had a mean score of 45.8 (± 24.3). 
An ANCOVA adjusting for degree of disability was carried out, looking for differences 
between PQoLc score in MSA and PSP carers. Disease type did not affect PQoLc score when 
the influence of patient disability was taken into account, F(1,43) =0.016, p = 0.901, ηp2 =0.00 
PQoLc was then explored for associations with study variables including carer demographics, 
patient study variables and carer study variables. See table 6.5. When patient variables were 
examined for associations with PQoLc, duration of falls was also included, as literature has 
discussed falling as having an impact upon carer QoL in a previous British study in PD 
(Schrag et al., 2006b).   
 
Independent variable Coefficient correlation Significance (p-value) 
Carer sex (PBS) -0.039
b 0.799 
Carer age -0.192P 0.205 
Duration of care 0.045P 0.764 
Care given per week -0.086P 0.570 
Duration of relationship -0.334P 0.023 
Carer physical well-being (RAND-36 PCS) -0.535P 0.001 
Carer mental well-being (RAND-36 MCS) -0.700R 0.001 
Carer subjective QoL (SEIQoL-DW) -0.401R 0.014 
Patient depression (DASS-21) 0.415P 0.004 
Patient disability (BADLS) 0.156R 0.302 
Palliative need score (POS-S-PD) 0.231R 0.123 
Patient disease-specific QoL (MSA-QoL/PSP-QoL) 0.163R 
0.339R 
0.456 
0.113 
Patient subjective QoL (SEIQoL-DW) 0.267R 0.083 
Duration of falls (months) 0.131P 0.415 
Table 6.5: Associations between study variables and PQoLc. R=Pearson’s correlation coefficient,  
P=Spearman’s Rho correlation coefficient, b=point-biserial correlation.  
Significant associations shown in bold text. 
 
As with MCSI, the only association seen with carer demographics was the duration of overall 
relationship between the patient with AP and their carer. Again, like MCSI, this relationship 
was a negative correlation; suggesting that as caring-specific QoL became poorer (using this 
instrument, a higher score) duration of relationship tended to decrease. Therefore, pairs with 
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longer relationships tended to have carers with a better carer-specific QoL (lower PQoLc 
score).  
There were negative correlations between PQoLc and the carer general physical and mental 
well-being as measured by the RAND-36, medium and large respectively in terms of strength. 
There was also a negative, medium-sized association with carer SEIQoL (subjective QoL) and 
a positive medium-sized association with patient depression (DASS-21).  
Univariate analysis with each of these measures which showed an association was performed 
and all showed some predictive value alone for PQoLc score. See table 6.6.  
 
 β SE p-value 95% CI R2 adj F-value 
    LB                 UB   
Relationship 
duration 
-0.346 0.18 0.019 -0.080 -0.008 0.100 5.976 
Carer PCS -0.485 0.300 0.001 -1.709 -0.499 0.218 13.532 
Carer MCS -0.700 0.230 0.001 -1.959 -1.032 0.479 42.360 
Carer 
SEIQoL 
-0.401 0.153 0.014 -0.709 -0.085 0.137 6.693 
DASS-
depression 
0.380 0.499 0.009 0.355 2.364 0.125 7.435 
Table 6.6: Univariate regression coefficients for PQoLc. Significant results highlighted in bold text.  
SE=Standard error, CI=Confidence Interval, LB=Lower bound, UB=Upper bound,  
R2 adj=R2 adjusted value 
 
A basic overall model was produced using backward elimination regression, shown in table 
6.7. All independent variables except for Carer MCS were removed as they did not contribute 
significantly to the model. 
 
 β SE p-value 95% CI R2 adj F-value 
    LB             UB   
Carer 
MCS 
-0.706 0.273 0.001 -2.168 -1.058 0.484 34.804 
Table 6.7: Overall basic model of regression coefficients for PQoLc. Significant results highlighted in bold text. 
SE=Standard error, CI=Confidence Interval, LB=Lower bound, UB=Upper bound,  
R2 adj=R2 adjusted value 
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The overall basic model produced for PQoLc after non-significant predictors were removed, 
contained only carer mental well-being (carer MCS). Carer mental well-being had an adjusted 
R2 of 0.484 (accounting for 48.4% of the variance of PQoLc).   
 
6.5.3 Carer SEIQoL-DW associations and predictions 
The third variable to be tested was carer SEIQoL-DW. This is a general, subjective QoL 
measure. Higher scores represent a higher QoL. Carer SEIQoL-DW was found to be normally 
distributed on visual inspection of histograms and SW testing.   
When SEIQoL-DW scores for MSA carers and PSP carers were compared using independent 
t-tests there were no significant differences between the two. MSA carers had a mean score of 
65.6 (± 18.4) and PSP carers a mean score of 62.2 (± 27.8). The carers were then considered 
for differences between SEIQoL-DW scores in terms of sex. Again, there were no significant 
differences between the groups. Male carers had a mean score of 65.6 (± 20.5) whilst female 
carers had a mean score of 61.9 (± 24.3). 
An ANCOVA to compare the two carer groups adjusting for degree of patient disability was 
carried out, looking for differences between SEIQoL-DW score in MSA and PSP carers. 
Disease type did not affect carer SEIQoL-DW score when disability was taken into account 
F(1,34) = 0.172, p = 0.681, ηp2 = 0.005. 
Subjective carer QoL using the SEIQoL-DW overall index was then investigated. 
Associations were found with carer age, duration of relationship, carer mental well-being and 
patient depression (see table 6.8). There was an association found between disease-specific 
QoL in the PSP group only (PSP-QoL) though not in the MSA group (MSA-QoL).  
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Independent variable Coefficient correlation Significance (p-value) 
Carer sex (PBS) 0.139b 0.413 
Carer age 0.400P 0.016 
Duration of care 0.280P 0.093 
Care given per week 0.188P 0.264 
Duration of relationship 0.450P 0.005 
Carer physical well-being (RAND-36 PCS) 0.283P 0.089 
Carer mental well-being (RAND-36 MCS) 0.451 R 0.005 
Patient depression (DASS-21) -0.516P 0.001 
Patient disability (BADLS) 0.092R 0.589 
Palliative need score (POS-S-PD) 0.254R 0.129 
Patient disease-specific QoL (MSA-
QoL/PSP-QoL) 
-0.204R 
-0.569R 
0.389 
0.017 
Duration of falls (months) 0.131P 0.415 
Table 6.8: Correlations of carer SEIQoL-DW index with carer and patient variables.  
R=Pearson’s correlation coefficient, P=Spearman’s Rho correlation coefficient, b=point-biserial correlation. 
Significant associations shown in bold text. 
 
Univariate regression analysis was carried out for each of these independent variables where 
an association had been found. For PSP-QoL, only the PSP subgroup was considered. See 
table 6.9. 
 
 β SE p-value 95% CI R2 adj F-value 
    LB UB   
Age  0.306 0.272 0.070 -0.043 1.061 0.067 3.510 
Relationship 
duration 
0.398 0.23 0.015 0.012 0.105 0.134 6.578 
Carer MCS 0.451 0.348 0.005 0.332 1.744 0.180 8.914 
DASS-depression -0.512 0.557 0.001 -3.094 -0.832 0.262 12.415 
PSP-QoL 
(subgroup only) 
-0.569 0.161 0.017 -0.774 -0.088 0.279 7.179 
Table 6.9: Univariate regression coefficients for carer SEIQoL-DW. Significant results highlighted in bold text. 
SE=Standard error, CI=Confidence Interval, LB=Lower bound, UB=Upper bound,  
R2 adj=R2 adjusted value  
 
When an overall basic regression model was produced with non-significant predictors 
removed, patient depression (using DASS-21) remained and had a R2 of 0.300 (meaning 
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depression in patients measured by the DASS-21 accounted for 30% of the variance of carer 
subjective QoL using SEIQoL-DW). See table 6.10.  
 
 β SE p-value 95% CI 
LB              UB 
R2 adj F-value 
DASS-
depression 
-0.548 0.542 0.01 -0.3173 -0.969 0.300 14.574 
Table 6.10: Overall basic model of regression coefficients for carer SEIQoL-DW. Significant results highlighted 
in bold text. SE=Standard error, CI=Confidence Interval, LB=Lower bound, UB=Upper bound,  
R2 adj=R2 adjusted  
 
When PSP-QoL was explored in just the PSP subgroup, carer age and patient depression 
remained in the model as significant predictors and PSP-QoL was removed as non-significant. 
See table 6.11. Therefore, in the PSP carer group only, both depression in the patient and age 
of the carer predicted for carer subjective QoL, accounting for 50.9% of the variance. 
 
 β SE p-value 95% CI R2 adj F-value 
    LB                 UB   
DASS-
depression 
-0.654 0.767 0.003 -4.423 -1.111  
0.509 
 
8.770 
Carer age 0.422 0.425 0.036 0.077 1.902 
Table 6.11: Overall basic model of regression coefficients for carer SEIQoL-DW (PSP sub-group).  
Significant results highlighted in bold text. SE=Standard error, CI=Confidence Interval, 
LB=Lower bound, UB=Upper bound, R2 adj=R2 adjusted  
 
6.5.4 Comparisons between four groups 
Two scales were completed in common by all four groups in the study. These were the 
RAND-36 and SEIQoL-DW. A limited number of comparisons between all four groups were 
conducted to look at the differences in ranking in well-being and subjective QoL. As the 
RAND-36 composite scores were non-normally distributed, Kruskall-Wallis tests to perform 
comparisons were used rather than 1-way ANOVA. See table 6.12.  
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RAND-36 
Category 
Test statistic, H (df), 
p-value 
Null hypothesis Rank order (low to high) 
RAND-36 PCS 39.185 (3), p ≤ 0.001 Rejected MSA patient, PSP patient, 
MSA carer, PSP carer 
RAND-36 MCS  12.894 (3), p = 0.005 Rejected MSA patient, PSP patient, 
MSA carer, PSP carer 
Table 6.12: Kruskall-Wallis H comparisons between patient and carer groups in RAND-36. Also shows order of 
ranked catagories (lower scores represent poorer health status).  
 
In both categories which showed significant differences between groups, the ranked orders 
were the same; the lowest well-being in MSA patients, then PSP patients, then MSA carers 
with PSP carers having the highest well-being scores (the significant differences were not 
necessarily between all groups. The group differences are explored in tables 6.13 and 6.14 
using Dunn’s pairwise comparison to assess where the significant differences lay and are 
shown below.  
 
Groups being compared Kruskall-Wallis 
Test Statistic 
Standard 
error 
Adjusted significance 
MSA patient, PSP patient -10.833 7.875 1 
MSA patient, MSA carer -36.087 7.959 0.001 
MSA patient, PSP carer -42.739 7.959 0.001 
PSP patient, MSA carer -25.199 7.875 0.000 (0.001) 
PSP patient, PSP carer -31.851 7.875 0.000 (0.001) 
MSA carer, PSP carer -6.652 7.959 1 
Table 6.13: Pairwise comparisons using Dunn's procedure with Bonferroni correction for the RAND-36 
Physical well-being composite score (RAND-36 PCS). Bold means significant differences detected between those 
two categories  
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Groups being compared Kruskall Wallis 
Test Statistic 
Standard 
error 
Adjusted 
significance 
MSA patient, PSP patient -17.124 7.876 0.178 
MSA patient, MSA carer -21.978 7.959 0.035 
MSA patient, PSP carer -26.783 7.959 0.005 
PSP patient, MSA carer -4.854 7.876 1 
PSP patient, PSP carer -9.659 7.876 1 
MSA carer, PSP carer -4.804 7.959 1 
Table 6.14: Pairwise comparisons using Dunn's procedure with Bonferroni corrections for RAND-36 Mental 
well-being composite score (RAND-36 MCS). Bold means significant differences detected between those two 
categories   
 
In the RAND-36 PCS composite score there were significant differences in ranked mean 
scores between the MSA and PSP patient groups and between patients and carers within 
disease groups. 
When the RAND-36 MCS composite score was considered there were significant differences 
between MSA patients and MSA carers (and MSA patients and PSP carers) though not 
between the different patient groups. 
 
6.5.5 SEIQoL-DW comparisons 
The most highly nominated response for the SEIQoL-DW for respondents in both patient and 
carer groups was ‘family’. Therefore, comparisons were made between the overall family cue 
(functioning) score and family weighting (importance) between groups. In both cases, there 
were no significant differences between any of the groups (cue 0.025, p = 0.999, weighting 
1.568, p = 0.667). This is shown in figure 6.5. 
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Figure 6.5: Boxplot comparisons showing similarities between family cue-level (functioning) and weight 
(relative importance) scores in SEIQoL-DW 
 
6.6 Discussion  
In the carer cohort, there was a trend toward older age in the PSP subgroup. PSP is a disease 
with a greater age of expected onset than MSA (O'Sullivan et al., 2008). The differences were 
not significant however, likely because of the contribution of carers who were not spouses or 
partners of differing ages. There was a non-significant trend seen. Female carers were more 
common in both disease groups but there was not a statistical difference in the numbers of 
male and female carers between the MSA and PSP categories. 
The median duration of care-giving in PSP was longer than MSA (4 years as opposed to 3 
years). However, the duration of disease for each condition was approximately 3 years (40 
months in each disease, see Chapter 4). One reason for this may be greater likelihood of more 
severe cognitive dysfunction in the PSP group necessitating more carer input and supervision 
from an earlier stage in disability than in the MSA group.  The definition given for care was 
‘the point at which you felt you needed to offer support [to the patient] without which they 
would not easily cope’. This is obviously variable and subjective, but what individuals 
defined as ‘care’ as opposed to everyday help also varied. As this project considers the impact 
care-giving has on individuals, the subjective definitions of care are of value.  
A greater proportion of MSA carers were in paid employment (52% compared with 26%). 
This might suggest several factors; one might be that as PSP carers tend to be older, more 
may have retired than the MSA carers.  Another possibility may be that PSP patients require 
more care or supervision than MSA patients, so their carers tend to retire earlier. An 
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implication may be that PSP carers could be offered more care-input allowing them to retain 
paid work, should they wish to.  
In terms of carer strain (measured by the MCSI), there were no differences between the two 
carer groups, nor between males and female carers. A single study in PSP has suggested that 
female carers may suffer more from the impact of care than males (Uttl et al., 1998).  
However, this finding has not been replicated in other studies looking at carer strain in 
Parkinsonism generally (Schrag et al., 2006b; Greenwell et al., 2015). A small, negative 
association was found between carer strain and duration of the patient-carer relationship. A 
regression analysis found that duration of relationship did predict for carer strain (longer 
relationships predicted less carer strain).  The effect was small though significant. More work 
to explore this association with greater numbers would be appropriate, also considering the 
quality of relationship, which has been suggested as having a buffering effect against carer 
burden in PD (Goldsworthy and Knowles, 2008).  
QoL in terms of carer role using PQoLc demonstrated no differences between disease types or 
sex of carer.  A number of associations were seen with PQoLc, including patient depression, 
physical and mental well-being of carers and duration of relationship. A basic regression 
model showed that once non-significant contributors had been removed, carer mental well-
being accounted for 48% of PQoLc.  Although the mental well-being score (RAND-36 MCS) 
does not provide information on individual aspects of mental health, it stands to reason that 
support of carers and treatment of mental health issues, such as depression, is important in 
maintaining carer QoL.  It is possible that identifying mental health needs in carers and 
addressing them could allow care to continue and keep patients and their carers together in the 
community for longer. 
In terms of overall subjective QoL in carers, after non-significant variables were removed, 
patient depression was found to predict 30% of the variance of SEIQoL-DW. This suggests 
that if the cared-for individual is depressed, this does not only affect the carer’s experience in 
terms of their role in being a carer, but their whole individual experience (as SEIQoL is a 
general QoL tool, not limited to the carer experience, as PQoLc is). This finding suggests that 
depression in the patient is pervasive in the carer’s outlook. This provides evidence for how 
important the recognition and management of depression is, not only to benefit patients but 
those who care for them. Interestingly, in PSP carers only, older age had some protective 
effect for subjective QoL. In Chapter 7, there will be a discussion of changing expectations 
and how this affects life plans (biographical disruption). It may be that older carers have more 
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of an expectation or preparation for serious illness, permitting adjustment, whereas this may 
not be the case in (generally) younger care-givers in the MSA group. From review of the 
literature, it is believed this demonstration of the impact of patient depression on subjective 
QoL in carers is novel. 
Finally, some comparisons were made between the two patient groups and the two carer 
groups in terms of SEIQoL domains and RAND-36 scores (as all four groups completed these 
comparable and general tools). 
The most commonly nominated response for all four groups was ‘family’. There were no 
statistical differences between the groups when perceptions of family functioning nor the 
importance of family were compared.  
In the RAND-36 tool, there were differences between overall composite scores with the 
significant differences between some (though not necessarily all) groups. For example, overall 
physical well-being (RAND-36 PCS) showed significant differences between MSA and PSP 
patients, with MSA patients having lower physical well-being and between MSA patients and 
their carers and PSP patients and their carers (though no differences between carer groups). In 
terms of mental well-being, MSA patients and carers had differences but PSP had not, nor did 
the two carer groups. 
All RAND scores with significant differences had the same ranks; lowest being MSA 
patients, then PSP patients, then MSA carers, then PSP carers. It was interesting that this 
ordering was preserved across physical and mental well-being. PSP patients, with greater 
frontal lobe dysfunction may have lesser distress at their situation and decline than individuals 
with MSA, who tend to have lesser cognitive involvement and maybe more insight into their 
condition. Similarly, carers may suffer adversely if those they care for are distressed by their 
illness; which might explain why MSA carers might therefore could have lower well-being 
than PSP carers, overall.  
It is vital to remember that individuals complete these tools according to their own 
perceptions. Therefore, if patients had marked disability but did not feel this was of concern to 
them, it was completed according to their outlook. It would be interesting in further work, for 
carers to complete these questionnaires as to how they felt the patient would respond, as it 
may be their perceptions of the experience of the person with illness and that of the individual 
themselves, are very different.  
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Chapter 7. Qualitative Exploration of Impact of AP on Patient and Carer 
Participants 
 
7.1 Background 
The implications of a diagnosis of a progressive and aggressive condition like MSA or PSP 
can be felt in both patients and carers, impacting markedly on QoL. To produce a rounded and 
holistic exploration of the experiences of the cohort in this study, qualitative methods were 
used (as discussed in Chapter 3: Methods) to try and gain a subjective view of living with 
MSA or PSP. These subjective insights can be helpful in not only gaining an understanding of 
the experiences of these participants but also how we might be able to tailor our approach and 
services to better manage these complex conditions. 
 
7.2 Methods 
The methods used for interviewing and data analysis were explored in depth in Chapter 3, 
Methods. Nineteen interviews were carried out, ten with patient-participants (four MSA and 
six PSP) and nine with carer participants (four MSA and five PSP). See table 3.6 in Chapter 3.  
Purposive sampling was used to obtain a range of viewpoints, including patients with severe 
speech difficulty, as this group has been poorly-represented in research.  The interviews were 
conducted with open-ended questions from an interview guide (formulated for the study) 
which helped guide the interviewer and interviewee toward issues being studied. Interviews 
were recorded and transcribed verbatim and then coded to produce overall meaningful themes 
which pervaded the data. Thematic analysis was the method used for analysis and this is fully 
discussed in Chapter 3.  
 
7.3 Results 
The three main themes that were produced from the analysis of interviews were firstly 
‘Connection’, encompassing speech as a means to communicate, how participants were able 
to connect to others and how they were perceived. Secondly, ‘Transition’ and the shift from 
one role or state to another, such as from spouse to carer or from independent individual to a 
person who is dependent on others. The last theme was ‘Accessing Support’ and what 
participants deemed as important and how they derived help from different sources.  
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7.4 Connection 
               
Figure 7.1: Key theme of “Connection” and associated sub-themes 
 
A prevalent theme is that of connection to the world around, which encompasses many facets. 
The most obvious is that of communication, more specifically, speech. This had an impact not 
only on patients with marked speech deficits, but those whose speech remained intelligible. 
The concept of connection is broad and represents the ability of an individual to reach out and 
establish an understanding. In previous work in PD, connection as a theme encompassed 
speech and social ability (Hudson et al., 2006), but I would argue connectedness also 
comprises of establishing meaning with oneself and others in this cohort, and is a deep, 
though difficult to define concept.  This may be as part of a social interaction, in the 
workplace, or in the healthcare setting where an individual feels a professional has insight into 
their difficulties. The unifying principle behind feeling connected is not with whom, nor the 
setting, nor the mode of communication, but that others have the understanding, time, and 
patience so that the individual (whether patient or carer) feels part of the wider world. This 
section explores how the participants experience and interact with others and how they feel 
their disease or role affects that. 
 
Connection
Communication 
difficulty
Restriction on 
social life
Perceptions of 
communication 
by others
Maintaining 
relationships in 
AP
Changing 
friendships
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7.4.1 Communication difficulty 
Although the speech of some patient-participants might have seemed clear and they had little 
difficulty in making themselves understood, their impression of their own voice, how it 
impacted upon their social interactions and perception of how they felt others saw them, was 
marked. Work in PD has shown that, given how key the ability to speak is in connecting to 
those around you, deficits do not need to be very severe to have a profound effect upon 
confidence as a communicator. However, individuals in this project also had marked speech 
problems requiring the use of electronic aids, in an effort to capture the impact varying speech 
abilities had upon the person. Sarah, below, could only produce single syllables intelligibly 
and this was not consistent.  
Interviewer:  So tell me what’s hard for you now?  
Sarah:  speaking  
Interviewer: speaking? 
Sarah:  Yes… *indistinct muttering* 
Sarah, age 67, who has PSP (bold text indicates typed on an electronic device) 
 
Feelings of control and frustration around being understood have been found to be an issue in 
PD. There was no association between the professional’s assessment of how severe the speech 
problems were and perceived impact on the individual’s ability to communicate (Miller et al., 
2011). This mismatch between how others saw participants’ disability and how they 
perceived it themselves, emerged as a theme in both patients with MSA and PSP. Both Doris, 
a participant with MSA, and Gary, a participant with PSP, discussed their speech difficulty 
and how it had declined, in their own view. Their speech was clearly understandable to 
myself, when compared to participants like Sarah, above. Those around them maintained that 
their speech was understandable, possibly making comparisons with other patients with AP 
who may need communication aids. It could be that this was an attempt from others to 
reassure and encourage conversation, or that the speech genuinely did not seem abnormal in 
their view. However, this did not act to comfort these participants and may have produced 
frustration, as they felt their concerns were being dismissed. Gary described embarrassment as 
a consequence of the changes in his speech. This influenced his willingness to communicate 
and participate in a social life. Although not stated directly in the interview, Gary retired from 
his job when he felt he could no longer contribute in meetings due to his speech problems. 
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Other people… I’ll ask them, “Do I come across...?” They always say, “Oh, you’re fine.” I 
don’t believe them, but they always say I come across fine. 
Doris, age 59, who has MSA 
 
The social life has deteriorated because I’m scared I might be a bit caught short or not 
being able to speak properly. You said earlier that my voice seemed okay. To me, it doesn’t 
seem okay. I’m not as confident as I used to be. I couldn’t sit down at a meeting anymore, a 
complete meeting, because I feel embarrassed losing my voice. 
Gary, age 58, who has PSP 
 
During the interview with Gary, he spoke of the changes that he had experienced within 
himself which he felt were profound, but that others did not feel were severe or noticeable. 
What I, as a clinician, had thought of as reassurance (during a recent clinic) by saying his 
voice sounded clear, had minimised his concerns. This is a point which should be considered 
by clinicians and medical teams. Objective observations do not capture the internal experience 
and perception of the person living with a chronic condition.  This has been seen in perception 
of swallowing in PD also; the severity of objective swallowing problems are not reflected in 
the experience of the patient, and may be subjectively much worse (or better) than the test 
result (Miller et al., 2006a). These internal experiences impact upon the ability of individuals 
to connect to others socially, despite a range of objective speech ability. The value of 
communication aids as a means to enable speech, and allow entry into society, was discussed 
by both patients and carers for patients who were unable to speak intelligibly.  
Interviewer:  And how…has the fact that she has to use the lightwriter to speak now, 
how has that impacted on both of your lives? 
Bob:  Oh, tremendous, great. Erm, beforehand, I would think, both of us, it was 
very, very frustrating. Erm, I would try and second-guess what she was 
trying to say to me, and because I was saying, well, say we're looking at a 
word, and I would say to her, “Shop?” “No, no, no.” And then I would try 
something else. “No, no.” Then she would get very irate at me. 
Bob, 69, carer of Mary who has PSP 
 
The presence of the aid may also act as a symbol of illness, helping to explain the condition of 
the patient, acting as a visual cue of illness or disability. This might prepare others to make 
allowances for speech disability, if they see a device is needed. This may trigger allowances 
on behalf of others, socially.  
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She took it [the light-writer] on holiday. And we were sitting at the table, there was a 
couple sitting…and, erm, this woman straight away asked what it was, and [Mary]typed in 
that it was a communicator….and she says, “Oh,” she says, “I tell you,” she says, “I had a 
brother-in-law with Parkinson's,” so that broke a bit of ice as well. 
Bob, age 69, carer of Mary who has PSP  
 
There is however, difficulty using a device which requires verbal fluency and dexterity in a 
condition which is progressing in both physical and cognitive respects. With progression of 
disease comes greater difficulty in using the device, providing an increasingly tenuous means 
to communicate. This can be seen in problems in using the device and observations from 
family, together with concerns that the individual will not be able to use the aid in the future, 
further curtailing their ability to interact and communicate. 
Interviewer:  Do you think your main problem is… speech? 
Sarah:  speech…. yes… 
Interviewer:  probably the speech 
Sarah:  *typing sounds for 5 min* 
Interviewer:  I think I can read what… 
Sarah:  mmmm… 
Sarah, age 67, who has PSP  
 
First, I tried to put it down to the fact that she was doing this, but I don't think that is the 
case. I think she is starting to misspell words…and when it gets to, to, to press 'Do', 
sometimes she presses it, and it repeats and repeats and repeats. And I'd say, “No, the 
wrong- thing that's wrong is, you've pressed it too many times with your finger,” and I 
don't think she realises… 
Bob, age 69, carer of Mary who has PSP 
 
Mary: *typing sounds* I sometimes think *typing sounds* …people don’t 
understand 
Interviewer: What do people not understand that you want them to, can you pin that 
down?... 
Mary: that I’m not stupid 
 
Mary:  *typing sounds* it’s very frustrating 
Interviewer: how do people react to your speech as it is? 
Mary:  *typing sounds* most people just ignore me 
Interviewer: ignore you? 
Mary:  yes 
Mary, age 69, who has PSP (bold text indicates typed on an electronic device) 
114 
 
A participant who also has PSP with a similar degree of speech impairment to Sarah, is Mary. 
She uses a light-writer device which has a ‘speech’ function. Like Sarah, she has physical 
issues with stiffness and slowness, making typing difficult and is known to have some 
cognitive impairment (bradyphrenia literally is ‘slow thought’ which is common in PSP). She 
described frustration that she is ignored and feels she is perceived as stupid because she 
cannot respond quickly.  This has serious implications for both the ability to connect socially 
for this group of people, but also in how medical care is provided. In the medical setting, the 
ability to communicate meaningfully with patients wherever possible, especially if they have 
these difficulties day-to-day, is very important. It allows patients to feel some empowerment 
and to feel considered in their care. It is also important to connect with patients to allow them 
to make decisions about their future if they wish to, while they are still able.  
 
Interviewer:  What do you think doctors and nurses, what do we do well and what do we do badly? 
Especially as you use a light-writer 
Mary:   *typing sounds* I sometimes think *typing sounds* 
Interviewer:  It is working its ticket, isn’t it? 
Mary: People don’t understand…that I’m not stupid…*typing sounds* people don’t have 
the time to listen 
Mary age 69, who has PSP (bold text indicates typed on an electronic device) 
 
Mary’s statement in response to a question about how doctors and nurses could do better was 
framed around time and understanding. Without the time to allow her to respond as she 
wished, whether constrained by her physical ability to type or cognitive issues, she felt 
dismissed as ‘stupid’ and did not feel heard. This aspect of AP, with significant and objective 
loss of the ability to easily communicate, has implications for medical teams. To allow these 
individuals to connect, we need to provide time, space and where appropriate, technological 
support. Beyond this stage, should people be no longer able to connect via speech or written 
means, due to cognitive and/or physical decline, it is still important to try and maintain a 
connection with these individuals, and to speak to them, rather than to their carers, 
exclusively. Indeed, it may be that some communication is possible, despite significant 
barriers, if sufficient time can be given (if only with simple hand gestures). 
 
In one interviewed participant who had PSP-RS, a pronounced lack of fluency was found. 
Despite having a previous career as a businessman, speech was very ‘pared down’ and to the 
point. Repeated use of ‘yes’ and ‘no’ responses, even when questions were not closed 
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suggested some ‘concrete’ thinking and lack of elaboration. Repeated use of the same phrase, 
often seen clinically in frontal cognitive syndromes was striking, despite efforts to widen the 
conversation up with open questions (Weder et al., 2007). The phrase ‘that’s it’ was used 
again and again, especially when Jack struggled to find words or lost his train of thought.  
 
Interviewer:  Do you and your wife ever talk about the way that the disease progresses? 
Jack:  Yes. 
Interviewer: Is that hard to talk about? 
Jack:  No. 
Interviewer: Have you thought about the future with your wife? 
Jack:  Yes. 
 
Interviewer:  Do you still take an interest in cars? 
Jack:  Not really. 
Interviewer: Is that because you can’t drive them as you did? 
Jack:  That’s it. 
 
Interviewer: Do you like going to see the consultant, or the nurses? 
Jack:  Yes. 
Interviewer: Why is that, just to try and understand what we do well and what we do 
badly? 
Jack:  Yes, that’s it. 
Jack, age 71, who has PSP 
 
7.4.2 Restriction on social life 
Social activities and interaction with others is affected when speech becomes more effortful or 
difficult. Some individuals may voluntarily pull back from meeting with and speaking to 
people, as they may feel embarrassed and lose confidence in themselves. This has been shown 
to occur in patients with PD. One frequent concern of patients with Parkinsonism is 
maintaining the volume of their voice. Work has suggested that patients with PD may have 
impaired ability to detect low volumes in their own voice; feeling that they are shouting when 
they are, in fact, difficult to hear. This likely adds to social awkwardness and feelings of effort 
or struggle in conversation (Kwan and Whitehill, 2011; Miller, 2012).  This may result in 
increased effort in being heard and the need to repeat things, impeding conversations and 
making them burdensome. This was seen particularly in participants with MSA who seemed 
to find it difficult to speak loudly or clearly enough, which from the example of Doris below, 
seemed demoralising. 
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I know my speech… nine times out of ten, I’ve got to repeat myself, and then I’ll think, 
“Oh, I can’t be bothered.” It’s not worth it usually. 
Doris, age 59, who has MSA 
 
Before I had MSA I was obviously quite a clear speaker, I could talk to anybody from the 
lowest of the low if I put it that way to a Duke, in my profession I’d talk to many people, 
many people in the population, wide variety of people...high flyers in business, don’t think I 
could do that now. Couldn’t have a long, intelligent conversation with a high flyer, would 
“pardon *name*, pardon”. 
Matthew, age 64, who has MSA 
 
Matthew identified himself as a communicator, his job as a solicitor involving interaction 
with important and articulate people seemed an intrinsic part of how he saw himself. The 
transitions which people felt have occurred due to their disease are discussed in the next 
section. When his speech was impaired by MSA, this had a profound effect upon him. His 
voice was his means to connect to all kinds of people and this had been affected by his 
disease. His comment ‘couldn’t have a long intelligent conversation with a high-flyer’ 
suggests that he felt he had lost a key skill which had opened up opportunities for him in his 
working life. Similarly, to Doris and Gary, Matthew could still be understood. However, he 
felt that the change in his voice affected the quality of his interactions with others. In AP, 
which affects speech earlier and more severely than PD, the impact on social life and 
relationships may be more extensive and occur earlier.  
A frequent barrier to social interaction, be it formal occasions or routine conversation, was the 
inability to make oneself understood or worry that one was less intelligible than before. This 
could be due to voice changes leading to a low volume resulting in withdrawal from social 
situations, taking more of a ‘spectator’ role, rather than being an active participator. This has 
also been described in patients with speech impairments from a number of causes including 
AP (Walshe and Miller, 2011). 
If I went to things, like the royalty dinners and things, there came to a certain point where 
really, I couldn’t take part in the conversation. ‘Course you’d have a big round table. 
People were talking of course backwards and forwards, and they didn’t, couldn’t hear me. 
So, I tended to just sort of sit back and just let things go on in front of me, and that was it, 
so I changed quite a bit  
Rose, age 71, who has MSA  
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Therefore, patients may be experiencing distress as they are less able to connect to others by 
speech; even if families and medical staff are not aware of any problem. The shift may be 
fairly innocuous, such as Rose’s gradual shift during social dinners to sitting back and letting 
the conversation flow around her, as she realised her voice was becoming less able to cut 
through many voices in a loud social setting.  
 
7.4.3 Perceptions of communication by others 
There was concern from patient-participants that speech problems could be misinterpreted by 
others as memory problems. This stigma of the perception of cognitive impairment, and how 
speech could be a sign of this, is apparent in both patients who feel they have some cognitive 
problems (Gary, below) and those who do not (Rose, first quote below). Miller et al. (2006b) 
discusses the effect that speech problems have on PD patients. Listeners not waiting for 
replies, answering for them, or assuming they are cognitively impaired, explained how those 
affected with speech difficulties interacted with and felt judged by, others. Some respondents 
welcomed humour and flexibility in an attempt to facilitate conversation, despite difficulties, 
such as Rose when there was problems picking up her quiet voice on the recording device in 
her second quote below. 
Gary:  Yes. I feel as it’s difficult. The others will take what I say and they’ll 
understand it, but then they’ll question it.  
Interviewer:  What do you mean, Gary?  
Gary:  It’s the way you say things to people. Words get jumbled up. They’ll then 
say they understood me, but they didn’t. 
Gary, age 58, who has PSP 
 
...you have people sort of waiting whilst I slowly spoke to them. I didn’t want them to think 
that I’d sort of- I think everybody thinks when you’ve got that and you slow down it might 
be a mental thing, which obviously it isn’t because inside your head, it’s all, it’s really 
going on 
Interviewer:  I think I’m going to put the microphone a little bit closer so that it can pick 
your voice up. 
Rose:   Very quiet, is it?  
Interviewer:   Yes, yes.  
Rose:    Are people there? Are you receiving me?  
Interviewer/Rose:  (Laughter) 
Rose, age 71, who has MSA 
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The use of humour on the part of Rose may have been to detract from embarrassment, either 
of herself or to relieve what she may perceive as uneasiness in others, because of her speech 
problems. She may, based upon her previous statement, also use wit to reassure others that 
she is cognitively astute.  A qualitative study in neurological disorders in Canada found that 
humour was a strategy that participants used to maintain a positive sense of self in the face of 
challenges (Roger et al., 2014). 
 
7.4.4 Maintaining relationships in AP 
Relationships and how they succeed or fail beyond a diagnosis of AP, was a frequent theme.  
Relationships with others were frequently discussed within interviews. These relationships 
did not only include that between patient and carer (in this study, spouses) but also with other 
family members, friends, and with medical professionals. Relationships are intrinsically about 
connection, the definition being: ‘The way in which two or more people or things are 
connected, or the state of being connected’.  Oxford English Dictionary (2017) 
Some carers were very aware of speech issues, either because their partner’s disease had 
impacted speech more, or because their disease was more advanced. Bill, who described a 
previously active social life which he shared with his wife, Doris, had noticed the impact of 
MSA on Doris’ voice.  Like the quote above in which Doris describes having to repeat herself 
and finding it effortful, Bill saw the effort that she had to make to speak clearly and how this 
had affected the quality of the social life they had shared. 
Interviewer:  It sounds like you were both pretty social people, pretty outgoing?  
Bill:   Yes, very social, very social. That’s one of the problems that I have now. 
Her voice, oh God. I say, “What? What?” She’s never been a loud talker, but she’s really 
quiet now. She just whispers and mutters away 
Bill, age 57, carer of Doris who has MSA 
 
So, the people that run the PSP [meeting] come and talk because they spend time, they’re 
used to it. But the other people may not talk to- They’ll talk to me, not to [her]. And that 
must be frustrating for [Sarah]. 
Tom, age 70, carer of Sarah who has PSP 
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Tom observes that in an environment with an awareness of the issues that AP can cause (a 
PSP support meeting), people take the time and effort to communicate with his wife Sarah, 
who has minimal speech and uses a tablet device to type on and ‘speak’ with. Outside of this 
‘safe space’ however, people speak to him rather than his wife, reflecting the ability to 
connect to others falling away as disease progresses. The reasons for this were not explored 
by Tom, but from Sarah’s interview, the pauses required to allow typing of responses were 
long and it was, from my own perspective, difficult not to interrupt. People may find it 
quicker or less socially awkward to bypass Sarah and speak directly to her carer, Tom. Tom 
did acknowledge the impact of possible frustration on his wife. Communication between 
patient and carer is seen as something very valuable, and when this breaks down or becomes 
more difficult, this seems to have a profound effect upon QoL for both parties.  Previous work 
in PD suggests that the quality of the relationship between the individual with PD and their 
carer, has a protective effect on carer well-being and that patient and carer QoL have an 
association.  In Chapter 6, analysis in this cohort of carers suggested that there was a small 
predictive influence between longer relationships between carer and patient, and reduced 
carer strain. As communication is so fundamental to relationships, the ability to have 
meaningful interactions with a partner seems very important in maintaining that relationship 
(Goldsworthy and Knowles, 2008; Greenwell et al., 2015). This can be seen with Jackie, a 
carer who feels he can still communicate meaningfully with his wife, Rose, and with Sally, 
whose spouse is less able to speak (and was not able to give an interview) but she feels they 
are still able to communicate with each other.  
Well deep down, no, it doesn't matter at all. We can have a nice night in together and we 
can communicate with one another. [Rose] loves talking although she has difficulty talking 
now and I have difficulty hearing her. She is a little bit deaf, you might have noticed that 
but I think quality of life, it is defining quality of life. When you get to real hardcore values, 
they're probably undiminished in my view but you have to be single minded to be able to 
identify that and I count myself fortunate 
Jackie, age 73, carer of Rose who has MSA 
 
Came back on the Sunday, I went straight to see [my husband]; tell him all about it and 
blah, blah, blah. He’s happy to hear…we have quality time. We have meals together. I take 
him out; we go for a beer. I’m falling in love with him again. 
Sally, age 70, carer of husband with PSP 
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Some of the discussions suggested that the relationship between participants with AP and 
their spouse were challenged by their diagnosis. Matthew felt that dealing with his illness was 
an injustice for his wife, Emma, whom he had married soon before his diagnosis, and that 
given the option, he would have preferred to shoulder the burden of his progressing disease 
alone, to spare her. Emma who was also interviewed, described loneliness as an effect of 
Matthew’s diagnosis. It may be that in an effort to relieve Emma of worry, by bearing it 
alone, Emma feels isolated as Matthew’s attention is taken up with coping with his illness. By 
contrast, other couples such as Tom and Sarah, and Rose and Jackie, who maintain as much 
open communication as possible, there is a loss of connection between Matthew and Emma, 
as a consequence of trying to protect the other. 
It’s affected my marriage very badly, very badly indeed… certainly if I’d known I had MSA 
coming on I wouldn’t have married [Emma-my wife… I would have stayed single, it’s not 
fair doing this to any woman 
Matthew, age 64, who has MSA 
 
Eeehhh-no, (laughs), it would be nice to say, that this has brought us together or something 
like that, you know I love him, I love him so much, but I don’t know that I love him more, 
it’s hard to say isn’t it? And he’s changed as well, but, there again, it’s quite lonely 
because of his preoccupation with his illness, and I don’t know that’s because of his 
character 
Emma, age 61, carer of Matthew who has MSA 
 
Julia, a participant with MSA, spoke positively of the impact her marriage and the 
relationships with her family had on maintaining home life with a degenerative disease. The 
use of the term ‘rock’ is an interesting one, suggesting her husband keeps her tethered or 
connected despite her illness. 
Exactly. Which is why I always refer to him as my rock. Because he is a stable influence in 
my life. He is just so down-to-earth, his feet are just so firmly cranked on the ground. He 
keeps saying, “That’s no bother. That’s no bother” 
Julia, age 62, who has MSA 
 
The relationship [changing]? No, not really. Still love each other. 
Tiberius, age 66, carer of Julia who has MSA 
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Similarly, Julia’s husband, Tiberius, as he simply put it, didn’t feel that the quality of his 
relationship with his wife had changed, despite the change in her health and abilities and that 
they still loved each other. This support for people with chronic conditions is very valuable 
and may trigger medical and social teams to consider patients and carers more as a pair; 
supporting both, as the well-being of one is so fundamental to the other. 
…I love my wife. I cannot say that 53 years has been the Hollywood movie because we've 
certainly had problems but we've always resolved them by caring for one another and 
really getting on with it. 
Jackie, age 73, carer of wife with MSA 
 
Jackie, describes ‘getting on with it’. He felt that certain types of people are better equipped to 
cope with problems. However, it may be that the ability to cope and adapt may be in part, due 
to secure relationships with others rather than being intrinsic to individuals.  
Family is known to be very important to both patients and to carers in terms of support and 
reassurance. In Lee et al. (2006) in the context of PD, family was the most frequently 
nominated category in the SEIQoL-DW by patients, and in Chapters 4 and 6 it is also worth 
noting, that this was also the case in both disease groups, in patients and carers in this study.  
In the case of patients with PSP who were interviewed, some family members used avoidance 
strategies, possibility out of fear or difficulty adjusting to the diagnosis, whilst others may not 
have understood the extent or severity of the illness. This was seen when Earl tried to discuss 
the gravity of his wife, Helen’s, diagnosis of PSP with his daughter, who had minimized her 
problems to just having problems with her leg. Bob who was the carer for his wife, Mary, felt 
the child that had the most difficulty coming to terms with Mary’s illness, was their daughter 
who had a medical background. He believed that this was because she understood some of the 
implications of the diagnosis and was therefore using avoidance strategies not to discuss it. 
 
See my daughter who is lovely at 41 when I told her, her expression was of absolute 
bewilderment. She said, and this is word perfect, “Dear me, Dad. I thought all that Mam 
had was a gammy leg”. 
Earl, age 70, carer of wife with PSP 
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Er, the one that's- the [daughter] that's a nurse, I think she- because she knows what it is. 
'Cause there's times when I say things, erm, about Mam, she'll, erm, go rather cold. And I 
think it's because she knows exactly what's what, but is she, erm, not wanting to accept it? 
Bob, age 69, carer of wife with PSP 
 
Other patients and carers, such as Julia, have described the importance of support from 
family, including spouses and the value that they bring, especially when the pre-existing 
family relationships are close. To that end, Earl mulled over the difficulties patients must face 
without a strong family network in place.  
…the family, I must be honest, I think God gave me a family, the sort of family that you 
need to have if you are to face hurdles in life. Because the family is more supportive and 
without their support and without their understanding of me, I just don’t think I would have 
survived at the time I have done 
Julia, age 62, who has MSA 
 
[illness] is a very personal heart-aching thing and lots of the elderly haven’t got the 
backup of families and friends and finances to help through some of the more difficult 
things 
Earl, age 70, carer of Helen who has PSP 
 
7.4.5 Changing Friendships 
Friendship was cited less in the SEIQoL-DW compared with family. Four PSP participants 
nominated friends as one of their five important domains, whilst five MSA carers nominated 
friends or friendship. Interviewed participants discussed the difficulties in maintaining 
friendships, which seemed to be multifactorial. The nature of friendship, and even the friends 
themselves, seemed to shift or change with diagnosis and increasing symptoms.  Bryce, a 
participant with PSP, who was the only interviewed participant who had no spouse or partner, 
felt that certain friends were only interested in socializing when he was well enough to do so 
and lost interest in him when he became less physically able. However, he found he 
increasingly spent time with other acquaintances, to whom he had become closer due to their 
shared experience of chronic illness and disability. This suggests the importance to some 
people of peer support with others who can relate to their condition. This will be discussed in 
the ‘Accessing Support’ section. 
123 
 
Bryce:  No, because- well, your friends yes, used to be. When you were all right 
your friends used to come around and see you. Since I've took bad I never 
see them. 
Interviewer:  Do you know why? 
Bryce:  Yes, because they don't care. That’s my opinion like. 
 
Bryce:  Yes, she'll say, "By, you went round the shops better today", you know 
what I mean? It gives you that bit of push. Poor lassie, she's got cancer, so 
we sort of help each other in different ways. We call it our moaning day on 
a Friday because we always moan about everything. We moan about the 
shops, we moan about the taxi, we moan about the traffic. 
Interviewer:  So, having somebody to have a moan to, to complain to, that helps? 
Bryce:  Yes, have a good moan as we call it. 
Bryce, age 76, who has PSP 
 
Matthew and Doris found an element of their social isolation and difficulty interacting with 
friends, to be self-imposed due to fatigue, speech difficulty, and self-consciousness around 
their symptoms. Doris, in particular, found that the safety of her home and being alone, was 
easier than coping with company, despite her retained desire to make contact with friends. 
Emotional lability (rapidly shifting emotions leading to tears or laughter) was also discussed 
by Matthew, as a source of embarrassment in terms of his social life.   
I get so emotional about it, which I’ve never experienced before, on any topic, about people 
with death, birth or marriage or anything else, I don’t understand why I get so emotional 
Matthew, age 64, who has MSA 
 
He [husband, Bill] does try to get me out, but it’s much easier for me to just stay put. So, 
because of that, I don’t really see much of my friends. Sometimes, they do want to come 
and visit. That puts me in a panic, and I don’t know why, because all they’re going to do is 
turn up at my door and have a cuppa. I think, a lot of the time, I’d just rather be on my 
own.  
Doris, age 59, who has MSA 
 
Friendship, unlike family ties, is frequently associated with common interests and activities. 
When the ability to carry out these activities or the enthusiasm is no longer there, these bonds 
may fall away, leaving a void and possibly, a sense of abandonment. A study examining the 
loss of friendships after stroke, found a number of factors involved in shrinking down the 
friendship networks that people had enjoyed prior, such as fatigue, speech difficulty, and the 
perceptions of others, as well as the physical disability caused by the stroke. These factors are 
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of relevance to AP too, with the difference that these issues are progressive and relentless. 
Whereas in stroke, the changes are sudden but fixed with a possibility of improvement 
(Northcott and Hilari, 2011). Carers too, found it more difficult to find the time to meet with 
friends, and if they did, might find it harder to connect with them due to the impact of their 
care-giving. Emma, who speaks later about the constant need to present a brave face on caring 
in the ‘Transitions’ section, found that even in what could be thought of as a ‘safe space’ with 
good friends, she was loathe to confide in them about the problems she faced as a carer. The 
reason is alluded to in the quote; it may be hard to put that brave face back on after sharing 
how she feels with her friends. 
Unless they’re very close to you… it’s hard to click back into the “hi, yes how you today?” 
when the day before you broken down in tears over coffee, but I find that even, with my 
good friends which I think I mentioned to you, that you think twice about opening up to 
them. I hardly see any friends. 
Emma, age 61, carer of Matthew who has MSA 
 
The sense of self and being able to connect, not just to others but to accept changes to oneself, 
encompasses some other themes which were found in this study; which were grouped into the 
overarching theme, transition. 
Connection to others is key in any relationship; to a spouse, friend or even a doctor-patient 
relationship. The participants in this study with AP felt that their condition reduced their 
ability to make connections; speech became impaired affecting confidence and intelligibility, 
which in turn, reduced the ease and pleasure of social contacts. As the existence of those with 
AP contracts, their carer, also trying to support someone with increasing dependence, has less 
contact with the world outside. This shrinking reality containing fewer people is noteworthy; 
and this is why trying to facilitate communication between medical teams and patients (with 
measures such as longer appointments or differently-structured clinics to allow the time for 
communication to be effective) is important. Equally, maintaining connection between 
individuals and their carers (despite speech problems) and keeping a channel of 
communication between patients and those they are closest to, has the potential to greatly 
affect the experience of people living with AP. 
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7.5 Transition 
          
Figure 7.2: Key theme of “Transition” and associated sub-themes 
 
A frequently cited issue during this study was that of change or transition.   
 
7.5.1 Totality of change 
Different aspects of change were discussed, but often change was described in terms of 
totality of experience when in context with a diagnosis of AP. This complete transition in life 
was not just found in patient-participants, but in carer-participants also; meaning that the all-
encompassing impact of diagnosis affects not only those with the disease, but their relatives 
and carers who share in that experience. 
It [the condition] changes you, every aspect of you is changed, it’s physical…physical and 
mental. 
Matthew, age 64, who has MSA 
 
Here, Matthew describes the shift he felt in his life as a result of his condition. He felt it 
touched on every aspect of his self. Interestingly, he describes the change as a personal thing; 
the disease has changed him rather than things having changed for him.  This may emphasise 
the intensity of the impact of the transition, as not only do patients have to adjust to a 
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difference in lifestyle, they themselves may have changed as a response to their diagnosis. 
Patients may have difficulty relating to themselves after this transformation. This can be seen 
by Mary’s quote, in which she found a shift in her whole being as a result of feeling cut-off 
from others by her lack of speech. This produced a boundary between who she was and who 
she is now.  
Mary:  *typing sounds* it’s very strange to have someone talking to you and you can’t talk 
back… 
Interviewer:  can’t talk back…? 
Mary:  *typing sounds* it’s affected my whole life, I used to be a very outward type of 
person 
Mary, age 69, who has PSP (bold text indicates typed on an electronic device) 
 
Mary describes how her diagnosis has changed not only her functional abilities (most 
obviously manifested in her inability to speak without the use of a communication device), 
but how this has transformed her personality and her self-image. She also describes the 
change she has experienced from her disease in terms of its completeness. Her whole life has 
been affected, culminating in the transformation of who she is and how she views herself. 
Previously, she perceived herself as ‘outward’ and she is no longer the person she used to be. 
Carer-participants tended to describe the changes they have experienced in terms of lifestyle 
and in expectations. Emma, whose husband had a fairly early diagnosis of MSA, found that 
his diagnosis seemed to produce a sense of continual discomfort in which there was never any 
sense of restfulness. She remarked that time together was no longer relaxed and there is a 
sense of the knowledge of the disease pervading all aspects of the relationship they share. 
 I think it just affects so many things…everything, everything just everything, life is just 
never normal, I don’t think we ever have any kind of really relaxed time together 
Emma, age 61, carer of Matthew who has MSA 
 
She, like Matthew, her partner, described how complete the sense of change has been to both 
of them. She uses the word ‘everything’ three times to emphasis her point. Earl, who cares for 
his partner, Helen, described the alteration in expectations since Helen’s diagnosis and again, 
described the totality of the change in their lives since the diagnosis and progression of 
Helen’s disease. He pulls back from using the word ‘significant’ for the degree of change they 
have experienced as a couple and instead uses the word ‘totally’ and that the effect of this 
upon their lives has been ‘savage’.  
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Shrunk. They have shrunk to, the horizons, I mean a holiday abroad now is, is a pie, pie in 
the sky and sorry for the pun…it’s, so how has it affected us? Significant? I don’t think 
significant. Totally? I don’t think significant describes it. It is, erm, savage really. 
Earl, age 70, carer of Helen who has PSP 
 
Earl also describes a ‘shrinking world’ as the horizons narrow with Helen’s growing disease-
burden, producing increasing disability and limiting their possibilities, changing how they 
expected their lives to be. Contraction of social spheres has been described in both physical 
illness and in carers of those with chronic illness (Sacks, 1984; Öhman and Söderberg, 2004).  
 
7.5.2 Reducing freedom  
Similar to Earl’s experience as a carer feeling shut off from certain places that he and his 
partner had previously enjoyed, Rose who has MSA, felt that her physical problems prevented 
her from accessing the places and activities which had been important to her. This separation 
from places or activities which previously had meaning, or were sources of enjoyment, was a 
recurrent theme amongst people with MSA and PSP who were interviewed. 
Once I was diagnosed, then life changed completely because I was limited to where I could 
go and what I could do.  
Rose, age 71, who has MSA 
 
Julia spoke of how important her contact with nature has been for her; her ability to walk in 
wooded areas and to take her dog to places that she found beautiful, such as the seaside. She 
then described how her access to nature is now detached or ‘indirect’ as she has to be taken to 
these places by others and is distanced from them as a spectator, unable to interact or ‘be’ in 
those places, as she is confined to her wheelchair. There is emerging evidence of the health 
and social benefits of green spaces; and empirical studies continue to further elucidate the 
strength of the association between natural environments and health (The Hague, 2004). 
[nature] always, for me, sparked an interest in life… [now]it is something I can’t get 
involved with directly…the only way I can get into it, unfortunately is indirectly is if 
somebody takes us out and I am sitting in a wheelchair and there are certain areas I can’t 
visit anymore, can’t walk anymore, can’t visit anymore because it is not wheelchair-
accessible. 
Julia, age 62, who has MSA 
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There were some positive aspects to the changes in expectations or previous lifestyles, at least 
in part, described by some of the participants. Tom discussed that since Sarah, who has PSP, 
required more care; they have spent much more time together, which he did feel was a good 
change.  However, the same issues discussed above were present; disability limiting travel or 
easy access to areas, often tempered these positive factors.  
I spend more time with [Sarah], which is good, but the sad thing is, whereas we planned to 
travel and do things, now we can’t...so your time that you were looking forward to has 
changed...there’s a different view of your life together. 
Tom, age 70, carer for Sarah who has PSP 
 
Tom who had worked all over the world, had discussed in his interview that he had assumed 
that in retirement he and Sarah would travel together. This thread of disruption of plans or 
changed expectations, recurs in interviews, with both patient and carer-participants who had 
invested not only financially, but also emotionally, in the idea of an enjoyable and active life 
after retirement. This phenomenon is known as ‘biographical disruption’ - the interference 
with life, including social networks and the envisioned future which illness can bring (Bury, 
1982). The unpredictable onset and rapid progression of AP is seen as having taken this 
opportunity, which Earl again describes as an almost visceral loss, below.  
It was very, very, it was a very hard fact of trying to come to terms with the change in 
circumstances, of things that we had taken for granted and enjoyed were no longer open to 
us. It was really a severe kick in the guts yes. 
Earl, age 70, carer of Helen who has PSP 
 
Sally, whose partner required nursing home care, described the plans that she and her husband 
(who attempted but was unable to interview due to cognitive and speech problems) had 
formulated during their working lives. They had particularly wanted to drive across 
continents, a physically demanding endeavour. Sally evoked a theme that was recurrent across 
the interviews; that of plans of travel after retirement, delayed due to work, family or financial 
commitments, which then were impossible due to the diagnosis of AP.  There was almost a 
sense of feeling ‘cheated’ out of these plans. 
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Overland to Australia in a Land Rover… people had done it and we read this book and 
thought, we’re going to do that on day…blah, blah, blah...when the kids are [grown] up. 
But then you couldn’t afford it because our business was da, da, da, da, da…and then you 
retire. And then you get ill. 
Sally age 70, carer of husband (not interviewed) who has PSP 
 
Although Sally and her husband had dreamed of extensive travel across the world, other 
participants discussed how their freedom of movement and travel had become constrained so 
that even a night in hotel was not possible, nor was going out for dinner. This suggests that not 
only ‘big dreams’ of the future are affected by the diagnosis of a disease such as MSA and PSP, 
but the smaller, more routine pleasures of life can become so difficult as to not be enjoyable or 
even possible any more. This again alludes to the ‘shrinking’ of existence and the constriction 
of choices that AP brings to individuals and those who care for them. 
I think the superficial elements of quality of life have obviously changed for the worse. I 
mean I would love to go away to a hotel, we used to go away for two days…to a nice hotel 
in Peebles…a nice view of the river behind the hotel…that's gone...somebody else to make 
the meals, we don't get out even for a meal now which is a little bit sad. 
Jackie, age 73, carer of Rose who has MSA 
 
Jackie, a carer in the quote above, describes trips to hotels and to restaurants as ‘superficial’ 
parts of QoL. He later goes on to describe what he feels are more fundamental or deeper 
constituents of QoL (the quality of the relationship and the conversations he shares with his 
partner, Rose). This was discussed in the ‘connection’ section. Therefore, if the ability to 
connect to others by being able to communicate adequately and maintaining quality of 
relationships can help to ameliorate the loss of functional ability, this should be prioritised more 
in terms of care, support and research. Some studies on adjustment have found benefit in 
expressing emotion and interventions, such as writing therapy and cognitive behavioural 
therapy, may reduce distress in patients with cancer. It should be noted that a diagnosis of the 
most aggressive cancers is associated with poorer adjustment overall, perhaps suggesting that 
time to accept these changes or transitions is needed. This may mean that patients with more 
aggressive diseases with rapid or uncertain trajectories such as AP should be prioritised for 
interventions which may support adjustment (de Ridder and Schreurs, 2001). 
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7.5.3 Changing bodies, changing minds 
AP is made up of conditions which are variable in terms of their symptoms, progression and 
impact on abilities. This study considered only MSA and PSP, but even these two conditions 
show a great deal of diversity in how they affect personality and cognition. Due to these 
diseases being rare and information on them not being so readily available as in more 
‘common’ diseases, people with the disease and those around them may struggle to 
understand the effects of AP.  
Although the physical changes of disease are most obvious to others and are often clearly 
visible, either as the direct result of illness e.g. tremor or use of an aid such as a wheelchair or 
stick, cognitive or personality changes are hidden and can be less easy for others to recognise 
or understand. AP, like PD and some other movement disorders, has the added challenge of 
having both prominent physical and cognitive aspects but, unlike PD, being rapidly 
progressive. 
One transition that a number of participants struggled with was a loss of drive or energy. It 
was difficult to distinguish from people’s personal experience whether this was due to a loss 
of physical energy because of their disease, loss of confidence or intrinsic change in 
personality or cognition due to (pathological) apathy, which is well described in AP. This 
affected participants in a range of ways; affecting their view of themselves as a person, such 
as Helen below: 
Helen:  But when I wake up I think I should be full of life and I'm not.  
Interviewer:  And is that a big change from how you were before?  
Helen:  Oh yes, completely. 
Helen, age 68, who has PSP 
 
Within the theme of changing personality there was a subtheme of withdrawal, from being 
less outgoing and acting as an instigator, to taking a back-seat and delegating responsibilities 
to others. This transition from participant to spectator can also relate to the theme of 
connection. Individuals who have related to others by their leadership or a very active style of 
interacting, may feel disenfranchised and detached should they then be obliged to take a 
‘back-seat’ due to cognitive, energy or personality change.  
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I just haven’t been so active and then being like the leader of things and a person who 
pushed things forward, I found that I really had to just- couldn’t do it. I had to leave it up 
to other people to do things. 
Rose age 71, who has MSA 
 
This transition to a more introverted state may also obligate the carer or partner to take on 
unfamiliar roles in addition to their growing responsibilities as care-giver. For example, some 
male carers might have found increasing housework responsibilities which may have been 
previously shared or performed mainly by their female partner. Above, Rose described herself 
as the person who ‘pushed things forward’. Below, from the carer point-of-view, Tom 
describes how the burden of maintaining social contacts, which used to be shared or mainly 
undertaken by his wife, must now be done by him; the instigation or motivation to do so is no 
longer there. 
We still see our friends and family, but not as often as we could do. Although we could do 
more, it’s all got to come from me, so it’s all instigated by me. And that’s… whereas 
before, it was both of us, or mainly [Sarah].  
Tom, age 70, carer of Sarah who has PSP 
 
These less obvious responsibilities, sometimes called ‘emotional labour’ may then be taken 
up by carers if the person with AP is no longer able to do it. Especially if these tasks have 
never been done by the care-giver before, these produce an added strain. There is a 
recognition that this role has been frequently, though not invariably, filled by women (James, 
1992). Doris who has MSA, still tried to organise social contacts, remember and respond to 
birthdays and prompt her husband, Bill. However, her progressing disease made this duty, 
which used to be easier for her, more challenging, leading her to use technology like 
computerised reminders.  
One time [Doris] used to remember, but not now. She’s got everything written down on a 
calendar and on her computer system, so it prompts her…a couple of times she’d forget 
because I never remember, I’m useless at it: birthdays, dates of birth, even my grandkids’ 
names. 
Bill, age 57, carer for Doris who has MSA 
 
One side-effect of these changes may be that social life for people with AP and their partners 
may be more restricted, if the affected individual tended to cultivate family and social 
relationships more than the other.  
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Changes in personality can also be more obviously apparent to others. In both MSA and PSP, 
but particularly in the latter, frontal lobe changes can produce a range of effects from 
withdrawal and apathy to disinhibition. Disinhibited behaviour is usually not perceived by the 
affected individual to be abnormal, so may cause frustration in relatives, particularly if at that 
point no diagnosis has been reached. These behaviours may be frightening or embarrassing, as 
described by Sally, whose husband had prominent behavioural changes before he was 
diagnosed with PSP.  
I didn’t know, I just knew there was something going on, “for God’s sake, don’t say…” [I 
would say] and I used to tell him off… “don’t do that again. You upset people”… and I 
was, sort of, treating him as a person without an illness. 
The man I married changed dramatically in to a bit of an- he needed motivating all the 
time. 
Sally, age 70, carer of husband (not interviewed) who has PSP 
 
Although apathy and disinhibition can be thought of as somewhat ‘opposite’, Sally’s 
experience shows that lack of restraint and withdrawal can co-exist. These behaviours, 
especially if they are very different to the personality that individuals had before, might be 
very troubling. Equally, without knowledge or understanding that there is an underlying 
disease producing the behaviour, this might lead to guilt over blame that was shifted to the 
individual before diagnosis. There can be varying amounts of insight from individuals as to 
how their behaviours might have changed because of their illness. In the case of Sally’s 
husband (not interviewed), there was none, so Sally seemed to bear the brunt of the social 
consequences. However, others might have awareness of how their public conduct has been 
altered by their disease. Emotional control and being easily moved to tears (or less often, 
laughter) was frequently cited as problematic for participants. This is a common problem in 
PSP, but MSA participants were also troubled by it.  
Part of the condition as well, which I’ve have found, it makes you very emotional, even if 
you’re watching something that’s daft on the TV, you start- tears start welling in your eyes. 
You think, “Why the hell am I crying for this for?”.  It’s- I don’t know. That can become 
embarrassing. 
Gary, age 58, who has PSP 
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Friends have stopped asking me how I am personally as I just break into tears which is 
quite rude of me I think… in some respect… but they understand. 
Matthew, age 64, who has MSA 
 
Although some participants had difficulty communicating and used communication aids, 
whilst others struggled with slower thinking and fluency, the participant whose interview 
demonstrated the greatest degree of cognitive change which is typical of frontal lobe problems 
was Jack, who has PSP. Despite efforts to ‘draw him out’, using open questions, he struggled 
with description and abstract thought. He tended to close down lines of questioning into 
‘yes/no’ answers, even if dichotomous answers weren’t always appropriate and used 
repetition of the same phrase. This ‘catch-phrasing’ is another feature of frontal lobe problems 
(Weder et al., 2007). However, given time and space, Jack did spontaneously respond 
meaningfully to questions or had insights (which did not necessarily relate to the question 
asked).  
Interviewer: How has [your wife] adjusted to the change in your social life? 
Jack: She’s adjusted very well, but basically there’s been no real change, she didn’t 
socialise. I [used to] go to the pub every night, I used to have more conversations in 
the pub, I don’t anymore.  
Interviewer:  [Would you] go if you were helped to the pub? 
Jack:  No. I just don’t enjoy it anymore 
Jack, age 71, who has PSP 
 
In one of the few parts of the interview which Jack spontaneously spoke without prompting, 
he was able to articulate the challenges of change, not only from a physical point of view of 
disease, but how his disease has changed his ability to enjoy a previous pleasure of drinking 
with friends. This loss of being able to speak with fluency, tying in with apathy and cognitive 
change and how this has affected his social life, is one of the most complete of the 
participants.  
 
7.5.4 Shifting from independent to dependent  
Physical changes were the most ubiquitous of the changes discussed by all individuals; those 
with AP and their carers. Physical changes were often the most visible landmark of decline 
and progressing disease and more readily perceived by others, as opposed to cognitive and 
emotional problems, which were more hidden. As individuals became less mobile, their 
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physical disability prevented a number of activities. However, even more sedentary activities 
such as eating, a very social experience, is affected by physical limitations such as dexterity, 
as discussed by Pat who found the physical reminders of her husband Gary’s deterioration 
upsetting.  
Erm, eating, erm, even, erm, some things, he finds difficult to swallow, so I’m mindful of 
that. Erm, the cutlery he uses, it does, so he uses a large version of children’s cutlery. 
(Emotional) 
Pat, age 62, carer for Gary who has PSP 
 
The description of Gary having to use a knife and fork akin to a child, suggests regression and 
loss of abilities. There is a sense of these basic functions being ‘taken away’ from Pat’s point 
of view. Eating and difficulty in doing so, captures a number of the concerns and challenges 
in AP; loss of dexterity, embarrassment at the perceptions of others, loss of functions once 
considered so fundamental such as swallowing, and requiring help for an intimate activity. 
Sarah found challenges in eating which encompasses the gamut of physical problems which 
co-exist in AP (PSP in particular). As well as struggling with the co-ordination needed to cut 
up her food and handle cutlery, she had the visual problems in PSP (blurring of vision, 
especially on looking down). This can make the process of eating uncomfortable and 
unpalatable.  
Sarah: *typing sounds* I tend to sit close to what I am doing for example when I am using 
my iPad or when I am eating *indistinct* everything is blurred, [my husband] has 
to cut up my food for me and also put food on my fork or spoon for me 
Interviewer:  so, your husband has to cut up your food and put it on your fork and spoon? How 
does that make you feel? 
Sarah:  *typing sounds* terrible 
Sarah, age 67, who has PSP (bold text indicates typed on an electronic device) 
 
The changes produced by AP are accompanied by a myriad of challenges in responding to 
these, by those who have the condition and those caring for them. These included 
experiencing or witnessing decline in a number of ways, physical and cognitive, the emotional 
burdens of care, and coping with the perception of others. 
One key difficulty cited by patients and by carers, was growing dependence of the individual 
with disease upon their carer and families. This was alluded to by Sarah above, who cannot 
cut up her food due to her motor problems and cannot get her spoon to her mouth due to 
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problems with blurred vision. This results in ever-growing reliance on others, with a 
recognition that advancing disease will result in reducing ability to care for oneself, was 
commented on as being an inhumane aspect of illness. 
My independence is the biggest thing I have lost. Before I could always do things for myself 
but now I can’t do it [it’s the hardest thing] in my life having to be dependent on other 
people and that I find bad. I find that very difficult to cope with. A human being should be 
able to perform functions without having to be reliant on another human being. 
Julia, age 62, who has MSA 
 
A thread running through the discussions of experiences by patients and carers was the 
alteration of the person and the disturbance of expectations of what someone is able to do or 
expected to be, compared with before their illness. Julia above, who discusses throughout her 
interview her adjustment to illness, has found that the loss of her physical autonomy and 
independence difficult to accept. When describing ‘functions’ she adopted a knowing tone 
and expression, not captured by the transcript, suggesting intimate care. During the study visit 
and after the interview, Julia struggled to mobilise to the bathroom alone, refusing assistance 
offered by her husband. This seemed to capture Julia’s resistance to her body’s decline and 
her belief in the right of the person to be able to self-care.  
Similarly, Doris wanted to retain whatever function and independence she could, despite 
inconvenience and slowness. In this case, Doris had recognised the challenge of walking as 
her MSA progressed, but was unwilling to use a walking aid until she absolutely had to. As 
well as being a symbol of dependence, one element of this could have been perception. Doris 
was one of the youngest participants and the use of a walking aid is often associated with old 
age.  
It’s too much, even though my other half’s got me a walking stick, a frame thing, so I can 
plonk myself down if I get tired, but I’m not using that. Not until I really have to. 
Doris, age 59, who has MSA 
 
AP was described as something taking from independence or abilities. Sometimes participants 
described ‘feeling’ like an older person, or their disease having affected their youth. Gary 
described his perspective of AP as advancing old age, as opposed to the disease taking youth 
away, which is how Matthew viewed his circumstances. When the challenges described by 
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participants were considered, such as loss of social life, reduced mobility, cognitive decline, 
and a fear of growing reliance, one can relate this to perceptions that many have of isolated 
and frail, elderly people. The visibility of a condition is a double-edged sword; if there is 
obvious manifestation of illness, it can confer legitimacy to the individual; unlike the people 
who have purely hidden illnesses, or like Sally’s husband who had early symptoms which 
were not understood as disease, but as strange behaviour (Bury, 1991). The downside is of 
course, as physical disability moves on, it cannot be concealed and people may feel ‘labelled’ 
or defined by it.  
I get very frustrated because I used to be a very fit young man, athletic and sporty, I can do 
very few things now although I’m still independent 
Matthew, age 64, who has MSA 
 
That’s scary because basically you meet…- old age is another thing that gets you and PSP 
pushes that old age to you. I feel that is part of it. With the PSP, old age seems sooner than 
it is. 
Gary, age 58, who has PSP 
 
As disability progresses and independence is lost, many patient-participants were concerned 
that they were a burden to others, particularly to their carer or family. Others who were more 
mildly affected were concerned about this eventuality in the future. This ties in with Gary’s 
comment that AP pushes ‘old age’ forward and these very ubiquitous fears of physical and 
mental deterioration, with a need for their loved ones to support and care for them, even 
attending to their most basic needs, which ageing is often associated with.  Feeling like a 
burden and requiring continual assistance also led to attempts to try to maintain privacy and 
self-sufficiency. Sarah felt that she was under constant surveillance, which limited her 
freedom and left her frustrated. Helen found the lack of alone-time so off-putting that she had 
begun depriving herself of fluids so that the number of toilet trips, with their incessant 
monitoring, could be reduced. This antagonism between a patient’s desire for self-governance 
and privacy and a carer’s aim of reducing risk and trying to enable patients, can be seen 
particularly around mobility and falling.   
 
*typing sounds 2mins* it makes me feel like I’m a burden to others…I feel like I’m  
being watched over constantly and I’m not allowed to do anything. 
Sarah, age 67, who has PSP (bold text indicates typed on an electronic device) 
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Oh, it's, it's horrible. It's even when I get up on a night to go the toilet, he's there, he 
stands, he gets up with me, he walks me to the toilet and I think, "Gee creepers". I've even 
cut down my drink during the day to try and see if I cannot get up [for] the toilet. 
Helen, age 68, who has PSP  
 
7.5.5 Shift from relative to carer 
Another transition that carers described, was the move towards the role of a 24-hour carer 
from that of spouse or partner, with its continual emotional as well as physical 
responsibilities. 
The lack of freedom to move around, make choices or take risks which are part of everyday 
life, was something that participants with PSP in particular, felt affected by. The added 
complication of this is that PSP can produce recklessness (because of frontal lobe 
involvement). This can lead to a risk of falls, which carers repeatedly described as something 
they feared and tried to avoid wherever possible. This can lead to conflict between patients 
who feel constrained and frustrated (which may be compounded by their frontal lobe 
problems) and carers who want to protect their relatives from injury. Falling was a prevalent 
and emotive subject which almost all of the carer-participants returned to. There was a 
combination of devastation when their partner fell and hurt themselves, and an undercurrent 
of feeling judged for providing inadequate care. 
Because he has some horrendous falls…when he was at home before I went off for some 
respite he’d had- oh, he’d fallen and he was bruised. He looked like a car crash. He was 
always bumping into walls and stuff and falling back over and cracking his head. But I 
managed to keep him reasonably safe and intact as best I could 
Sally, age 70, carer of partner with PSP 
 
What happens if I am not here, if she falls over?” 
Earl, age 70, carer of Helen who has PSP 
 
I said, “Every fall to me, it kills me.” I shout at [Sarah], “There’s a reason for your 
falling, you [can’t lean on the] door handle. 
if you don’t use your walker, you’ll have a fall. And falls vary: sometimes she stumbles, 
which is almost fine, but the bad falls… It’s bruises…it’s… 
Tom, age 70, carer for Sarah who has PSP 
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There is a sense of the constant vigilance which is required; the 24-hour nature of care and the 
fear that any lapse in attention or period of absence could result in a fall which the carer feels 
responsible for. When the duties of a household are considered, if it is too difficult for the 
person receiving care to leave the house, how are everyday tasks achieved? Most of the 
participants interviewed had no or very little respite input, either from professional carers or 
informal care from family or friends. Essentials, such as shopping, become hard, and free-
time for carers almost unthinkable as the guilt of being away from their partner and the worry 
of harm they could come to whilst away, overwhelms any enjoyment of a break. As Earl said, 
‘What if I’m not here?”. Even if someone was standing in for him to provide support to his 
wife, if something happened whilst he was away, he would feel responsible for it. This lack of 
relief from the pressure of caring, obviously weighed heavy on the carers interviewed. 
Especially poignant was Tom’s comment that each fall that his wife Sarah had ‘kills me’ and 
that he tries to stop the behaviours that lead to the falls. Sarah, who interviewed herself, felt a 
lot of frustration at being governed in this way, but has had numerous falls and often does not 
use her walking aids, reflecting the conflict between the couple and their prerogatives. 
Carers describe being subsumed by the care they needed to provide, reflecting the transition 
from partner or spouse to care-giver. As the partner of the patient, the care required was not 
confined to the physical. Carers felt obliged to reassure, support and maintain the social lives 
of their partners, a demanding role. Carers also seemed to push their own health, social and 
psychological needs into the background, as they prioritised their partner. 
There's a physical side of it, but I think, of the whole lot, the mental side is bigger than the 
physical. Erm, because I have went and said to the doctor, I need to go to the gym to put 
muscles on, so that I can lift my wife up. But I've had to go to the doctor's and say, “I need 
tablets, 'cause I cannot cope.” And that is the difference between physical and mental. 
Bob, age 69, carer of Mary who has PSP 
 
I think it’s just the, for me, the constant, the constant feeling of responsibility, and I feel 
that I’m very, very much needed, and in the supporting role… because I know how much he 
depends on me, and I think that’s just very tiring 
it’s hard to keep enthusiastic and pretend, I feel I have to pretend… I’m all steeled-up, 
jolly… it’s, you put on, like a shield…but it’s not the real person, really 
Emma, age 61, carer of Matthew who has MSA 
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In both the cases of Bob and Emma, they had made efforts to hide their difficulties from their 
partners. Bob had hidden from his partner that he was now taking antidepressants for 
depression, which he felt arose from the strain of becoming a carer. Emma described putting 
on a shield to hide how she really felt, which gave an external impression of positivity. This 
shield was described as being ‘up’ both for the benefit of the public, including hospital staff, 
as well as Matthew, her partner, to disguise the weariness she felt. This suggests that the 
pressures carers feel to hide the impact of the caregiving role are from every angle; not only 
do they feel they need to provide consistent and multifaceted support to their relative, but also 
to protect them from the effect of the strain they experience, as a consequence. 
This forced transition from relative or spouse to carer has implications for the carer’s identity 
and well-being. Some carers attempt to maintain some of their former selves by continuing to 
work or continuing with a hobby. In some cases, patients try to encourage their carer’s 
continuing outside lives. In other cases, carers felt pulled back to the carer environment either 
by the needs of their partner or their own anxieties about them, such as Earl’s remark on 
falling above.  
I’ve always been a grafter. She wants us to sell it. She wants us to get out. She wants [me to 
stop the club] and she wants me to sell my business. What am I going to do? Sit there? I 
cannot sit [7 days and 24 hours] I love her, but I can’t do that. 
Bill, age 57, carer of Doris who has MSA 
 
I feel as though I can still add value into what I do at work, and I get value from it, and 
that value helps me as a person, so maybe although it is quite tough going, I can come 
away with it, with a strength, that I might not have, if I was a carer 24/7, at this moment in 
time. 
Pat, age 62, carer for Gary who has PSP 
 
At the same time, I think in a way, now I wouldn’t say it to [Jackie] but I’ll say it to you, 
I’ve tried to get him to keep doing the things that he was doing before I was ill, but I don’t 
want to stop him having a life. 
Rose, age 71, who has MSA 
 
In the case of Bill, he seemed to be struggling with the conflicting drives to be there in a 
supporting role to Doris, who had withdrawn by a combination of self-consciousness over her 
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condition and physical limitations, and stayed in the home the majority of the time. His 
perception of himself was as a ‘grafter’, a man whose work is tied up with who he is. He also 
had an active social life and a position in the organising committee of a recreational club.  The 
pressure that he felt from Doris to sell his business, seemed to represent for him the loss of the 
life outside his role as carer. This tension between ‘his’ life outside and the carer life indoors, 
was clearly something he struggled with. He felt he could not reconcile between Doris’ needs 
and his own.  Pat, meanwhile, although she seemed to foresee that the role of carer might 
become more prominent in her life as Gary’s disease progressed, appreciated her work-life 
enabling her to hold on to her individual identity. She also felt that despite the inevitable 
pressures of balancing a full-time job with caring, this division between these two roles was 
empowering; that she would not be as able to cope with caring and with Gary’s PSP, without 
her job, and the personal satisfaction it gave her. Finally, Rose described her efforts to 
maintain her husband’s interests outside of the home and care for herself. Rose used the 
phrase ‘I wouldn’t say it to [him]’ which out of the context of the interview seems strange, but 
within the context, she wanted to keep his interests outside of the home alive because she 
could foresee a time beyond her own death, when friends and an active social circle could 
help Jackie continue. This marks the ultimate transition from the carer’s point of view, from 
relative to carer and then to widow/er. Sudden loss of a feeling of purpose and difficulties in 
re-constructing a life after being a carer, has been described in PD; continued interests and 
links outside the caring-life may act to buffer against a complicated grief reaction (Hasson et 
al., 2010). 
 
7.5.6 Acceptance 
In contrast to change imposed upon the participants, whether physical or cognitive symptoms 
in participants with AP, or the transition from partner to carer, adjustment seemed to be 
distinct in its generation from within the person as a force for change, rather than externally 
imposed. Although the adjustment could have been triggered by the external force, adjustment 
and acceptance seemed to be a way of re-establishing control of a narrative which had the 
disease in charge, up until that point.  
As with everything, I tend to be in life organised. So I find when somebody tries to 
disorganise it, such as illness. I try to get it back in order again as quickly as I can so I can 
take over again. In that way I feel I have got some control of the illness. I am not letting the 
illness control me, I am controlling the illness. 
Julia, age 62, who has MSA 
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I was feeling fine with it. I was helping other people get through it. They would get upset, 
and I would say, “Well, deal with it. Man up.” Like my other half. He was getting upset, 
and I’m thinking, “It should be me, not you.” So, I think I dealt with it okay. I think I still 
am 
Doris, age 59, who has MSA 
 
Julia interprets her illness as disruptive and has tried to adapt to the changes it has imposed. 
To her, order is important, so her efforts are to control and to feel that she has some mastery 
over the illness. As the illness continues to progress, to maintain this feeling of order, Julia 
may feel the need to predict and plan for this. Julia had made practical plans within her home 
for her further decline, in advance. These two aspects of change fit with the discussion above 
of the chaotic nature of change due to circumstances (in Julia’s case, diagnosis and 
progression of MSA) and change in oneself, in response to an event to re-impose order and 
adjustment, allowing change to be more on one’s ‘own terms’.  
Doris, who had previously been a medical librarian, put a lot of emphasis on information and 
facing truth. When discussing her diagnosis and discovering her prognosis, she felt that she 
faced the reality of her disease and rather than becoming upset, spent her time comforting 
family. The statement ‘it should be me, not you’ refers to her husband coming to terms with 
his feelings about the diagnosis of MSA. Her last statement “I think I still am” reflects the 
truth about adjustment to a progressing condition; it is not a process to be completed. 
Adjustment and acceptance are continual and cyclical things, and the added difficulty of 
progressive disease is that once you have adjusted to how things are right now, after a period 
there will be further change, requiring more adjustment. Some aspects of acceptance may be 
easier than others for different people. Changing strategies in the face of disease moving on, is 
recognized to be part of the adaptive process (Bury, 1991).  
Accepting that death would be hastened by AP was discussed by patients and by carers. For 
some participants, the offer of palliative support triggered the realisation that AP is a life-
limiting condition. The internet as an information source (be it reliable or not) was the way in 
which some participants such as Doris above or Mary below, found out that their disease 
would bring their lives to an earlier close. 
 
 
 
142 
 
Mary:   I researched it (repeats on light-writer several times) 
Interviewer:  online? 
Mary:  my husband did 
Interviewer: the research you did, what did you find out about PSP, the two of you? 
Mary:  that I’d have a much shorter life (repeated on light-writer several times) 
 
Mary, age 69, who has PSP (bold text indicates typed on an electronic device) 
 
He’s an amazing man. Considering what he’s got to put up with. He just accepts his fate. 
Now I think I would be a nightmare if it was me. I wouldn’t accept it… 
Sally, age 70, carer of husband (not interviewed) who has PSP 
 
Sally admired her husband’s acceptance, his thinking about his future and facing the prospect 
of death. As he moved from being independent to increasingly reliant, now residing in 
supported living, Sally remarked upon how peaceably he has accepted these changes and how 
she doesn’t feel she could. This respect for her husband seems to have helped her make the 
transitions necessary to become his carer, and the change in their lifestyle. 
(Sighs) I think the main challenges for me, is to make sure I change whatever I need to 
change, at the right time for him, so to be there more for him. Erm, without pushing him 
too much, to do things, to understand, you know, seeing if he can’t do it now. Erm, to 
accept certain things. (Emotional) 
Pat, age 62, carer for Gary who has PSP 
 
Oh, yes. Oh god. I think the world’s still so good. You have your little bit of time, and that’s 
it. It’s good. The world has been very good to me, I have to say, and now I think we’re 
getting to the end of the line, and it doesn’t frighten me. It doesn’t scare me or anything. 
You just take every day and accept it as a good day, and that’s the way it goes. 
Rose, age 71, who has MSA 
 
Ultimately, for Pat, the challenge in accepting her husband Gary’s illness was to maintain a 
balance. As his needs increased she wanted to be there to support him, though she emphasised 
that she wanted to time things correctly. She did not want to do things for him when he was 
still able, but was not forcing him to take on tasks he could no longer cope with. This 
compromise between facilitating independence and assistance included, for her, helping him 
to gradually adjust to his changing condition. Clearly however, this was a difficult process for 
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her. Rose, as someone with MSA, spoke frankly about her life coming to an end. Earlier in 
the interview she had described how she wanted her husband to continue with his hobbies and 
pursuits as something to support him, and in terms of her own condition she was resigned to 
her own death, and took every day as ‘a good day’ no matter what it brought. This suggests 
that when acceptance is more ‘complete’ and expectations have adjusted as a consequence, 
time that patients have is of better quality, as previous expectations have shifted to encompass 
the new reality. 
Transitions and change were an integral part of the experiences of all the participants’ 
narratives. This comprised of the move from a person with symptoms to a person diagnosed 
with an aggressive condition, a shift to uncertainty and away from plans and dreams often 
made over years. Carers found themselves in that role, sometimes insidiously, sometimes 
quickly, but their contribution increased as their partner’s status from an independent 
individual to a more dependent one took place. Finally, some interviewees described a more 
active way of coping with the uncertainty of progressive illness in adaptation and adjustment; 
a more ‘active’ way of responding to change. This may enable some feelings of mastery over 
their lives, especially the patients, as they themselves become less physically or socially able. 
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7.6 Accessing Support 
 
 
Figure 7.3: Key theme of “Accessing Support” and associated sub-themes  
 
The theme of support and its availability was prevalent as an overall theme in the study and 
different aspects were discussed.  
 
7.6.1 Seeking a diagnosis  
The first need for expert support, guidance and input was in seeking a diagnosis. The 
difficulties that were described by every participant, both patients and carers, were that of 
achieving the correct diagnosis, not knowing who the correct specialists were and moving 
beyond the GP to find the expertise to get them their diagnosis. In some cases, this process 
took many visits to the GP, referrals to different medical specialities and required revisions in 
their diagnosis. Coming to terms with a life-changing diagnosis such as PD requires time, 
acceptance and adjustment. The upheaval of then having this diagnosis overturned and 
replaced with another which is more sinister, was an extreme experience after a long period of 
frustration. Earl discusses the process that his wife Helen had, in which their GP attempted to 
facilitate Helen’s diagnosis by referring to what he felt was the correct specialist. As AP has a 
myriad of presentations it can be very variable in appearance and in Helen’s case, by the time 
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she received a diagnosis, she and her husband had been struggling with her progressing 
disability for half a decade. 
The diagnosis itself took an awful long time… five years, which involved being referred to 
various consultants by the doctor who…was struggling and floundering with her 
symptoms, [she] went to various consultants and after three months to wait to see them…to 
get a letter back… “Nothing to do with me” and we’d be referred back to the [GP] who 
then took another best guess. 
Earl, age 70, carer for Helen who has PSP 
 
Interviewer:  There was a bit of a rocky road when you were diagnosed. 
Rose:  Yes, that took quite a while. It took a long time actually, and I saw my doctor I don’t 
know how many times because [my husband] had noticed how shuffly I was and how 
tired.  They just said, “Oh, look, you’re just completely exhausted from looking after 
your mother.” 
Rose, age 71, who has MSA 
 
In some cases, the journey to receive their diagnosis was a very long one, such as for Helen 
and Earl. Rose had a similar experience in which her advancing symptoms were thought to be 
a reaction to caring for her mother who happened to have Parkinson’s disease (which has 
some features in common with MSA). Rose re-presented to her GP despite reassurances, as 
her physical condition continued to decline, seeking answers and the correct input.  
Sometimes the diagnosis was only received due to the efforts of carers. An extreme example 
was Sally, whose husband was diagnosed as having dementia, but requested a referral to 
movement disorder services after a friend suggested that her husband had features of PSP, 
which she had encountered in her work as a hospice volunteer. 
[the consultant said] “Your [GP]’s very good because not many people can blah, blah, 
blah.” And I said, “Well don’t give her all the credit it was [my friend] who works in a 
hospice who had come across it down in Oxford.”  
Sally, age 70, carer for husband (not interviewed) who has PSP 
 
7.6.2 Importance of expertise 
The scene for trying to seek support and services in AP may be set by the initial, often 
protracted battle to get a diagnosis in the first place.  The difficulty in reaching the appropriate 
specialist and how they were diagnosed, may impact upon the reactions people had to it. 
Many participants felt relief that they finally had answers, though the impact of hearing they 
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had a life-limiting condition (and if the diagnosis was a revision from PD to AP, hearing they 
had something worse) was difficult. Work has been done showing the devastation that a 
diagnosis of PD brings (Phillips, 2006). Having this then changed to a related but more 
aggressive diagnosis, is likely to combine further upheaval after an initial coming-to-terms, 
with shock and fear. How the news was imparted was important to participants; face-to-face 
breaking of bad news seems to have been appreciated. In one case, diagnosis by letter caused 
upset and distress. 
The way he told me… like a fireside chat…I was very impressed with him, I read up about 
him on the internet, I knew who to expect and what to expect…but his manner was 
wonderful, he …well…he has my complete confidence  
Matthew, age 64, who has MSA 
 
After the, after the DAT scan and everything, we actually got a letter, informing us what it 
was, I just gave [Mary] the letter, and I went in the back kitchen, came back out, and she 
was in a flood of tears. So, I says, “What's the matter?” and she gave me her letter 
Bob, age 69, carer for Mary who has PSP 
 
The contrast between these two stories can show the difference that expertise and support can 
provide to a patient who has heard difficult news. This could impact upon trust given to 
professionals by patients and carers throughout the disease process. A more traumatic, 
unsupported diagnosis might lead to greater difficulties in adjustment. Matthew’s diagnosis, 
though not the news he wanted, and like many other participants, delayed and revised from an 
earlier diagnosis of PD, was given by a clinician he had faith in and felt reassured by. He had 
the ability to ask questions from a respected source. Mary however, had little time to prepare, 
no knowledgeable professional to hand to ask, and as a result, her experience of diagnosis was 
not a positive one. After receiving a diagnosis, there was a theme of feeling left to deal with 
the condition after the intensity of the diagnostic testing and bad news. There was a sense of 
feeling abandoned to deal with the disease alone from the participants. 
I think in the hospital once you were diagnosed, that was it. You were out and you had to 
get on with it. So it went very short from having a lot of input to nothing to taking your 
prescription and leaving and getting on with it 
Rose, age 71, who has MSA 
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Well, I was told it’s a totally separate condition (from PD) and they couldn’t do anything 
about it. There was no magic cure for it. Basically, I’d have to manage the PSP with help 
from the hospice. 
Gary, age 58, who has PSP 
 
Gary’s experience of hospice input was very positive and pervaded his interview. However, at 
this point in his narrative, he had no experience of PC and his diagnosis was coloured by the 
impression that his illness had no cure and that only the hospice could offer him anything. 
From perceptions of PC (Chapter 4), the most frequent response of participants who had a 
diagnosis of AP (some of whom had already received PC) was being unable to define what 
PC was and the next most frequent response was that it was a service for the dying. Therefore, 
hearing that you had a more progressive condition than PD and that you would be referred for 
hospice care was likely to be a frightening one. The phrase ‘they couldn’t do anything about 
it’ again suggests withdrawal of active management and abandonment, without explanation of 
how PC might be able to help. In a review exploring giving a diagnosis of cancer, the 
importance of setting, ample time, and a face-to-face delivery is emphasised as beneficial and 
helpful in reducing the suffering of patients, as well as avoiding nihilistic comments like ‘we 
cannot help you’ (Baile et al., 2000).  
 
7.6.3 Information on disease 
After diagnosis, participants on the whole, sought more information about their disease, 
though the amount they wanted to know varied. There was a realisation that the condition 
they had was not well known generally, including amongst health care professionals. A theme 
amongst the carer-participants was to try and disseminate information in their local 
community, possibly in the hope that this might benefit their partner if more people were 
aware of their condition. Of note, this theme of carers distributing information on their 
partner’s illness was seen in the male and not female carer group. Possibly, male carers felt 
that this activity was a way of actively addressing the root of the problem of poor public 
information, as opposed to female carers.  
Even nurses and doctors don’t even know what the hell it is, man. I just say, “Not a 
problem. I’ll send you a pack.” And I do it. I get in touch with the [MSA] Trust and say, 
“Send them a pack.” Or I’ll take them any leaflet in I’ve got, and I’ve got leaflets in my 
reception for people to read because a lot of people don’t know what it is.  
Bill, age 57, carer for Doris who has MSA 
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I've taken magazines down, and I've put them in the doctor's surgery for people, the public 
to see, so that the public are, become aware.  
Bob, age 69, carer for Mary who has PSP 
 
The information that was available tended to be either from specialist organisations, like the 
MSA Trust and UK PSP Association, or information from the internet, whether from official 
sources or not. Aside from these support groups and the internet, only one participant had 
heard of MSA or PSP before the diagnosis was made; Sally, from her friend, prompting her to 
seek further referral, above. Her GP had not heard of the diagnosis prior to her raising the 
issue. Information and making information more available through various means, be it open 
communication within communities, medical education or charity outreach, was a universal 
issue for all participants, patients and carers. There is a suggestion that bringing their disease 
out into the public understanding might make constant explanations less necessary and 
increase the understanding of their situation. Work into rare diseases in Australian families 
has shown that there is a desire for as much reliable information as possible, which becomes 
more vital the more unheard-of the disease is and aid in connecting to others who can offer 
peer support (Anderson et al., 2013). 
Well I think PSP is so unheard of. Even in the medical situation. My doctor had never 
heard of it. It’s just so unheard of. I think it needs a little bit more publicity but it’s such a 
rare thing, you know. 
Sally, age 70, care for her husband (not interviewed) who has PSP 
 
Like everyone knows about Parkinson’s and everyone knows about cancer. I would like 
everyone to know about [PSP] so that they would have more of an understanding of daft 
people like me. 
Helen, age 68, who has PSP 
 
Specialist services, who were knowledgeable about AP, were important to the well-being of 
the participants interviewed. This not only comprised of medical services who had experience 
of AP, like specialist nurses, but also charitable organisations like the PSP Association or 
MSA Trust. Participants found that access to a number of experts and agencies were required 
to help them navigate the problems which arose through their disease. Matthew, who felt 
well-informed and supported since diagnosis, thought having to cope without them would be 
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very detrimental. These groups not only provided the guidance and networking which can be 
so useful in finding useful contacts and advice in rare, complex conditions, but in finding 
other people to connect with. This is especially important for individuals who feel that the 
symptoms of their disease, such as speech problems or socially-difficult symptoms such as 
continence issues, are shared and understood by others.  
I wouldn’t have known what I’d been missing, but...it would be pretty awful. It’s such a 
horrible disease to have and the more back-up you’ve got, the more support the better it is, 
and…living in this area, you get tremendous encouragement. 
Matthew, age 64, who has MSA 
 
That was the time I went and sat in that group, and, er, got very emotional that night, 
actually, that I told them that… [Mary] didn't have Parkinson's, but it was something on a 
darker, down a side road, and I got really upset that night, expressing myself to them, and 
they were all really supportive of us. 
Bob, age 69, carer for Mary who has PSP 
 
The role of the group meeting and the peer support which is provided, appears immediately 
applicable to patients who share the same features of disease, but carers too, described the 
benefits of having access to people who were dealing with similar pressures of care-giving. 
Not all of these groups were specific to AP. Some were general carers groups of people with 
long-term illnesses, and some were Parkinson’s carers groups. However, finding people who 
you could confide in, and who you felt had the life-experience to empathise with you, 
appeared important to this group of participants.  
 
7.6.4 Peer support 
Peer support was not only found in support groups but also from palliative care services, from 
other patients with various life-limiting illnesses, as well as from staff who attempted to 
provide more holistic care for the whole person. Therefore, the care provided by PC services 
may not only have relieved symptoms from physical issues, but gave time and access to other 
people, staff and patients, thus addressing psychosocial and spiritual needs. 
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It helps due to the fact that people- you’re in with a group of people who’s going to have 
the same endings you are. I’m not saying it’s going to be quicker or time-wise, but 
psychologically you feel that you’re on par with them, and they help you and you help them 
in different ways. 
Gary, age 58, who has PSP 
 
When participants described experiences that they had had with PC services, they tended to 
describe the human interactions, rather than specifically the treatments received or services 
provided. PC is a varying ‘package’, be it day hospice, home visits or clinic appointments, in 
keeping with the heterogeneous presentation of AP and different elements which constitute 
QoL, shown in Chapters 4 and 6. This suggests that some of the benefits participants derive 
from PC are from the extra time and service design allowing greater connection with others. 
This includes meeting other patients, one-to-one nursing and volunteer input, protracted and 
more frequent clinic reviews with continuity of care, and personalisation. Gary experienced 
this from his time in day hospice, where he could relate to the others in the group, though 
their conditions and trajectories might vary.  
 
7.6.5 Palliative care 
The contribution of generalists, such as GPs using a palliative approach, was also described. 
Sally’s GP who had not heard of PSP before making a referral, as described earlier, had 
become informed on PSP and maintained continuity of care with Sally’s husband. This had 
culminated in her helping Sally’s husband with advance care planning so his wishes were 
respected as he approached the last days of his life. Sally found the process difficult, though 
the discussions seemed to orientate and began to prepare her for the future. She seems to have 
a great deal of gratitude to the GP for her work with her husband, using the word ‘incredible’ 
which might allude to the journey the GP has made to educate herself on the disease so she 
could apply a palliative approach to improve his care. 
My doctor [GP] was incredible. I mean she has gone, and we’ve done his end-of-life thing, 
where he can tell you what he wants. I had to walk out of the conversation because I 
was…I sort of pulled myself back together and went back in.   And I suppose that’s when 
the word palliative hit me. The meaning of the word palliative hit me. I think that was it. 
And I now know that he won’t live forever. 
Sally, age 70, carer for her husband (not interviewed) who has PSP 
151 
 
I think it means people like nurses who are coming and sort of help you to do things, talk to 
you about your disease, check on your medication, perhaps advise on maybe a bit of extra 
help and say things that you can do to make your life easier  
Rose, age 71, who has MSA 
 
Rose had not had any input from PC but was open to the possibility and that it could enhance 
her experience. This is contrasted with participants who felt PC was the last refuge before 
death and seemed to fear it or dismiss it as unhelpful to them at their point in their illness. 
Viewpoints varied between the perception of PC as extra support and as a staging post, a 
referral to PC being made when your doctor felt you were dying. It can be seen that in this 
later group, especially if PC as a concept is not fully and openly explained from an early stage 
in the disease process, that people might defer engaging with the service out of fear; losing the 
opportunity to benefit from it in the ways discussed by Gary, Sally and Rose. Matthew 
appears to fit into this category. Doris seems between these two viewpoints, as though she is 
in transition between anticipating her advancing illness and beginning to appreciate that PC 
may have a role to play in enhancing her QoL. This appreciation for PC and its outlook into 
facing the future, possibly mirrors participants’ adjustment to their diagnosis. 
I don’t think I need the help. I might later on. I don’t know. Like now, some people might 
be in bits, talking like this, but I know what to expect. 
Doris, age 59, who has MSA 
 
I would say the end of your life, er, that sort of care is offered, I’ve heard of 
organisations…I don’t know whether if I’ve reached that stage 
Matthew, age 64, who has MSA 
 
In terms of adjustment and acceptance, the expectations of research from participants may 
vary (as seems to be the case with opinions on PC). Some participants were involved in 
multiple types of research. There appeared be widespread solace in the fact that though there 
was, as yet no curative treatment for AP, active research was going on seeking to address that. 
 
Interviewer:  So you think being informed about the research and things, does that help you? 
Rose:   Yes. It makes you feel if you hang on long enough there’ll be something out there. At 
least if you don’t, well, there’ll be something, if you can help a little bit, there’ll be 
something for somebody else later on. Mightn’t be in my time, but I’m sure like the 
cancer research, it’ll come.  
 
Rose, age 71, who has MSA 
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7.6.6 Research as hope 
Motivations, however, varied from envisioning cures which would come about quickly and 
effect a cure, to wanting to contribute to the possibility of a cure for others in the future. The 
cure seemed to be tied up with the notion of hope, though Rose for example did not seem to 
have lost hope, despite not foreseeing a cure for herself; rather she has shifted the hope from 
herself onto others. Bryce particularly discussed the need to have the possibility of a cure as a 
reality. To dispel this idea or to suggest that this might not come to pass for him was seen as a 
cruelty on behalf of doctors, destroying hope. One doctor who suggested that he might 
consider the future if, by chance a cure was not found, was considered in his words a 
“menace” for dispelling his prospect of being healthy again. This indicates that an ‘absolutist’ 
attitude to always telling patients all the facts may be harmful. There is a delicate balance to 
assessing how and when to convey information to patients when they are ready. This allows 
them to prepare and plan. In some cases, divulging the full truth may damage patients’ well-
being (Begley and Blackwood, 2000). Expectations of cures and interventions may have 
changed perceptions of mortality in illness, making the concept and idea of death and dying 
unexpected and frightening; leading to a ‘dehumanised’ and medicalised dying (Clark, 2002). 
A cure … I just think it's all lies, you can get cured. I'm not saying you're going to get 
cured tomorrow or the next day or next week but in years to come…. as long as people like 
them stupid doctors don't turn around and say you're never going to get cured. Give you a 
bit of hope. 
Bryce, age 76, who has PSP 
 
Interviewer:  is there are a lot of discussion of cures and research in the house? 
Emma:  all the time, all the time… he’ll present me with the latest thing he’s been reading 
about …-I think that, he’s clinging to this to give him hope. 
 
Emma, age 61, carer for Matthew who has MSA 
 
Emma describes Matthew’s avid scrutiny of the medical literature, desperate for news of a 
new effective treatment as a means to maintain hope in the face of his disease. This may be in 
tandem with his current position on palliative input; he is not yet ready to consider that a cure 
may not be found. It may be that this is a position he could come to in the future, he might 
then be open to PC input (though these two viewpoints may not be mutually exclusive). This 
balance between hope for curative treatment and embracing a different kind of care, 
encompassing holistic management and looking to the future, is something that all physicians 
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and care teams will face, as medical technology increases. It also become more important as 
our knowledge of the needs beyond the traditional biophysical model grows (Clark, 2002).  
 
7.7 Discussion 
The main themes that pervaded this qualitative study were connection, transition and 
accessing support. The first two lead very much into the last; connectedness allowing access 
to support and in turn, increasing the feeling of connection for patients and carers as 
transitions lead to the need to access services. 
Connection was described as the ability to relate to others by speech, communication 
generally, quality and maintenance of relationships, and being able to relate to oneself and 
how identity can be affected by such a pervasive disease. Identity was profoundly affected in 
the patient-participants; some described the strangeness or oddness of what the disease had 
done to them, especially in terms of personality or cognitive changes. Others withdrew, either 
voluntarily from social interactions due to self-consciousness about their progressing 
disability, or felt that this withdrawal was imposed upon them as their voices faded, and 
became weaker; literally, in terms of volume, but also metaphorically, as fatigue and the 
burden of their illness weighed them down. Participants emphasised that the voice of the 
patient and of the carer was not heard and that the public was not aware of the struggle they 
faced with a rare, little-known illness, as the demands of the condition severed the 
connections and ties to their previous lives.  Pre-morbid poor social networks have been seen 
in work on stroke to predict for poor outcomes. The influence of the social network in 
neurological disease has been found to have such an impact on the outcome of patients that 
incorporating key members of the network into clinical discussions has been found to 
improve health behaviours and influence depression (Boden-Albala et al., 2005; Dhand et al., 
2016). Patients and relatives should be considered together; what impacts one will influence 
the other, especially true of the sole spouse-carer with a limited family network for wider 
support. Connectedness is as important for carers as for patients. AP has more rapid and 
devastating effects upon speech and communication than PD and in the latter, Hudson 
described the social sphere shutting down to just the patient and carer. However, as 
communication became more difficult even between them, both ended up being cut off from 
meaningful human contact (Hudson et al., 2006; Miller et al., 2011; Rusz et al., 2015). Carers 
are frequently isolated from their social networks by the 24-hour nature of care, and this was 
captured particularly by the carer’s fear of the patient falling. It should be a priority to keep 
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the channels of communication open to patients and to carers as long as possible. This 
encompasses speech therapy, technological devices and trained staff to recognise 
communication difficulty, but also simple, meaningful measures such as eye contact with a 
mute patient, speaking to patients themselves rather than their carer, and asking carers about 
their well-being and signposting them to sources of support. 
The transition theme also recognises the link between patients and carers. Both groups 
endured a narrative of change which has been described in the literature as ‘biographical 
disruption’ - chronic illness causing the defined path of life up until that point and the 
projected or expected course after, to deviate in unexpected ways. This disruption is  
associated with chronic illnesses, particularly when associated with uncertainty and part of 
acceptance is coming to terms with this impact upon the planned life and adjusting to the new 
unexpected reality (Williams, 2000). This alteration to the planned life affected the 
partnership of patients and carers. The bond between the patient and the care-giver appeared 
key to coping and adjustment. However, there was tension inherent in these relationships 
which was shown particularly clearly in patients with frontal cognitive problems and motor 
recklessness. The aims of maintaining independence and keeping ambulant in these patients 
(especially as there may be loss of insight about the risk of injury) and the conflicting 
objective of carers keeping their partner safe whilst promoting their well-being, often 
downplaying the increasing amount they need to do to keep their partner going, were 
sometimes in opposition. This view of the life together and the contribution of each person to 
the relationship has been described as the ‘biographical we’ (Aasbo et al., 2016). Carers have 
this ‘safety versus independence’ dilemma, which is often not seen by the patient and 
pervades the whole relationship with ongoing worry. 
The nature of the changes or transitions made in response to illness can be seen as reactive 
due to the demands of the illness (be it from patient or carer), or proactive as a consequence of 
shifting one’s own expectations and adjusting to the new reality. In terms of how this can be 
seen narratively, the changes imposed by disease can be seen as chaotic and out of the 
person’s control, further cementing the impact that the disease has upon the person’s reality. 
This could be seen from the retreat of patient-participants from the active roles and social 
circles due to their disease silencing their voices, slowing their thoughts and bodies, and from 
carers whose social outlets are trimmed away as the needs of their partner grow. By contrast, 
the internal changes described by participants, of outlook, expectations and viewpoints, mirror 
acceptance and adjustment. These transitions seek to limit the power the chaotic disease has 
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upon the participants as they shift their expectations. These adjustments are difficult to 
maintain in the face of uncertain disease, but participants whose interviews evoked the themes 
of adjustment and acceptance, seemed to fix their gaze beyond the immediate challenges as 
they arose, almost as though they were prepared for a difficult journey with obstacles, the 
ending of which they were prepared for. This perception of chronic illness as a quest to the 
final destination of death, with its alternative as a tumultuous imposition of events upon the 
person, is described by Frank (2013) in his narrative on the illness journey. These narratives 
are not exclusive, and individuals can simultaneously experience the buffeting of the chaos 
narrative, and learning about themselves and their illness in the quest narrative or, pass from 
one to the other.  
The nature of MSA and PSP is complex and seemed to affect multiple elements of the person; 
physical, cognitive, psychosocial and spiritual. For this reason, the transitions that individuals 
(both patients and carers) endure and impose upon themselves in the course of their illness-
journey, are many and varied. The ‘totality of change’ is therefore a good descriptor of the 
transitions made during the course of the illness; seeking a diagnosis, experiencing the 
changing self, and the shift from relative to carer. 
These two previous themes feed into the access of support theme. Support seeks to make 
transitions easier, to address the ‘shrinking down’ of horizons, and re-open the door to the 
outside world via peer support, addressing a lack of information, helping with symptoms and 
engaging with research as a source for hope into the future. Palliative care stood as a beacon 
for some, enabling this re-connection and helping the journey to acceptance. For others it was 
a symbol of decline and loss, preparing for a future without a cure. Palliative care is 
envisioned as a multi-system, holistic and individual approach to the well-being of people 
with chronic or life-limiting illness (World Health Organisation, 2002). As the prevalent 
threads of this qualitative work have shown, much distress from the cohort interviewed 
springs from lack of information, perceived expertise, time and loss of social networks. A 
palliative approach, by its very remit is better equipped to salvage quality from the lives 
affected by AP than the traditional biomedical model.  
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7.8 Reflections 
I have reflected upon the analysis in this chapter using criteria described by Yardley (2000), 
as was discussed in the Methods chapter. 
As part of the requirement of qualitative work is commitment and rigour, necessitating 
immersion, I tried hard to engage with the experiences of the participants. This was on some 
levels difficult to do, as clinicians are encouraged to have some professional detachment from 
their patients, but in the context of the research, I sought to consider the participant’s 
experiences not from a medical-practitioner standpoint but from a neutral stance so best to 
appreciate their story.  Equally, some participants who had known me from clinical work 
prior to the study, regarded me as a doctor primarily, which at times influenced their interview 
responses. They may have assumed I would want to hear more ‘technical’ and medical details 
rather than their own concerns and narratives. This required frequent reminders and guides to 
the participant to give their own story rather than listing appointments and tests. However, 
during interviewing and analysis, I was conscious of my tendency to try to ‘diagnose’ issues 
interviewees described, rather than allow participants to discuss them in terms of their own 
experience. Consequently, I needed to constantly check and review my interviewing to ensure 
I was not interviewing as a doctor rather than as a researcher. However, I accept that this 
background likely coloured the interactions with participants and influenced the tone of the 
analysis. 
As well as my standpoints and beliefs influencing the study, there were impressions made on 
me from the project and working with its participants. Compared to my clinical work, the 
qualitative part of the project allowed me to understand the participants better, gaining insight 
into other aspects of their disease beyond the ‘safe space’ of the clinic.  This has positive sides 
in that it may help me to gain perspective when considering difficulties and patient needs in 
clinical care and planning of service provision in the future. Potential negative impacts were 
due to the greater relationship developed between myself and these participants. Seeing these 
patients progress and, in some cases, die whilst still reviewing their words in written interview 
format and hearing their voice recordings was, at times, difficult. Previous interaction with 
patients and carers has had a fairly defined boundary in clinical practice; when invited into 
people’s homes to take very personal interviews, these individuals made a far deeper 
impression and their subsequent deterioration was challenging to deal with. Debriefings with 
KB were helpful in this regard. 
157 
 
Chapter 8. Discussion 
 
8.1 Discussion 
There is a growing body of work exploring QoL in chronic, progressive disease, with the aim 
of giving individuals and their families the best possible experience as they live with their 
condition. Rare illnesses, like MSA and PSP, may have unique symptom profiles and the 
added burden of delayed diagnosis and fewer practitioners with experience of managing the 
disease (Moore and Guttman, 2014; Wiblin, 2017).  
Although some studies have explored QoL in MSA and PSP, and scales have been developed 
to measure it, there has been a paucity of studies looking at subjective QoL; HR-QoL tends to 
measure well-being related only to illness and is limited in assessing how other factors in the 
individual’s life influence patient satisfaction (Schrag, 2005; Schrag et al., 2006a; Schrag et 
al., 2006c; Meissner et al., 2012; Pekmezovic et al., 2015). 
Palliative care aims to maximise QoL by embracing all aspects of the person and alleviating 
distress and managing symptoms wherever possible, including psychological distress, and 
taking carers and families into account (up to and beyond the patient’s death) (Sepulveda et 
al., 2002; World Health Organisation, 2002). The palliative approach, which as discussed in 
Chapter 1, can be used by anyone, not just doctors or nurses working in Specialist Palliative 
Care. It advocates a style which is personalised to the individual, incorporating future 
planning and preparation but only at a pace determined by, and according to the wishes of, the 
patient. Greater complexity may involve liaison with or referral to SPC services, and part of 
the palliative approach is recognising when this is required (Ghoche, 2012; Miyasaki, 2015). 
PC has been increasingly recognised as helpful in neurodegenerative disease such as PD and 
dementia, in part due to the example of MND which incorporates PC into best practice from 
diagnosis with improvement in QoL consequently (Borasio, 2013; Veronese et al., 2015; 
Oliver et al., 2016). There has been little work which considers the use of PC in MSA and 
PSP nor the PC needs of these conditions, the majority being in PD alone or PD together with 
some AP (Higginson et al., 2012; Saleem et al., 2013). 
This study aimed to describe QoL in MSA and PSP both in terms of HR-QoL and subjective 
QoL and compare the two groups. It also assessed QoL in the carers of MSA and PSP-
affected participants. Symptom profiles were explored using a palliative symptom 
questionnaire and subjective symptom onset was recorded to give a view of retrospective 
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symptom trajectories over time. Interviews were carried out with a sample of participants to 
allow a nuanced and rich view of participants’ experiences with MSA and PSP.  
Depression and palliative care need (using DASS-21 and the POS-S-PD) were shown to 
predict HR-QoL (using MSA-QoL) in MSA whilst depression, palliative care need and 
disease-specific severity predicted HR-QoL (PSP-QoL) in PSP.  This is the first evidence we 
are aware of looking specifically at palliative care requirement as a predictor for QoL in MSA 
and PSP. Furthermore, the difference highlighted between the two conditions in terms of how 
severity impacts HR-QoL (significant effect on QoL in PSP though not in MSA).  Subjective 
QoL showed diverse and varied domains in patients and carers, highlighting that QoL is 
heterogeneous. The importance of relationships was the most frequently nominated issue in 
all patient and carer groups: Family/family-life was most nominated and marriage/partner 
second overall. Scores on subjective QoL showed no significant differences between MSA or 
PSP (between patients or between carers), though MSA patients had lower mean scores than 
PSP patients. MSA carers also had lower mean scores than PSP carers. Possible reasons for 
this include the possibility that greater cognitive involvement might afford some relative 
‘protection’ from considering the future implications of a progressive disease (which might 
make PSP patients’ QoL more reliant on direct physical impact of disease, such as HR-QoL 
being affected by severity).  Similarly, carers for MSA patients may have greater distress if 
the people they care for are more distressed. Work in PD has suggested that age does not 
seem to affect care-giver burden, though the carers in the two disease groups in this study 
showed different characteristics (Greenwell et al., 2015; Navarta-Sanchez et al., 2016).  PSP 
carers were older and almost all were retired. In the MSA group, carers and patients tended to 
be younger and some carers were still in employment. It may be that disruption of plans and 
expectations and the subsequent adjustments required, were more substantial and demanding 
in the MSA group, leading to greater impact on all aspects of QoL and well-being.  The 
SEIQoL-DW is a powerful tool which can capture complex data on subjective, individualised 
QoL. Although SEIQoL has been used to generate continuous scores in AP cohorts together 
with PD, there is currently no literature which explores subjective QoL in MSA or PSP. As 
there are no current treatments which can prolong life or have a disease-modifying effect in 
these conditions (and indeed in any other neurodegenerative disease at present), looking at 
ways to improve the experience of these people beyond symptom control should be sought. 
As QoL means different things to different individuals, a personalised approach, possibly with 
social as well as medical input, may be required, but more work should be done in future to 
explore the benefits of this. 
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From a carer perspective, other than a single paper in 1998, there has not been any work 
looking into QoL, strain or well-being of carers of people with MSA or PSP (Uttl et al., 
1998). Clearly this is a group who deal with a complex disease affecting physical and 
cognitive health as well as the fairly unique pressures of delayed diagnosis and the ‘re-
diagnosis’ from PD, which is a frequent emotional aspect of dealing with these conditions. 
This project not only used generic tools to look into carer well-being, but also specific carer 
QoL scores for this group of diseases and subjective QoL scores which allowed comparison 
between carer groups and between carers and the people they cared for. The findings suggest 
some protection afforded by a longer relationship-duration between patient and carer. As the 
predictive value is modest and the qualitative work in this project produced findings that 
emphasised the importance of connecting to others and particularly, a meaningful relationship 
with a partner and family, it is possible that the quality of the relationship between patients 
and carers have a more profound influence on QoL. Exploring this and how quality 
relationships could be preserved or enhanced would be a logical progression in future work, 
which could also have implications for well-being and service planning for other conditions.     
Exploration of palliative symptom profiles showed that burden was higher than in previous 
work (PD with some MSA and PSP patients) using the same tools. There were no significant 
differences in palliative symptom severity between MSA and PSP, though there was a trend 
toward greater urinary disturbance and fatigue in the MSA group. Symptom profiles were 
similar, suggesting that services for both MSA and PSP patients are appropriate, though 
assessment of individual concerns is important. How patients’ palliative or symptom needs 
can be addressed in different locales depends very much upon the culture of the team and 
geography of the area. It may be that teams could be fully integrated, with movement disorder 
services and palliative care teams sharing the care of patients as well as physiotherapists, 
occupational therapists etc. Other regions may have rehabilitation teams incorporating a 
palliative ethos, as symptom control is part of routine care for neurological conditions such as 
Multiple Sclerosis in rehabilitation medicine. In very rural conditions, nursing teams or 
palliative care nursing and therapy teams in the community could keep patients and carers 
connected to their specialists; be they neurologists, elderly care consultants or specialist 
palliative care consultants.  Increasingly, as hospitals try to concentrate on outpatient care and 
reducing admissions to hospital, more creative solutions to provide care and support to 
patients need to be trialled for efficacy and patient satisfaction. These include community 
outreach clinics, possibly held in hospice or community hospital settings or virtual clinics 
using video-conferencing (which could link up multiple disciplines together whilst the patient 
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does not have to leave their home - which can be very difficult in advanced disease). 
Exploration of technology and community work and how they could benefit people with AP 
would be a meaningful subject for research and service improvement projects. 
Qualitative interviewing and analysis revealed three main themes; connection, transition and 
seeking support. Connection was concerned with relating to others and how this is affected by 
the impact of AP affecting speech, cognition and concerns about how one is perceived. 
Transitions comprised of subthemes of changing roles, shifting physical and mental 
conditions, and adjustment to these changes. Finally, seeking support highlighted the 
difficulties in obtaining a diagnosis and getting appropriate help and assistance with a rare 
disorder which is poorly understood. These themes related to each other (i.e. support could 
help individuals undergoing particular transitions re-connect to others, such as family or peer 
groups).  Interestingly there was some cross-over between the SEIQoL-DW domains and 
interview themes (see Appendix C), particularly in the emphasis patients and carers placed on 
how relationships were affected by disease, the nature of 24-hour care, and the burden this 
produces and delayed diagnoses. However, the interviews tended to discuss experiences 
people had had whilst the SEIQoL-DW tended to focus on the more positive aspects that 
participants had.  
 
8.2 Limitations and future perspectives 
This study comprised of a relatively small sample and was cross-sectional in design. In order 
to gain greater insight and more definite conclusions on QoL, palliative care needs and 
symptom profiles, further work should be done with larger groups and on a longitudinal basis. 
Assessing the validity of depression scores in patients with MSA and PSP, taking into account 
a measure of apathy, might also be helpful in better assessing the mood of this patient group.  
Another limitation of this work was the lack of formal cognitive testing. Although it is well-
described in standard medical texts and the research literature that cognitive dysfunction tends 
to be more severe in PSP than MSA, it would have been helpful to have a measure to 
ascertain how different cognitive scores were between groups and whether these profiles 
impacted upon QoL (and QoL of care-givers).  
MSA and PSP have profound effects on the QoL of patients and carers. Palliative symptom 
burden appears higher than PD at an equivalent H&Y stage, and participants were particularly 
troubled by the impact of their condition upon relationships. Depression and palliative burden 
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impacted on QoL. SPC seemed to be of benefit to patients, though prior perceptions of PC 
were often that it was a service for cancer, or the imminently-dying. Service provision should 
consider the benefits of a blended approach with palliative care integrated from the beginning. 
Depression and symptoms such as drooling and pain, should be sought as much as motor 
symptoms in neurological reviews to improve QoL. When communication is impaired, efforts 
should be made to retain the patient’s input, such as prior sessions to obtain concerns and 
issues with volunteers or therapy staff, and more time in clinic. Measures to support carers 
should be researched in the future, as caregiver-burden in chronic disease is sizeable, growing 
and their well-being is intrinsically connected with that of the patient. 
This work produced some findings that show the importance of identifying and treating 
depression and how symptoms often classified as ‘palliative’ such as drooling can influence 
QoL in MSA and PSP. It also explored the differences that different scales purporting to 
measure the same construct (‘QoL’) look at different aspects of a complex concept and are 
complementary rather than alternatives. Disease-specific QoL tools cannot capture the same 
holistic and individual meaning as subjective QoL tools, but in turn would not pick up 
personal concerns around these unique diseases and their specific symptoms. It is therefore 
reasonable to suggest that future work exploring QoL should incorporate both HR-QoL and 
subjective, more reflective measures of QoL, not only to capture a fuller picture, but to see 
what influences different aspects, and how they can be improved.  
Similarly, the majority of tools used in this study were validated for AP (or at least PD). The 
depression scales have not been validated in AP and there seemed to be no consensus on 
which measure was best suited to frontal dyscognitive problems. As it can be difficult to 
distinguish apathy and depression from each other clinically, work to verify the most suitable 
tool, with apathy measures such as the Lille score and a clinical psychiatric assessment, would 
be extremely useful to find the most reliable ways to measure depression when apathy is also 
present. 
Finally, I worked with supportive neurologists and palliative care physicians to complete this 
project.  In the future, medical specialities may consider training physicians to acquire 
palliative care expertise within their own area to complement and work with SPC teams as our 
awareness of patient needs grow. 
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Appendix A: Questionnaires 
Patient Demographics 
Age    
Sex               Female                 Male       
Diagnosis MSA          PSP     
Age at diagnosis 
Age at (perceived) onset 
Ethnicity 
Marital state:  Married/Partner/Widowed/Single 
Occupation 
Hoehn and Yahr Stage:  1  2  3  4  5 
Medications: 
 
Key Symptoms: 
1. Frequent falls (more than or equal to 2/yr or documented freq falls) 
2. Wheelchair 
3. Postural drop/other autonomic 
4. Speech problems 
5. Swallowing problems 
6. PEG insertion 
7. Catheter insertion 
8. Emergency admission to hospital for symptom control/sequelae of disease 
9. Admission to institutional care 
10. Tracheostomy 
Do you have pain    Yes    No      
If yes, type and any treatment  
Do you have drooling?   Yes    No   
If yes, type and any treatment 
Do you have poor sleep?   Yes    No     
If yes, type and any treatment 
Do you have anxiety?   Yes    No   
If yes, any treatment? 
Do you have depression?   Yes    No    
If yes, any treatment? 
Memory problems?   Yes    No  
Do you know what PC is?   Yes    No  
What is it? 
Have you had any palliative care input?  Yes   No  
Details 
 
 
164 
 
Carer Demographics 
Age      
Sex                      Female             Male   
Caree Diagnosis:   MSA      PSP   
Ethnicity 
Occupation 
Marital status:   Married/Partner/Widowed/Single 
Lives with caree?      Yes       No   
Driver:             Yes       No  
Length of time they've known participant/patient:  
 
Length of time as caregiver/carer:  
 
Length of time spent per week as caregiver:  
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PSPRS 
I. History (Score 0-24) 
1. Withdrawal (relative to baseline personality) 
0) None 
1) Follows conversation in a group, may respond spontaneously, but rarely if ever initiates 
exchanges 
2) Rarely or never follows conversation in a group 
2. Irritability (relative to baseline personality) 
0) No increase in aggressiveness 
1) Increased, but not interfering with family interactions 
2) Interfering with family interactions 
3. Dysphagia for solids 
0) Normal; no difficulty with full range of food textures 
1) Tough foods must be cut up into small pieces 
2) Requires soft solid diet 
3) Requires pureed or liquid diet 
4) Tube feeding required for some or all feeding 
4. Using knife and for, buttoning clothes, washing hands and face (rate the worst) 
0) Normal 
1) Somewhat slow but no help required 
2) Extremely slow; or occasional help needed 
3) Considerable help needed but can do some things alone 
4) Requires total assistance 
5. Falls (average frequency if patient attempt to walk unaided) 
0) None in the past year 
1) <1 per month; gait may otherwise be normal 
2) 1-4 per month 
3) 5-30 per month 
4) >30 per month (or chairbound) 
6. Urinary incontinence 
0) None or few drops less than daily 
1) A few drops staining clothes daily 
2) Large amounts, but only when asleep; no pad required during day 
3) Occasional large amounts in daytime; pad required 
4) Consistent, requiring diaper or catheter awake and asleep 
7. Sleep difficulty 
0) Neither 1° or 2° insomnia (i.e. falls asleep easily and stays asleep) 
1) Either 1° or 2° insomnia; averages at least 5 hours sleep nightly 
2) Both 1° and 2° insomnia; averages at least 5 hours sleep nightly 
3) Either 1° or 2° insomnia; averages less than 5 hours sleep nightly 
4) Both 1° and 2° insomnia; averages less than 5 hours sleep nightly 
II. Mental exam (Score 0-16) 
Items 8-11 use this scale: 0 = Clearly absent, 1 = Equivocal or minimal, 2 = Clearly present, but not affecting 
activities of daily living (ADL), 3 = Interfering mildly with ADL, 4 = Interfering markedly with ADL 
8. Disorientation 
9. Bradyphrenia 
10. Emotional incontinence 
11. Grasping/imitative/utilizing behaviour 
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III. Bulbar exam (Score 0-8) 
12. Dysarthria (ignoring palilalia) 
0) None 
1) Minimal; all or nearly all words easily comprehensible (to examiner, not family) 
2) Definite; moderate; most words comprehensible 
3) Severe; may be fluent but most words incomprehensible 
4) Mute; or a few poorly comprehensible words 
13. Dysphagia (for 30-50cc of water from a cup, if safe) 
0) None 
1) Fluid pools in mouth or pharynx, or swallows slowly, but no choking/coughing 
2) Occasionally coughs to clear fluid; no frank aspiration 
3) Frequently coughs to clear fluid; may aspirate slightly; may expectorate frequently rather than 
swallow secretions 
4) Requires artificial measures (oral suctioning, tracheostomy or feeding gastrostomy) to avoid 
aspiration 
IV. Supranuclear ocular motor exam (Score 0-16) 
Items 14-16 use this scale. Rate by inspection of saccades on command from the primary position of gaze to a 
stationary target.  0 = Not slow or hypometric; 86-100% of normal amplitude, 1 = Slow or hypometric; 86-100% 
of normal amplitude, 2 = 51-85% of normal amplitude, 3 = 16-50% of normal amplitude, 4 = 15% of normal 
amplitude or worse 
14. Voluntary upward saccades 
15. Voluntary downward saccades 
16. Voluntary left and right saccades 
17. Eyelid dysfunction 
0) None 
1) Blink rate decreased (<15/minute) but no other abnormality 
2) Mild inhibition of opening or closing or mild blepharospasm; no visual disability 
3) Moderate lid-opening inhibition or blepharospasm causing partial visual disability 
4) Functional blindness or near-blindness because of involuntary eyelid closure 
V. Limb exam (Score 0-16) 
18. Limb rigidity (rate the worst of the four) 
0) Absent 
1) Slight or detectable only on activation 
2) Definitely abnormal, but full range of motion possible 
3) Only partial range of motion possible 
4) Little or no passive motion possible 
19. Limb dystonia (rate worst of the four; ignore neck and face) 
0) Absent 
1) Subtle or present only when activated by other movement 
2) Obvious but not continuous 
3) Continuous but not disabling 
4) Continuous and disabling 
20. Finger tapping (if asymmetric, rate worse side) 
0) Normal (>14 taps/5 sec with maximal amplitude) 
1) Impaired (6-14 taps/5 sec or moderate loss of amplitude) 
2) Barely able to perform (0-5 taps/5 sec or severe loss of amplitude) 
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21. Toe tapping (if asymmetric, rate worse side) 
0) Normal (>14 taps/5 sec with maximal amplitude) 
1) Impaired (6-14 taps/5 sec or moderate loss of amplitude) 
2) Barely able to perform (0-5 taps/5 sec or severe loss of amplitude) 
22. Apraxia of hand movement 
0) Absent 
1) Present, not impairing most functions 
2) Impairing most functions 
23. Tremor in any part 
0) Absent 
1) Present, not impairing most functions 
2) Impairing most functions 
VI. Gait/Midline exam (Score 0-20) 
24. Neck rigidity or dystonia 
0) Absent 
1) Slight or detectable only when activated by other movement 
2) Definitely abnormal, but full range of motion possible 
3) Only partial range of motion possible 
4) Little or no passive motion possible 
25. Arising from chair 
0) Normal 
1) Slow but arises on first attempt 
2) Requires more than one attempt, but arises without using hands 
3) Requires use of hands 
4) Unable to arise without assistance 
26. Gait 
0) Normal 
1) Slightly wide-based or irregular or slight pulsion on turns 
2) Must walk slowly or occasionally use walls of helper to avoid falling, especially on turns 
3) Must use assistance all or almost all the time 
4) Unable to walk, even with walker; may be able to transfer 
27. Postural stability (on backward pull) 
0) Normal (shifts neither foot or one foot) 
1) Must shift each foot at least once but recovers unaided 
2) Shifts feet and must be caught by examiner 
3) Unable to shift feet; must be caught, but does not require assistance to stand still 
4) Tends to fall without a pull; requires assistance to stand still 
28. Sitting down (may touch seat or back but not arms of chair)  
0) Normal 
1) Slightly stiff or awkward 
2) Easily positions self before chair, but descent into chair is uncontrolled 
3) Has difficulty finding chair behind him/her and descent is uncontrolled 
4) Unable to test because of severe postural instability 
Total Score 0-100 
 
 
 
168 
 
UMSARS 
Part I: Historical Review 
1. Speech 
0) Not affected 
1) Mildly affected. No difficulties being understood 
2) Moderately affected. Sometimes (less than half of the time) asked to repeat statements 
3) Severely affected. Frequently (more than half of the time) asked to repeat statements 
4) Unintelligible most of the time 
2. Swallowing 
0) Normal 
1) Mild impairment. Choking less than once a week 
2) Moderate impairment. Occasional food aspiration with choking more than once a week 
3) Marked impairment. Frequent food aspiration 
4) Nasogastric tube or gastrostomy feeding 
3. Handwriting 
0) Normal  
1) Mildly impaired, all words are legible 
2) Moderately impaired, up to half of the words are not legible 
3) Markedly impaired, the majority of words are not legible 
4) Unable to write 
4. Cutting food and handling utensils 
0) Normal 
1) Somewhat slow and/or clumsy, but no help needed 
2) Can cut most foods, although clumsy and slow; some help needed 
3) Food must be cut by someone, but can still feed slowly 
4) Needs to be fed 
5. Dressing 
0) Normal 
1) Somewhat slow and/or clumsy, but no help needed 
2) Occasional assistance with buttoning, getting arms in sleeves 
3) Considerable help required, but can do some things alone 
4) Completely helpless 
6. Hygiene 
0) Normal 
1) Somewhat slow and/or clumsy, but no help needed 
2) Needs help to shower or bathe; or very slow in hygienic care 
3) Requires assistance for washing, brushing teeth, combing hair, using the toilet 
4) Completely helpless 
7. Walking 
0) Normal 
1) Mildly impaired. No assistance needed. No walking aid required (except for unrelated 
disorders) 
2) Moderately impaired. Assistance and/or walking aid needed occasionally 
3) Severely impaired. Assistance and/or walking aid needed frequently 
4) Cannot walk at all even with assistance 
8. Falling (rate the past month) 
0) None 
1) Rare falling (less than once a month) 
2) Occasional falling (less than once a week) 
3) Falls more than once a week 
4) Falls at least once a day (if the patient cannot walk at all, rate 4) 
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9. Orthostatic symptoms (Syncope, dizziness, visual disturbances or neck pain, relieved on lying flat) 
0) No orthostatic symptoms 
1) Orthostatic symptoms are infrequent and do not restrict activities of daily living (ADL) 
2) Frequent orthostatic symptoms developing at least once a week. Some limitation in ADL.  
3) Orthostatic symptoms develop on most occasions. Able to stand >1 min on most occasions. 
Limitations in most of ADL 
4) Symptoms consistently develop on orthostasis. Able to stand <1 min on most occasions. 
Syncope/presyncope is common if patient attempts to stand 
10. Urinary function (urinary symptoms should not be due to other causes) 
0) Normal 
1) Urgency and/or frequency, no drug treatment required 
2) Urgency and/or frequency, drug treatment required 
3) Urge incontinence and/or incomplete bladder emptying needing intermittent catheterization 
4) Incontinence needing indwelling catheter 
11. Sexual function 
0) No problems 
1) Minor impairment compared to healthy days 
2) Moderate impairment compared to healthy days 
3) Severe impairment compared to healthy days 
4) No sexual activity possible 
12. Bowel function 
0) No change in pattern of bowel function from previous pattern 
1) Occasional constipation but no medication needed 
2) Frequent constipation requiring use of laxatives 
3) Chronic constipation requiring use of laxatives and enemas 
4) Cannot have a spontaneous bowel movement 
Part II: Motor examination scale 
1. Facial expression 
0) Normal 
1) Minimal hypomimia, could be normal (“Poker face”) 
2) Slight but definitely abnormal diminution of facial expression 
3) Moderate hypomimia; lips parted some of the time 
4) Masked or fixed facies with severe or complete loss of facial expression, lips parted 0.25 inch 
or more 
2. Speech (The patient is asked to repeat several times a standard sentence) 
0) Normal 
1) Mildly slow, slurred, and/or dysphonic. No need to repeat statements 
2) Moderately slow, slurred, and/or dysphonic. Sometimes asked to repeat statements 
3) Several slow, slurred, and/or dysphonic. Frequently asked to repeat statements 
4) Unintelligible 
3. Ocular motor dysfunction (Eye movements are examined by asking the subject to follow slow hori-
zontal finger movements of the examiner, to look laterally at the finger at different positions, and to 
perform saccades between two fingers, each held at an eccentric position of approximately 30°. The 
examiner assesses the following abnormal signs: (1) broken-up smooth pursuit, (2) gaze-evoked 
nystagmus at an eye position of more than 45°, (3) gaze-evoked nystagmus at an eye position of less 
than 45°, (4) saccadic hypermetria. Sign 3 suggests that there are at least two abnormal ocular motor 
signs, because Sign 2 is also present) 
0) None 
1) One abnormal ocular motor sign 
2) Two abnormal ocular motor signs 
3) Three abnormal ocular motor signs 
4) Four abnormal ocular motor signs 
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4. Tremor at rest (rate the most affected limb) 
0) Absent 
1) Slight and infrequently present 
2) Mild in amplitude and persistent. Or moderate in amplitude, but only intermittently present 
3) Moderate in amplitude and present most of the time 
4) Marked in amplitude and present most of the time 
5. Action tremor (Assess postural tremor of outstretched arms (A) and action tremor on finger pointing 
(B). Rate maximal tremor severity in Task A and/or B (whichever is worse), and rate most affected 
limb) 
0) Absent 
1) Slight tremor of small amplitude (A). No interference with finger pointing (B) 
2) Moderate amplitude (A). Some interference with finger pointing (B) 
3) Marked amplitude (A). Marked interference with finger pointing (B) 
4) Severe amplitude (A). Finger pointing impossible (B) 
6. Increased tone (Rate the most affected limb. Judged on passive movement of major joints with patient 
relaxed in sitting position; ignore cogwheeling.) 
0) Absent 
1) Slight or detectable only when activated by mirror or other movements 
2) Mild to moderate 
3) Marked, but full range of motion easily achieved 
4) Severe, range of motion achieved with difficulty 
7. Rapid alternating movement of hands (Pro-supination movement of hands, vertically or horizontally, 
with as large an amplitude as possible, each hand separately, rate the worst affected limb. Note that 
impaired performance on this task can be caused by bradykinesia and/or cerebellar incoordination. Rate 
functional performance regardless of underlying motor disorder) 
0) Normal 
1) Mildly impaired 
2) Moderately impaired 
3) Severely impaired 
4) Can barely perform the task 
8. Finger taps (Patient taps thumb with index finger in rapid succession with widest amplitude possible, 
each hand at least 15 to 20 seconds. Rate the worst affected limb. Note that impaired performance on 
this task can be caused by bradykinesia and/or cerebellar incoordination. Rate functional performance 
regardless of underlying motor disorder) 
0) Normal 
1) Mildly impaired 
2) Moderately impaired 
3) Severely impaired 
4) Can barely perform the task 
9. Leg agility (Patient is sitting and taps heel on ground in rapid succession, picking up entire leg. 
Amplitude should be approximately 10cm, rate the worst affected leg. Note that impaired performance 
on this task can be caused by bradykinesia and/or cerebellar incoordination. Rate functional 
performance, regardless of underlying motor disorder) 
0) Normal 
1) Mildly impaired 
2) Moderately impaired 
3) Severely impaired 
4) Can barely perform the task 
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10. Heel-knee-shin test (The patient is requested to raise one leg and place the heel on the knee, and then 
slide the heel down the anterior tibial surface of the resting leg toward the ankle. On reaching the ankle 
joint, the leg is again raised in the air to a height of approximately 40cm and the action is repeated. At 
least three movements of each limb must be performed for proper assessment. Rate the worst affected 
limb.) 
0) Normal  
1) Mildly dysmetric and ataxic 
2) Moderately dysmetric and ataxic 
3) Severely dysmetric and ataxic 
4) Can barely perform the task 
11. Arising from chair (Patient attempts to arise from a straight-back wood or metal chair with arms folded 
across chest) 
0) Normal 
1) Clumsy, or may need more than one attempt 
2) Pushes self up from arms of seat 
3) Tends to fall back and may have to try more than once but can get up without help 
4) Unable to arise without help 
12. Posture 
0) Normal  
1) Not quite erect, slightly stooped posture; could be normal for older person 
2) Moderately stooped posture, definitely abnormal; can be slight leaning to one side 
3) Severely stooped posture with kyphosis; can be moderately leaning to one side 
4) Marked flexion with extreme abnormality of posture 
13. Body sway (Rate spontaneous body sway and response to sudden, strong posterior displacement 
produced by pull on shoulder while patient erect with eyes open and feet slightly apart. Patient has to be 
warned) 
0) Normal 
1) Slight body sway and/or retropulsion with unaided recovery 
2) Moderate body sway and/or deficient postural response; might fall if not caught by examiner 
3) Severe body sway. Very unstable. Tends to lose balance spontaneously 
4) Unable to stand without assistance 
14. Gait 
0) Normal 
1) Mildly impaired 
2) Moderately impaired. Walks with difficulty, but requires little or no assistance 
3) Severely impaired. Requires assistance 
4) Cannot walk at all, even with assistance 
Part III. Autonomic examination 
(Supine blood pressure and heart rate are measured after 2 minutes of rest and again after 2 minutes of standing. 
Orthostatic symptoms may include lightheadedness, dizziness, blurred vision, weakness, fatigue, cognitive 
impairment, nausea, palpitations, tremulousness, headache, neck and “coat-hanger” ache.) 
Systolic blood pressure  Supine____/Standing (2 minutes)____/Unable to record 
Diastolic blood pressure  Supine____/Standing (2 minutes)____/Unable to record 
Heart rate   Supine____/Standing (2 minutes)____/Unable to record 
Orthostatic symptoms  Yes/No 
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Part IV. Global disability scale 
1. Completely independent. Able to do all chores with minimal difficulty or impairment. Essentially 
normal. Unaware of any difficulty 
2. Not completely independent. Needs help with some chores  
3. More dependent. Help with half of chores. Spends a large part of the day with chores  
4. Very dependent. Now and then does a few chores alone or begins alone. Much help needed 
5. Totally dependent and helpless. Bedridden 
 
RAND-36 
1. In general, would you say your health is:  
1) Excellent 
2) Very good 
3) Good 
4) Fair 
5) Poor 
2. Compared to one year ago, how would you rate your health in general now? 
1) Much better now than one year ago 
2) Somewhat better now than one year ago 
3) About the same 
4) Somewhat worse now than one year ago 
5) Much worse now than one year ago 
The following items are about activities you might do during a typical day. Does your health now limit you in 
these activities? If so, how much?  
 Yes, limited a lot [1] 
 Yes, limited a little [2] 
 No, not limited at all [3] 
3. Vigorous activities, such as running, lifting heavy objects, participating in strenuous sports 
4. Moderate activities, such as moving a table, pushing a vacuum cleaner, bowling, or playing golf 
5. Lifting or carrying groceries 
6. Climbing several flights of stairs 
7. Climbing one flight of stairs 
8. Bending, kneeling or stooping 
9. Walking more than a mile 
10. Walking several blocks 
11. Walking one block 
12. Bathing or dressing yourself 
During the past 4 weeks, have you had any of the following problems with your work or other regular daily 
activities as a result of your physical health? Yes [1]/No [2] 
13. Cut down the amount of time you spent on work or other activities 
14. Accomplished less than you would like 
15. Were limited in the kind of work or other activities 
16. Had difficulty performing the work or other activities (for example, it took extra effort) 
During the past 4 weeks, have you had any of the following problems with your work or other regular daily 
activities as a result of any emotional problems (such as feeling depressed or anxious)? Yes [1]/No [2] 
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17. Cut down the amount of time you spent on work or other activities 
18. Accomplished less than you would like 
19. Didn’t do work or other activities as carefully as usual 
 
20. During the past 4 weeks, to what extent has your physical health of emotional problems interfered with 
your normal social activities with family, friends, neighbours, or groups?  
1) Not at all 
2) Slightly 
3) Moderately 
4) Quite a bit 
5) Extremely 
21. How much bodily pain have you had during the past 4 weeks?  
1) None 
2) Very mild 
3) Mild 
4) Moderate 
5) Severe 
6) Very severe 
22. During the past 4 weeks, how much did pain interfere with your normal work (including both work 
outside the home and housework)? 
1) Not at all 
2) A little bit 
3) Moderately 
4) Quite a bit 
5) Extremely 
These [next] questions are about how you feel and how things have been with you during the past 4 weeks. For 
each question, please give the one answer that comes closest to the way you have been feeling. How much of the 
time during the past 4 weeks… 
 All of the time [1] 
 Most of the time [2] 
 A good bit of the time [3] 
 Some of the time [4] 
 A little of the time [5] 
 None of the time [6] 
23. Did you feel full of pep? 
24. Have you been a very nervous person? 
25. Have you felt so down in the dumps that nothing could cheer you up? 
26. Have you felt calm and peaceful? 
27. Did you have a lot of energy? 
28. Have you felt downhearted and blue? 
29. Did you feel worn out? 
30. Have you been a happy person? 
31. Did you feel tired? 
 
32. During the past 4 weeks, how much of the time has your physical health or emotional problems 
interfered with your social activities (like visiting with friends, relatives, etc.)? 
1) All of the time 
2) Most of the time 
3) Some of the time 
4) A little of the time 
5) None of the time 
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How TRUE or FALSE is each of the following statements for you?  
 Definitely True [1] 
 Mostly True [2] 
 Don’t Know [3] 
 Mostly False [4] 
 Definitely False [5] 
33. I seem to get sick a little easier than other people 
34. I am as healthy as anybody I know 
35. I expect my health to get worse 
36. My health is excellent 
 
MSA-QoL 
[0] No Problem 
[1] Slight Problem 
[2] Moderate Problem 
[3] Marked Problem 
[4] Extreme Problem 
In the last 4 weeks have you: 
1. Had difficulty moving? 
2. Had difficulty walking? 
3. Had problems with your balance? 
4. Had difficulty standing up without support? 
5. Had difficulty speaking? 
6. Had difficulty swallowing food? 
7. Had too much saliva or drooling? 
8. Had difficulty with handwriting? 
9. Had difficulty feeding yourself? 
10. Had difficulty drinking fluids? 
11. Had difficulty dressing yourself? 
12. Needed help to go to the toilet? 
13. Had to stop doing that you liked to do, e.g. your hobbies? 
14. Had difficulty doing things around the house, e.g. housework? 
15. Experienced bladder problems? 
16. Experienced problems with constipation? 
17. Experienced dizziness when standing up? 
18. Suffered from cold hands or feet? 
19. Experienced pain in your neck or shoulders? 
20. Experienced pain elsewhere, e.g. in your legs or your back? 
21. Had difficulty getting comfortable during the night? 
22. Had difficulty breathing during the night? 
23. Been feeling tired very quickly (without exerting yourself)? 
24. Experienced lack of energy? 
25. Experienced slowness of thinking? 
26. Had difficulty with your concentration, e.g. reading or watching TV? 
27. Felt frustrated? 
175 
 
28. Felt depressed? 
29. Experienced a loss of motivation? 
30. Been feeling incapable? 
31. Worried about the future? 
32. Worried about your family? 
33. Felt on your own or isolated? 
34. Experienced loss of confidence when interacting with others?  
35. Felt that your role in your family or among friends has changed? 
36. Experienced difficulty seeing your friends? 
37. Had to give up social activities, e.g. going out for a meal, participating in events? 
38. Had difficulty talking to friends about your illness? 
39. Been embarrassed to talk to people? 
40. Felt that life has become boring? 
Visual Analog Scale (1-100) to indicate how satisfied you feel overall with your life at the moment 
 
PSP-QoL 
[0] No Problem 
[1] Slight Problem 
[2] Moderate Problem 
[3] Marked Problem 
[4] Extreme Problem 
In the last 4 weeks have you: 
1. Had difficulty moving? 
2. Had difficulty walking? 
3. Had difficulty climbing stairs? 
4. Had difficulty turning in bed? 
5. Had falls? 
6. Had problems moving your eyes? 
7. Had problems opening your eyes? 
8. Had difficulty eating? 
9. Had difficulty swallowing? 
10. Had drooling of saliva? 
11. Had problems communicating? 
12. Had difficulty with your writing? 
13. Had difficulty grooming, washing or dressing yourself? 
14. Had difficulty using the toilet on your own? 
15. Had difficulty holding urine? 
16. Had difficulty reading? 
17. Had difficulty doing your hobbies e.g. playing chess or an instrument? 
18. Had problems doing things around the house, e.g. housework, DIY? 
19. Had difficulty enjoying sports, including gardening or walking? 
20. Had difficulty going out to see a play or film? 
21. Had difficulty going out for a meal? 
22. Had difficulty using public transport? 
23. Felt not in control of your life? 
24. Felt frustrated? 
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25. Felt a bit down, sad or depressed? 
26. Felt pessimistic about the future? 
27. Felt anxious? 
28. Felt isolated? 
29. Had difficulty sleeping not due to problems moving? 
30. Found yourself crying? 
31. Become more withdrawn? 
32. Felt stuck at home? 
33. Felt embarrassed in public? 
34. Felt you cannot show your feelings?  
35. Found your personality is different compared to before your illness? 
36. Felt the relationship with your spouse/partner has changed? 
37. Felt your relationship with other family members has changed? 
38. Seen family less than before you had this condition? 
39. Had problems with your memory? 
40. Found yourself repeating things a lot? 
41. Found your thinking is slower than before the illness? 
42. Found your thinking is muddled? 
43. Felt confused? 
44. Felt not motivated to do things? 
45. Found it difficult to make decisions? 
Visual Analog Scale (1-100) to indicate how satisfied you feel overall with your life at the moment. 
 
DASS-21 
Please read each statement and circle a number 0, 1, 2 or 3 which indicates how much the statement applied to 
you over the past week. The rating scale is as follows:  
[0] Did not apply to me at all 
[1] Applied to me to some degree, or some of the time 
[2] Applied to me to a considerable degree, or a good part of time 
[3] Applied to me very much, or most of the time 
1. I found it hard to wind down 
2. I was aware of dryness of my mouth 
3. I couldn’t seem to experience any positive feeling at all 
4. I experienced breathing difficulty (e.g. excessively rapid breathing, breathlessness in the absence of 
physical exertion) 
5. I found it difficult to work up the initiative to do things 
6. I tended to over-react to situations 
7. I experienced trembling (e.g. in the hands) 
8. I felt that I was using a lot of nervous energy 
9. I was worried about situations in which I might panic and make a fool of myself 
10. I felt that I had nothing to look forward to  
11. I found myself getting agitated 
12. I found it difficult to relax 
13. I felt downhearted and blue 
14. I was intolerant of anything that kept me from getting on with what I was doing 
15. I felt I was close to panic 
16. I was unable to become enthusiastic about anything 
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17. I felt I wasn’t worth much as a person 
18. I felt that I was rather touchy 
19. I was aware of the action of my heart in the absence of physical exertion (e.g. sense of heart rate 
increase, heart missing a beat) 
20. I felt scared without any good reason 
21. I felt that life was meaningless 
 
BADLS 
Thinking of the last 2 weeks, tick the box that represents AVERAGE ability 
1. Preparing food 
a) Selects and prepares food as required 
b) Able to prepare food if ingredients set out 
c) Can prepare food if prompted step by step 
d) Unable to prepare food even with prompting and supervision 
e) Not applicable 
2. Eating 
a) Eats appropriately using correct cutlery 
b) Eats appropriately if food made manageable and/or uses spoon 
c) Uses fingers to eat food 
d) Needs to be fed 
e) Not applicable 
3. Preparing drink 
a) Selects and prepares drinks as required 
b) Can prepare drinks if ingredients left available 
c) Can prepare drinks if prompted step by step 
d) Unable to make a drink even with prompting and supervision 
e) Not applicable 
4. Drinking 
a) Drinks appropriately 
b) Drinks appropriately with aids, beaker/straw, etc. 
c) Does not drink appropriately even with aids but attempts to 
d) Has to have drinks administered (fed) 
e) Not applicable 
5. Dressing 
a) Selects appropriate clothing and dresses self 
b) Puts clothes on in wrong order and/or back to front and/or dirty clothing 
c) Unable to dress self but moves limbs to assist 
d) Unable to assist and requires total dressing 
e) Not applicable 
6. Hygiene 
a) Washes regularly and independently 
b) Can wash self if given soap, flannel, towel, etc. 
c) Can wash self if prompted and supervised 
d) Unable to wash self and needs full assistance 
e) Not applicable 
7. Teeth 
a) Cleans own teeth/dentures regularly and independently 
b) Cleans teeth/dentures if given appropriate items 
c) Requires some assistance, toothpaste on brush, brush to mouth, etc. 
d) Full assistance given 
e) Not applicable 
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8. Bath/Shower 
a) Bathes regularly and independently 
b) Needs bath to be drawn/shower turned on but washes independently 
c) Needs supervision and prompting to wash 
d) Totally dependent, needs full assistance 
e) Not applicable 
9. Toilet/Commode 
a) Uses toilet appropriately when required 
b) Needs to be taken to the toilet and given assistance 
c) Incontinent of urine or faeces 
d) Incontinent of urine and faeces 
e) Not applicable 
10. Transfers 
a) Can get in/out of chair unaided 
b) Can get into a chair but needs help to get out 
c) Needs help getting in and out of a chair 
d) Totally dependent on being put into and lifted from chair 
e) Not applicable 
11. Mobility 
a) Walks independently 
b) Walks with assistance i.e. furniture, arm for support 
c) Uses aids to mobilise i.e. frame, sticks, etc. 
d) Unable to walk 
e) Not applicable 
12. Orientation – Time 
a) Fully orientated to time/day/date etc. 
b) Unaware of time/day etc. but seems unconcerned 
c) Repeatedly asks the time/day/date 
d) Mixed up night and day 
e) Not applicable 
13. Orientation – Space 
a) Fully orientated to surroundings 
b) Orientated to familiar surroundings only 
c) Gets lost in home, needs reminding where bathroom is, etc. 
d) Does not recognise home as own and attempts to leave 
e) Not applicable 
14. Communication 
a) Able to hold appropriate conversation 
b) Shows understanding and attempts to respond verbally with gestures 
c) Can make self understood but difficulty understanding others 
d) Does not respond to, or communicate with others 
e) Not applicable 
15. Telephone 
a) Uses telephone appropriately, including obtaining correct number 
b) Uses telephone if number given verbally/visually or predialled 
c) Answers telephone but does not make calls 
d) Unable/unwilling to use telephone at all 
e) Not applicable 
16. Housework/Gardening 
a) Able to do housework/gardening to previous standard 
b) Able to do housework/gardening but not to previous standard 
c) Limited participation with a lot of supervision 
d) Unwilling/unable to participate in previous activities 
e) Not applicable 
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17. Shopping 
a) Shops to previous standard 
b) Only able to shop for 1 or 2 items with or without a list 
c) Unable to shop alone, but participates when accompanied 
d) Unable to participate in shopping even when accompanied 
e) Not applicable 
18. Finances  
a) Responsible for own finances at previous level 
b) Unable to write a cheque. Can sign name & recognises money values 
c) Can sign name but unable to recognise money values 
d) Unable to sign name or recognise money values 
e) Not applicable 
19. Games/Hobbies 
a) Participates in pastimes/activities to previous standard 
b) Participates but needs instructions/supervision 
c) Reluctant to join in, very slow, needs coaxing 
d) No longer able or willing to join in 
e) Not applicable 
20. Transport 
a) Able to drive, cycle or use public transport independently 
b) Unable to drive but uses public transport or bike, etc. 
c) Unable to use public transport alone 
d) Unable/unwilling to use transport even when accompanied 
e) Not applicable 
 
POS-S-PD 
Please put a tick in the box to show how you feel each of these symptoms has affected you and how you been 
feeling over the past week. 
[0] Not at all 
[1] Slightly 
[2] Moderately 
[3] Severely 
[4] Overwhelmingly 
1. Pain 
2. Spasms 
3. Fatigue or lack of energy 
4. Shortness of breath 
5. Nausea (feeling you are going to be sick) 
6. Vomiting (being sick) 
7. Poor appetite 
8. Problems swallowing 
9. Feeling sleepy 
10. Difficulty in sleeping 
11. Constipation 
12. Difficulty in bowel control 
13. Difficulty controlling urine 
14. Pressure sores 
15. Problems using your arms 
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16. Problems using your legs 
17. Difficulty communicating 
18. Dribbling of saliva 
19. Falls 
20. Hallucinations 
21. Any other symptoms 
Which symptom has affected you the most? 
Which symptom has improved the most? 
 
MCSI 
Please [choose the options] that apply to you.  
[0] No 
[1] Yes, sometimes 
[2] Yes, on a regular basis 
 
1. My sleep is disturbed (e.g. the person I care for is in and out of bed or wanders around at night) 
2. Caregiving is inconvenient (e.g. helping takes so much time or it’s a long driver over to help)  
3. Caregiving is a physical strain (e.g. lifting in or out of a chair; effort or concentration is required) 
4. Caregiving is confining (e.g. helping restricts free time or I cannot go visiting) 
5. There have been family adjustments (e.g. helping has disrupted my routine; there is no privacy) 
6. There have been changes in personal plans (e.g. I had to turn down a job; I could not go on vacation) 
7. There have been other demands on my time (e.g. other family members need me) 
8. There have been emotional adjustments (e.g. severe arguments about caregiving) 
9. Some behaviour is upsetting (e.g. incontinence; the person cared for has trouble remembering things; or 
the person I care for accuses people of taking things) 
10. It is upsetting to find the person I care for has changed so much from his/her former self (e.g. he/she is a 
different person than he/she use to be) 
11. There have been work adjustments (e.g. I have to take time off for caregiving duties) 
12. Caregiving is a financial strain 
13. I feel completely overwhelmed (e.g. I worry about the person I care for; I have concerns about how I 
will manage) 
 
PQoLc 
When answering, please think about your role as a carer. Please tick one box to show how much of a problem 
you are having, if any with the following. 
[0] No Problem 
[1] Slight Problem 
[2] Moderate Problem 
[3] Marked Problem 
[4] Extreme Problem 
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In the last 4 weeks: 
1. Do you find it a physical strain to look after your relative/partner? 
2. Do you find it difficult to look after your own health needs? 
3. Has your own health suffered e.g. have you suffered back or joint pain? 
4. Do you find caring a stressful job? 
5. Do you feel fatigued or tired? 
6. Do you feel frustrated or fed up? 
7. Do you feel sad? 
8. Do you feel alone or lonely? 
9. Do you feel angry or betrayed? 
10. Do you feel stressed? 
11. Do you feel your sleep is disturbed? 
12. Do you worry about your relative/partner? 
13. Do you find it emotionally difficult to deal with your relative’s/partner’s physical problems? 
14. Has your ability to communicate with your relative/partner suffered? 
15. Has your relationship to your relative/partner changed? 
16. Do you find it difficult to deal with your relative’s/partner’s changed personality? 
17. Do you find it difficult to deal with a change in roles between you and your relative or partner? 
18. Do you feel your privacy has been invaded? 
19. Do you feel trapped? 
20. Do you feel you do not do much for yourself now? 
21. Has it become difficulty to do things spontaneously? 
22. Do you find life boring? 
23. Do you see friends and family less? 
24. Has your family life been affected? 
25. Do you find you have to take more responsibility than you should? 
26. Do you find there is not enough support for you? 
Visual Analog Scale (1-100) to indicate how satisfied you feel overall with your life at the moment. 
What is your relationship to the patient? 
 Spouse/Partner 
 Daughter/Son 
 Other 
 
Does your relative or partner live:  
 With you? 
 On his or her own? 
 Or in a nursing home? 
 
How much time do you spend with your relative partner?  
 ____hours per day or ____% of the day 
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SEIQoL-DW 
Administration Procedure 
Step 1: Introduction 
Read the following to the respondent: 
“For each of us, happiness and satisfaction in life depends on those parts or areas of life which are important to 
us. When these important areas are present or are going well, we are generally happy but when they are absent or 
going badly we feel worried or unhappy. In other words, these important areas of life determine the quality of 
our lives. What is considered important varies from person to person. That which is most important to you may 
not be so important to me or to your husband/wife/children/parents/friends (mention one or two of these groups 
as appropriate)… and vice versa”. 
“I am interested in knowing what the most important areas of your life are at the moment. Most of us don’t 
usually spend a lot of time thinking about these things. Indeed, we often only notice that certain things are 
important when something happens to change them. Sometimes it is easier to identify what is important by 
thinking about the areas of life that would (or do) cause us most concern when they are missing or going badly”.  
 
Step 2: Eliciting the Five Most Important Aspects of Life (Cues) 
Ask the respondent:  
“What are the five most important areas of your life at present – the things which make your life a relatively 
happy or sad one at the moment… the things that you feel determine the quality of your life?” 
If the respondent does not understand what is required the question may be rephrased in the following ways:  
“What parts of your life are most important?/What things are most important?/The most important things in my 
life are..?” 
Elicit areas NOT individuals e.g. marriage, not wife. Do not give examples.  
The meaning of each cue for the respondent must be documented at this stage on the Cue Definitions Record 
Form. Establish what the respondent means by each quality of life area named as being important. For example, 
if an individual were to name “golf” as a cue, this may relate primarily to leisure activity, but equally it may 
represent social activity, or physical mobility. Similarly, if “religion” were named as a cue it might relate to the 
respondent’s spiritual life, but might equally relate to being physically able to get to church, or to the social 
dimension of meeting one’s friends at church. This is particularly important for subsequent review of data, and 
of obvious relevance when respondents must be re-assessed at some future date in order to ensure that the same 
cues are being considered.  
Having defined what the respondent means by the cure, it is important that the cue, as labelled by the individual, 
be used by the interviewer and not the interviewer’s interpretation of what the respondent is saying.  
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Should the respondent volunteer cues which resemble “quality of life” in meaning (e.g. satisfaction, life quality), 
the interviewer should probe for more specific cues. Cues such as “happiness”, “attitude to life”, “morale” are 
acceptable.  
If it is absolutely necessary to make some suggestions, then read the following list, excluding any cues already 
mentioned – family, relationships, health, finances, living conditions, work, social life, leisure activities, 
religion/spiritual life. This list is derived from our findings with a range of populations and represents the cues 
most commonly elicited, in descending order of frequency. It provides for consistency across the interviewers 
where such prompting is absolutely necessary.  
 
Step 3: Determining Levels 
Say to respondent:  
“Now that you have named the five most important areas in your life, I am going to ask you to rate how each of 
these areas are for you at the moment. First I will show you an example of how the rating is done”.  
Place the Sample Cue Levels Record Form between you and the respondent so that the respondent can clearly 
see how you carry out the rating.  
“First look at this box (indicate). As you can see, there are spaces at the bottom in which I can write the five 
important areas of my life (indicate), and there is a scale along the left hand side (indicate). The scale ranges 
from ‘worst possible’ on the bottom to ‘best possible’ on the top, and passes through levels such as ‘very bad’ – 
‘bad’ – ‘neither good nor bad’ – ‘good’ – and ‘very good’ between the two extremes.  
The first important area of my life is X (use a cue not already nominated by the respondent and write it in the 
first space at the bottom of the rating box) and if this is going very well at the moment, I can show this by 
drawing a bar like this (draw a bar approx. 80mm high). I am using the scale (indicate) to decide how high my 
bar should be. The nearer I draw the bar to the bottom line, the poorer my rating of that area of my life. A mark 
in the middle range would indicate that I am rating life as neither good nor bad, but somewhere in between”.  
Now proceed with the ratings for the remaining cues: 
Second cue – “if X2 (use a cue not already nominated by the respondent and write it in the second space) is going 
well as is possible, I would rate it by drawing a bar like this…” (draw a bar 100mm high).  
Third cure – “if X3 (use a cue not already nominated by the respondent and write it in the third space) is going 
very badly, I would rate it like this…” (draw a bar approx. 15mm high).  
Fourth cue – “if X4 (use a cue not already nominated by the respondent and write it in the fourth space) is just all 
right, or ‘fifty/fifty’, I would rate it like this…” (draw a bar approximately 50mm high).  
Fifth cue – X5 (use a cue not already nominated by the respondent and write it in the fifth space) – (draw a 
random rating).  
“This provides a picture of life as I might think of it as the moment”.  
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Step 4: Elicit Rating of Present Life 
Place the Cue Levels Record Form between you and the respondent. Write the respondent’s five cues in the 
appropriate spaces under the box. Give the respondent a pen or pencil.  
Say to the respondent:  
“Now I want you to rate the five most important areas of your life, as you see presented here (indicate). Firstly, 
draw a bar which represents how you would rate yourself on each of this areas at the moment. As in the example 
I’ve just shown you, the nearer you draw the bar to the bottom line, the poorer you are rating that area of your 
life and the nearer you draw it to the top line, the better your rating of that area of your life”.  
Have respondent draw bars.  
 
Step 5: Direct Weighting Procedure 
Say to respondent: 
“I would like you to show me how important the five areas of life you have nominated are in relation to each 
other by using this disk (indicate SEIQoL-DW). People often value some areas in life as more important than 
others. This disk allows you to show me how important each area in your life is by giving the more important 
areas a larger area of the disk, and the less important areas a smaller area of the disk. In my life, for example, X 
(name cue not already chosen by respondent) is about this important (manipulate disk so that X represents 30% 
of space available). X2 however is less important that X, so it has only this much of the pie (manipulate disk so 
that X2 represents 20% of the space available). X3 on the other hand is more important than X, so it has this 
much of the pie (manipulate DWP so that X3 represents 40% of space available). Finally, X4 and X5 are the least 
important areas of life for me, and I value them about the same (manipulate disk so that X4 and X5 represent 5% 
each of space available). Now thinking about the five areas of life you mentioned (write the name of each cue 
along the cut edge of one of the 5 coloured disks with a non-permanent marker [disks may also be marked with 
stick-on ‘post-it’ labels indicating the cues if preferred]), I would like you to show me how important these areas 
are in relation to each other by moving the disks around until their relative size represents your view of their 
importance”. 
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Appendix B: Semi-Structured Interview Guides 
Patient interview guide 
Prior to your diagnosis, what was life like? 
Tell me how you came to be diagnosed? 
- What would have helped? 
- What was difficult? 
Has your life changed? (work, relationships, leisure)? 
How is your relationship (partner, friends, family)? 
- Has it changed? 
- How? 
What parts of (MSA/PSP) do you find most difficult to deal with? 
- Has that changed over time? 
- How 
What help would you have wanted? 
- At diagnosis?   
- Now? 
Tell me about your contact with doctors, nurses and others 
- What do you think works well? 
- How could things be done better? 
What is your understanding of palliative care? 
- How do you think you would feel if you were offered it? 
- What if it was mentioned at diagnosis? 
 
Carer interview guide 
How did you meet X? 
Tell me about the process of diagnosis 
- What would have helped? 
- What was difficult? 
Has your life changed (work, relationships, leisure)? 
How is your relationship (partner, friends, family)? 
- Has it changed? 
- How? 
Which parts of caring do you find most difficult to deal with? 
- Has that changed over time? 
- How? 
What help would you have wanted? 
- At diagnosis?   
- Now? 
Tell me about what you think troubles X most? 
Tell me about your contact with doctors, nurses and others 
- What do you think works well? 
- How could things be done better? 
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What is your understanding of palliative care? 
- How do you think you would feel if you were offered it? 
- What if it was mentioned at diagnosis? 
How do you feel about the future? 
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Appendix C. SEIQoL-DW Domain Details 
 
Table C.1: All domains nominated and proportion that nominated them for MSA patient-participants (left) and 
PSP-patient participants (right).) Bold and shaded area represents top five domains for that group (including 
ties) 
 
 
 
 
 
 
 
MSA Patients 
Domain 
Proportion nominated  
(N) 
PSP Patients Domain Proportion nominated  
(N) 
Family 
Home/House 
Social life 
Travel/Holidays 
Marriage/Partner 
Independence 
Sports 
Hobbies 
Pets/Animals 
Television 
Health 
Food/Cooking 
Work 
Outdoors/Nature 
Reading/Books 
Cars/Driving 
Connectedness 
Organising/Planning 
Friendship 
Grandchildren 
Music/Singing 
Walking 
Happiness 
Sexual intimacy 
Sunshine 
Environment 
Birds 
Beach 
Staying together 
Cleanliness 
Nostalgia/Memories 
Keeping informed/News 
Sympathy 
Gardening 
Theatre/Cinema 
Finance 
Communicating 
81.8% (18) 
36.4% (8) 
31.8% (7) 
31.8% (7) 
27.3% (6) 
22.7% (5) 
18.2% (4) 
18.2% (4) 
13.6% (3) 
13.6% (3) 
13.6% (3) 
13.6% (3) 
13.6% (3) 
13.6% (3) 
13.6% (3) 
9.1% (2) 
9.1% (2) 
9.1% (2) 
9.1% (2) 
9.1% (2) 
9.1% (2) 
9.1% (2) 
9.1% (2) 
4.5% (1) 
4.5% (1) 
4.5% (1) 
4.5% (1) 
4.5% (1) 
4.5% (1) 
4.5% (1) 
4.5% (1) 
4.5% (1) 
4.5% (1) 
4.5% (1) 
4.5% (1) 
4.5% (1) 
4.5% (1) 
Family 
Marriage/Partner 
Hobbies 
Gardening 
Home/House 
Walking 
Pets/Animals 
Grandchildren 
Cars/Driving 
Friendship 
Happiness 
Music/Singing 
Travel/Holidays 
Finance 
Health 
Television 
Independence 
Reading/Books 
Going out/Trips 
Sports 
Social life 
Routine 
“Light nights” 
Organising/Planning 
Food 
Writing 
Outdoors/Nature 
Freedom 
Nursing home staff 
Security 
Caring for appearance 
Sense of humour 
Comfort 
Quality of life 
Faith 
Birds 
77.3% (17) 
59.1% (13) 
27.3% (6) 
22.7% (5) 
22.7% (5) 
18.2% (4) 
18.2% (4) 
18.2% (4) 
18.2% (4) 
18.2% (4) 
13.6% (3) 
13.6% (3) 
13.6% (3) 
13.6% (3) 
13.6% (3) 
13.6% (3) 
13.6% (3) 
9.1% (2) 
9.1% (2) 
9.1% (2) 
9.1% (2) 
4.5% (1) 
4.5% (1) 
4.5% (1) 
4.5% (1) 
4.5% (1) 
4.5% (1) 
4.5% (1) 
4.5% (1) 
4.5% (1) 
4.5% (1) 
4.5% (1) 
4.5% (1) 
4.5% (1) 
4.5% (1) 
4.5% (1) 
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Table C.2: All domains nominated and proportion that nominated them for MSA carer-participants (left) and 
PSP carer-participants (right). Bold and shaded area represents top five domains for that group (including ties) 
 
 
 
 
 
 
 
MSA Carers 
Domain 
Proportion nominated  
(N) 
PSP Carers  
Domain 
Proportion nominated 
(N) 
Family 
Marriage/Partner 
Travel/Holidays 
Hobbies 
Health 
Friendship 
Pets/Animals 
Work 
Connectedness 
“Alone Time” 
Cars/Driving 
Freedom 
Walking 
Finance 
Gardening 
Home/House 
Spouse well-being 
Staying together 
Food/Cooking 
Sports 
Nostalgia/Memories 
Pub 
Music/Singing 
Phone 
Outdoors/Nature 
Beach 
Birds 
Faith 
Happiness 
Sleep 
Reading/Books 
Role model 
Conversation 
Independence 
 
80.0% (16) 
40.0% (8) 
30.0% (6) 
25.0% (5) 
25.0% (5) 
25.0% (5) 
20.0% (4) 
20.0% (4) 
15.0% (3) 
15.0% (3) 
15.0% (3) 
15.0% (3) 
15.0% (3) 
15.0% (3) 
15.0% (3) 
15.0% (3) 
10.0% (2) 
10.0% (2) 
10.0% (2) 
10.0% (2) 
10.0% (2) 
5.0% (1) 
5.0% (1) 
5.0% (1) 
5.0% (1) 
5.0% (1) 
5.0% (1) 
5.0% (1) 
5.0% (1) 
5.0% (1) 
5.0% (1) 
5.0% (1) 
5.0% (1) 
5.0% (1) 
 
Family 
Hobbies 
Health 
Gardening 
Marriage/Partner 
Happiness 
“Alone Time” 
Walking 
Travel/Holidays 
Staying together 
Freedom 
Finance 
Pets/Animals 
Reading/Books 
Music/Singing 
Connectedness 
Outdoors/Nature 
Social life 
Grandchildren 
Faith 
Food/Cooking 
Home/House 
Work 
Car 
Birds 
Independence 
Sports 
Spontaneity 
Culture 
93.8% (15) 
50.0% (8) 
43.8% (7) 
31.3% (5) 
25.0% (4) 
18.8% (3) 
18.8% (3) 
18.8% (3) 
18.8% (3) 
12.5% (2) 
12.5% (2) 
12.5% (2) 
12.5% (2) 
12.5% (2) 
12.5% (2) 
12.5% (2) 
12.5% (2) 
12.5% (2) 
6.3% (1) 
6.3% (1) 
6.3% (1) 
6.3% (1) 
6.3% (1) 
6.3% (1) 
6.3% (1) 
6.3% (1) 
6.3% (1) 
6.3% (1) 
6.3% (1) 
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Table C.3: Participant SEIQoL-DW domains and their individual interview themes 
  
Participant SEIQoL-DW five nominated domains Interview themes 
Matthew (MP1) Marriage, sexual intimacy, conversation, walking, food (being able to 
eat and drink) 
Change, guilt for needing help from spouse, decline, hope for cure, loss of speech 
Emma (CM1) Not performed Carer identity, protecting partner from strain on self, concealing difficulty, transition from wife 
to carer 
Sally (CP1) Not performed Delayed diagnosis, changing personality of husband, 24-hour caring, rediscovering relationship 
and self, planning for the end 
Bryce (PP3) Happiness, family, good health, pets, value of friendship Grief, loss of abilities and abandonment by friend-groups, blame, information as cruel, need for 
cure 
Doris (MP2) Not performed Decline, embarrassment, safety of home, withdrawing, making family understand challenges of 
MSA 
Bill (CM2) Not performed Frustration, seeing loved one suffer, value of work in maintaining own identity, need for social 
interaction, little-known disease 
Rose MP3 Family, connectedness, environment, cleanliness, keeping informed on 
progress 
Acceptance, hope for progress beyond own death, physical change, speech and perception of 
others, care for spouse after own death 
Jackie (CM3) Not performed Importance of carer's identity, being a problem-solver, relationships as true QoL, 
communication as key for happiness 
Julia MP7 Marriage, family support, home, human contact/social, outdoors and 
nature 
Acceptance, faith and family as a source of support, the patient-carer as a team, importance of 
nature, talking about death 
Tiberius (CM7) Marriage, family, financial security, home life, walking Duty, strain on own health as a carer, the value of PC to patients and to carers, the resilience of 
relationships in illness 
Sarah (PP4) Family, marriage, being a grandparent, gardening/outdoors, happiness Communication difficulty, frustration, being limited by body and speech, loss of freedom 
 
Tom (CP3) Not performed Communication when speech is limited, disruption of retirement dreams, loss of spouse 
motivation, new obligations as a carer 
Helen (PP18 Marriage, family (unity), being positive, security, independence Individuality, resisting dependence, struggle for diagnosis, judgement of others, feeling barred 
due to lack of access for those with disability 
Earl (CP17) Family, alone time, food, holidays, time with partner 24hr caring, need for more than 'material' support for patients and carers, breaking bad news, 
truth, PC as vital 
Mary (PP24) Family (love), marriage, home, hobbies (crafting), birds (symbolise 
escape) 
Speech and communication difficulty, feeling judged as 'stupid', as silent, personhood being 
taken away, need for more time from clinicians 
Bob (CP23) Marriage, family, community, nature, freedom  Need for sensitive delivery of news, constant worry and vigilance, respite, peer support, 
communication, teaching others about disease 
Gary (PP20) Family (deep bonds), financial security, friendship (peer support), 
travel, hobbies (sport) 
Truth and transparency, the holistic needs PC addresses in incurable illness, becoming closer to 
family, legacy and future planning 
Pat (CP19) Happiness, security, family, health (to allow caring), alone time Personhood and carer identity, value of work in preserving identity, conversation and 
connection, importance of expertise and time for patients 
Jack (PP19) Marriage, family, driving (just me and the road), reading ('go to' new 
places), social life 
Speech difficulty, changing desires and changing self, the strangeness of disease, difficulty in 
maintaining a conversation 
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Appendix D. Coding Web 
 
Figure D.1: Overall coding structure for thematic analysis 
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Figure D.2: Detailed Connection coding structure 
193 
 
 
Figure D.3: Detailed Transition coding structure 
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Figure D.4: Detailed Accessing Support coding structure
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Appendix E. COREQ (COnsolidated criteria for REporting Qualitative 
research) Checklist 
 
Domain 1: Research team and reflexivity 
Personal Characteristics 
1. Interviewer/facilitator 
• Which author/s conducted the interview or focus group? 
• Louise Wiblin (LW) conducted all interviews in this study. The interviews were one-to-one to 
exclude peer pressure bias. 
2. Credentials 
• What were the researcher’s credentials? E.g. PhD, MD 
• LW is medically qualified (MBBS, MRCP, SCE neuro) and had three years of specialist in AP. 
LW was formally trained in interview techniques and qualitative analysis by Newcastle 
University. 
3. Occupation 
• What was their occupation at the time of study? 
• Clinical research fellow in movement disorder neurology. 
4. Gender 
• Was the researcher male or female? 
• Female. 
5. Experience and training 
• What experience or training did the researcher have?  
• Medical degree and 8 years clinical experience (3 years in neurology), training courses in 
qualitative methods and interview techniques. 
Relationship with participants 
6. Relationship established 
• Was a relationship established prior to study commencement? 
• Some patients had encountered LW researcher before in a clinical capacity in a clinic setting 
or presenting at charity outreach events (MSA Trust and PSP Association). 
7. Participant knowledge of the interviewer 
• What did the participants know about the researcher? e.g. personal goals, reasons for doing the 
research 
• Participants aware that project was part of an MD project. 
• That the aim of the work would be to build evidence to improve clinical services and to guide 
future research. 
• That findings would be disseminated to charities such as PSP Association and presented at 
conferences and journals. 
8. Interviewer characteristics 
• What characteristics were reported about the interviewer/facilitator? e.g. Bias, assumptions, 
reasons and interests in the research topic  
• Participants were aware of the topics of interest, namely QoL and palliative care. 
• They were aware of LW’s role as a neurology doctor as well as researcher. 
• All participants knew that AP had been an interest of LW before the conceptions of the project. 
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Domain 2: Study design 
Theoretical framework 
9. Methodological orientation and theory 
• What methodological orientation was stated to underpin the study? e.g. grounded theory, 
discourse analysis, ethnography, phenomenology, content analysis 
• A thematic approach to analysis of semi-structured interviews was used. A thematic approach 
retains the production of codes from data to describe themes. Unlike grounded theory 
however, without the constraints of needing to build up all theory from the data without prior 
theories or focused aims. 
Participant selection 
10. Sampling 
• How were participants selected? e.g. purposive, convenience, consecutive, snowball  
• Participants were selected by purposively. There was an element of convenience sampling, as 
those well enough to interview during the interview phase were those who participated. 
11. Method of approach 
• How were participants approached? e.g. face-to-face, telephone, mail, email 
• Participants were approached face-to-face in clinic by LW or by their consultant or specialist 
nurse, then then contacted by telephone (by LW) after permission for this was obtained. 
12. Sample size 
• How many participants were in the study? 
• There were 19 participants; 10 patients and 9 carers. 
13. Non-participation 
• How many people refused to participate or dropped out? Reasons? 
• 14 participants were approached to give an interview which did not take place due to ill-health 
or conflicting time-tables. No-one approached for interview after consent refused for other 
reasons.37 of the 47 patients consented to be approached for interview and 40 of the 46 
consented. 
Setting 
14. Setting of data collection 
• Where was the data collected? e.g. home, clinic, workplace 
• The data was collected in clinical settings (CRESTA clinic or St Benedict’s) or the patient’s 
home; depending on their preference. 
15. Presence of non-participants 
• Was anyone else present besides the participants and researchers? 
• Family members could not be present for the interview so that the interviewee did not feel 
coerced or anxious talking about their true thoughts and feelings which might potentially 
worry or offend a relative. 
16. Description of sample 
• What are the important characteristics of the sample? e.g. demographic data, date 
• Sex, age, previous occupation, patient or carer role and disease-type were the demographics 
collected as well as any relationship between participants. 
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Data collection 
17. Interview guide 
• Were questions, prompts, guides provided by the authors? Was it pilot tested? 
• A semi-structured guide was produced and scrutinized. It was pilot-tested on the first two 
interviewees but no further changes were felt to be desirable as it seemed to elicit a full and 
natural account. 
18. Repeat interviews 
• Were repeat interviews carried out? If yes, how many? 
• Only single interviews were carried out. 
19. Audio/visual recording 
• Did the research use audio or visual recording to collect the data? 
• Audio recordings were made. No-one refused audio recordings. 
20. Field notes 
• Were field notes made during and/or after the interview or focus group? 
• Field notes were made after the interview (as LW wanted greater immediacy and attention on 
the subject). Field notes were made immediately after and within 24-48 hours, with the benefit 
of listening back to the recording. 
21. Duration 
• What was the duration of the interviews or focus group? 
• Interviews ranged from 20 minutes to 4 and a half hours (depending on how much they wished 
to say and speech difficulty). Participants were reminded before and during they should stop 
when they wished or rest if they needed to. 
22. Data saturation 
• Was data saturation discussed? 
• Data saturation was discussed during briefings between LW, KB and ML. Interview 
transcripts and codings were used to verify whether any new meaningful content was being 
generated. 
23. Transcripts returned 
• Were transcripts returned to participants for comment and/or correction? 
• No; as participants had been assured their spouse would not see their recordings, sending 
them back when patient is vulnerable and dependent on their carer to read for them would 
have compromised patient confidentiality and ethical approval for this project. 
 
Domain 3: Analysis and findings 
Data analysis 
24. Number of data coders 
• How many data coders coded the data? 
• One coder and one debriefer. 
25. Description of the coding tree 
• Did authors provide a description of the coding tree or system? 
• Coding network included. 
26. Derivation of themes 
• Were themes identified in advance or derived from the data? 
• Entirely derived from the data. 
27. Software 
• What software, if applicable, was used to manage the data? 
• QSR International NVIVO version 11 for Mac was used together with a card and paper web-
system. 
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28. Participant checking 
• Did participants provide feedback on the findings? 
• See point 23. 
Reporting 
29. Quotations presented 
• Were participant quotations presented to illustrate the themes / findings? Was each quotation 
identified? e.g. participant number 
• Quotations were presented throughout the analysis to illustrate findings and identified 
according to the pseudonym assigned on the demographic table. 
30. Data and findings consistent 
• Was there consistency between the data presented and the findings? 
• LW with the supervision and collaboration of KB, ML and DJB feel that the quotations and 
pervading themes were well-integrated and that the former illustrated the latter. 
31. Clarity of major themes 
• Were major themes clearly presented in the findings? 
• Three overarching themes with five or six subthemes derived from codes were used to describe 
findings in discrete sections, though feeding into one another, their inter-relationships and 
impact upon each other commented upon. 
32. Clarity of minor themes 
• Is there a description of diverse cases or discussion of minor themes? 
• Subthemes were stated rather than being alluded to and were shown diagrammatically for 
each of the three main themes. 
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